<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="//cdn.jsdelivr.net/npm/mathjax@2.7.5/MathJax.js?config=TeX-AMS-MML_SVG.js"></script><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/deZPtuf2wPtTGO6NfQbJxpwwlVUMT-LizgVGsiQtg-YjozptyjC5zwgwg96RnobfaezHK1KfieHFeqESqOlv3A=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"melanoma;peptide-vaccines;phase-ii-trials;translational-research","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-021-01544-x"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Julie Westerlin Kjeldsen","Cathrine Lund Lorentzen","Evelina Martinenaite","Eva Ellebaek","Marco Donia","Rikke Boedker Holmstroem","Tobias Wirenfeldt Klausen","Cecilie Oelvang Madsen","Shamaila Munir Ahmed","Stine Emilie Weis-Banke","Morten Orebo Holmström","Helle Westergren Hendel","Eva Ehrnrooth","Mai-Britt Zocca","Ayako Wakatsuki Pedersen","Mads Hald Andersen","Inge Marie Svane"],"publishedAt":1639008000,"publishedAtString":"2021-12-09","title":"A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Melanoma,Peptide vaccines,Phase II trials,Translational research"},"journal":{"pcode":"nm","title":"nature medicine","volume":"27","issue":"12","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script><script id="js-position4" data-test="math-js" async="" src="/static/js/math-es6-bundle-23597ae350.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma","description":"Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study (\n                https://clinicaltrials.gov/\n                \n              , NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7–90.5%) was reached, with 43% (CI, 27.4–60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4–69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of >93% of patients during vaccination. Vaccine-reactive T cells comprised CD4+ and CD8+ T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach. A first-in-class immune-modulating IDO/PD-L1-targeting vaccine combined with nivolumab in a phase 1/2 trial achieved very promising clinical activity and long-lasting immune responses in patients with advanced melanoma.","datePublished":"2021-12-09T00:00:00Z","dateModified":"2022-03-08T00:00:00Z","pageStart":"2212","pageEnd":"2223","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-021-01544-x","keywords":["Melanoma","Peptide vaccines","Phase II trials","Translational research","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig5_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"27","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Julie Westerlin Kjeldsen","url":"http://orcid.org/0000-0001-6201-1758","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Cathrine Lund Lorentzen","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Evelina Martinenaite","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"},{"name":"IO Biotech Aps","address":{"name":"IO Biotech Aps, Copenhagen, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Eva Ellebaek","url":"http://orcid.org/0000-0001-6748-9232","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marco Donia","url":"http://orcid.org/0000-0003-4966-9752","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rikke Boedker Holmstroem","url":"http://orcid.org/0000-0002-5476-9937","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Tobias Wirenfeldt Klausen","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Cecilie Oelvang Madsen","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shamaila Munir Ahmed","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Stine Emilie Weis-Banke","url":"http://orcid.org/0000-0002-6037-494X","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Morten Orebo Holmström","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Helle Westergren Hendel","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Eva Ehrnrooth","affiliation":[{"name":"IO Biotech Aps","address":{"name":"IO Biotech Aps, Copenhagen, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Mai-Britt Zocca","affiliation":[{"name":"IO Biotech Aps","address":{"name":"IO Biotech Aps, Copenhagen, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ayako Wakatsuki Pedersen","affiliation":[{"name":"IO Biotech Aps","address":{"name":"IO Biotech Aps, Copenhagen, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Mads Hald Andersen","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Copenhagen","address":{"name":"Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Inge Marie Svane","url":"http://orcid.org/0000-0002-9451-6037","affiliation":[{"name":"Copenhagen University Hospital","address":{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark","@type":"PostalAddress"},"@type":"Organization"}],"email":"inge.marie.svane@regionh.dk","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-021-01544-x">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma">
    <meta name="dc.source" content="Nature Medicine 2021 27:12">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2021-12-09">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2021 The Author(s)">
    <meta name="dc.rights" content="2021 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study ( https://clinicaltrials.gov/ , NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7–90.5%) was reached, with 43% (CI, 27.4–60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4–69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of &amp;gt;93% of patients during vaccination. Vaccine-reactive T cells comprised CD4+ and CD8+ T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach. A first-in-class immune-modulating IDO/PD-L1-targeting vaccine combined with nivolumab in a phase 1/2 trial achieved very promising clinical activity and long-lasting immune responses in patients with advanced melanoma.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2021-12-09">
    <meta name="prism.volume" content="27">
    <meta name="prism.number" content="12">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="2212">
    <meta name="prism.endingPage" content="2223">
    <meta name="prism.copyright" content="2021 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-021-01544-x">
    <meta name="prism.doi" content="doi:10.1038/s41591-021-01544-x">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-021-01544-x.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-021-01544-x">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma">
    <meta name="citation_volume" content="27">
    <meta name="citation_issue" content="12">
    <meta name="citation_publication_date" content="2021/12">
    <meta name="citation_online_date" content="2021/12/09">
    <meta name="citation_firstpage" content="2212">
    <meta name="citation_lastpage" content="2223">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-021-01544-x">
    <meta name="DOI" content="10.1038/s41591-021-01544-x">
    <meta name="size" content="244272">
    <meta name="citation_doi" content="10.1038/s41591-021-01544-x">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-021-01544-x&amp;api_key=">
    <meta name="description" content="Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study ( https://clinicaltrials.gov/ , NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7–90.5%) was reached, with 43% (CI, 27.4–60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4–69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of &amp;gt;93% of patients during vaccination. Vaccine-reactive T cells comprised CD4+ and CD8+ T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach. A first-in-class immune-modulating IDO/PD-L1-targeting vaccine combined with nivolumab in a phase 1/2 trial achieved very promising clinical activity and long-lasting immune responses in patients with advanced melanoma.">
    <meta name="dc.creator" content="Kjeldsen, Julie Westerlin">
    <meta name="dc.creator" content="Lorentzen, Cathrine Lund">
    <meta name="dc.creator" content="Martinenaite, Evelina">
    <meta name="dc.creator" content="Ellebaek, Eva">
    <meta name="dc.creator" content="Donia, Marco">
    <meta name="dc.creator" content="Holmstroem, Rikke Boedker">
    <meta name="dc.creator" content="Klausen, Tobias Wirenfeldt">
    <meta name="dc.creator" content="Madsen, Cecilie Oelvang">
    <meta name="dc.creator" content="Ahmed, Shamaila Munir">
    <meta name="dc.creator" content="Weis-Banke, Stine Emilie">
    <meta name="dc.creator" content="Holmström, Morten Orebo">
    <meta name="dc.creator" content="Hendel, Helle Westergren">
    <meta name="dc.creator" content="Ehrnrooth, Eva">
    <meta name="dc.creator" content="Zocca, Mai-Britt">
    <meta name="dc.creator" content="Pedersen, Ayako Wakatsuki">
    <meta name="dc.creator" content="Andersen, Mads Hald">
    <meta name="dc.creator" content="Svane, Inge Marie">
    <meta name="dc.subject" content="Melanoma">
    <meta name="dc.subject" content="Peptide vaccines">
    <meta name="dc.subject" content="Phase II trials">
    <meta name="dc.subject" content="Translational research">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study; citation_author=C Robert; citation_volume=20; citation_publication_date=2019; citation_pages=1239-1251; citation_doi=10.1016/S1470-2045(19)30388-2; citation_id=CR1">
    <meta name="citation_reference" content="Weber, J. S., Postow, M., Lao, C. D. &amp; Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21, 1230–1240 (2016).">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Five-year survival with combined nivolumab and ipilimumab in advanced melanoma; citation_author=J Larkin; citation_volume=381; citation_publication_date=2019; citation_pages=1535-1546; citation_doi=10.1056/NEJMoa1910836; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations; citation_author=PA Ascierto; citation_volume=28; citation_publication_date=2017; citation_pages=v611-v612; citation_doi=10.1093/annonc/mdx440.011; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Warming ‘cold’ melanoma with TLR9 agonists; citation_author=L Angeles; citation_volume=8; citation_publication_date=2018; citation_pages=670; citation_doi=10.1158/2159-8290.CD-ND2018-004; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=Front. Oncol.; citation_title=Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma; citation_author=JE Mullinax; citation_volume=8; citation_publication_date=2018; citation_pages=44; citation_doi=10.3389/fonc.2018.00044; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer; citation_author=PA Ott; citation_volume=183; citation_publication_date=2020; citation_pages=347-362; citation_doi=10.1016/j.cell.2020.08.053; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=An immunogenic personal neoantigen vaccine for patients with melanoma; citation_author=PA Ott; citation_volume=547; citation_publication_date=2017; citation_pages=217-221; citation_doi=10.1038/nature22991; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Semin. Immunopathol.; citation_title=Anti-cancer immunotherapy: breakthroughs and future strategies; citation_author=MH Andersen; citation_volume=41; citation_publication_date=2019; citation_pages=1-3; citation_doi=10.1007/s00281-018-0711-z; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Oncoimmunology; citation_title=The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells; citation_author=S Munir, GH Andersen, IM Svane, MH Andersen; citation_volume=2; citation_publication_date=2013; citation_pages=e23991; citation_doi=10.4161/onci.23991; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=PD-L1-specific T cells; citation_author=SM Ahmad, TH Borch, M Hansen, MH Andersen; citation_volume=65; citation_publication_date=2016; citation_pages=797-804; citation_doi=10.1007/s00262-015-1783-4; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase; citation_author=MH Andersen; citation_volume=61; citation_publication_date=2012; citation_pages=1289-1297; citation_doi=10.1007/s00262-012-1234-4; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2; citation_author=RB Sørensen; citation_volume=71; citation_publication_date=2011; citation_pages=2038-2044; citation_doi=10.1158/0008-5472.CAN-10-3403; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Leukemia; citation_title=Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway; citation_author=SM Ahmad, SK Larsen, IM Svane, MH Andersen; citation_volume=28; citation_publication_date=2014; citation_pages=236-238; citation_doi=10.1038/leu.2013.261; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Oncoimmunology; citation_title=CD4 responses against IDO; citation_author=MH Andersen; citation_volume=1; citation_publication_date=2012; citation_pages=1211-1212; citation_doi=10.4161/onci.20780; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother. Cancer; citation_title=Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses; citation_author=S Dey; citation_volume=8; citation_publication_date=2020; citation_pages=e000605; citation_doi=10.1136/jitc-2020-000605; citation_id=CR16">
    <meta name="citation_reference" content="Ellebaek, E. et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 73, 101943 (2021).">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Combined nivolumab and ipilimumab or monotherapy in untreated melanoma; citation_author=J Larkin; citation_volume=373; citation_publication_date=2015; citation_pages=23-34; citation_doi=10.1056/NEJMoa1504030; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Hum. Immunol.; citation_title=Optimization of an Elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes; citation_author=B Godard; citation_volume=65; citation_publication_date=2004; citation_pages=1307-1318; citation_doi=10.1016/j.humimm.2004.06.006; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients; citation_author=A Meier; citation_volume=54; citation_publication_date=2005; citation_pages=219-228; citation_doi=10.1007/s00262-004-0578-9; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol.; citation_title=HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals; citation_author=SA Calarota; citation_volume=180; citation_publication_date=2008; citation_pages=5907-5915; citation_doi=10.4049/jimmunol.180.9.5907; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Overall survival with combined nivolumab and ipilimumab in advanced melanoma; citation_author=JD Wolchok; citation_volume=377; citation_publication_date=2017; citation_pages=1345-1356; citation_doi=10.1056/NEJMoa1709684; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Nivolumab in previously untreated melanoma without BRAF mutation; citation_author=C Robert; citation_volume=372; citation_publication_date=2015; citation_pages=320-330; citation_doi=10.1056/NEJMoa1412082; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations; citation_author=CHK Iii; citation_volume=24; citation_publication_date=2019; citation_pages=5347-5356; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma; citation_author=L Bastholt; citation_volume=119; citation_publication_date=2019; citation_pages=122-131; citation_doi=10.1016/j.ejca.2019.06.022; citation_id=CR25">
    <meta name="citation_reference" content="Yan, X., Tian, X., Wu, Z. &amp; Han, W. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. Front. Oncol. 10, 1671 (2020).">
    <meta name="citation_reference" content="citation_journal_title=Immunotherapy; citation_title=Efficacy of immune checkpoint inhibitors and age in cancer patients; citation_author=XZ Huang; citation_volume=12; citation_publication_date=2020; citation_pages=587-603; citation_doi=10.2217/imt-2019-0124; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=J. Natl Cancer Inst.; citation_title=Real-world data for clinical evidence generation in oncology; citation_author=S Khozin, GM Blumenthal, R Pazdur; citation_volume=109; citation_publication_date=2017; citation_pages=1359-1360; citation_doi=10.1093/jnci/djx187; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy; citation_author=A Ribas; citation_volume=170; citation_publication_date=2017; citation_pages=1109-1119; citation_doi=10.1016/j.cell.2017.08.027; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother. Cancer; citation_title=429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB–IVM1c melanoma; citation_author=G Long; citation_volume=8; citation_publication_date=2020; citation_pages=A261; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study; citation_author=GV Long; citation_volume=20; citation_publication_date=2019; citation_pages=1083-1097; citation_doi=10.1016/S1470-2045(19)30274-8; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase; citation_author=TZ Iversen; citation_volume=20; citation_publication_date=2014; citation_pages=221-232; citation_doi=10.1158/1078-0432.CCR-13-1560; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Front. Immunol.; citation_title=Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study—a brief research report; citation_author=JW Kjeldsen; citation_volume=9; citation_publication_date=2018; citation_pages=2145; citation_doi=10.3389/fimmu.2018.02145; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma; citation_author=U Sahin; citation_volume=585; citation_publication_date=2020; citation_pages=107-112; citation_doi=10.1038/s41586-020-2537-9; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators; citation_author=RB Sørensen; citation_volume=117; citation_publication_date=2011; citation_pages=2200-2210; citation_doi=10.1182/blood-2010-06-288498; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase; citation_author=RB Søorensen; citation_volume=4; citation_publication_date=2009; citation_pages=e6910; citation_doi=10.1371/journal.pone.0006910; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase; citation_author=S Munir; citation_volume=7; citation_publication_date=2012; citation_pages=e34568; citation_doi=10.1371/journal.pone.0034568; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients; citation_author=S Munir; citation_volume=73; citation_publication_date=2013; citation_pages=1764-1776; citation_doi=10.1158/0008-5472.CAN-12-3507; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=Cell Stress; citation_title=The targeting of tumor-associated macrophages by vaccination; citation_author=MH Andersen; citation_volume=3; citation_publication_date=2019; citation_pages=139-140; citation_doi=10.15698/cst2019.05.185; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen; citation_author=R Andersen; citation_volume=22; citation_publication_date=2016; citation_pages=3734-3745; citation_doi=10.1158/1078-0432.CCR-15-1879; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Front. Immunol.; citation_title=Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: a phase I first-in-human trial; citation_author=NG Jørgensen; citation_volume=11; citation_publication_date=2020; citation_pages=595035; citation_doi=10.3389/fimmu.2020.595035; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=PD-1 blockade induces responses by inhibiting adaptive immune resistance; citation_author=PC Tumeh; citation_volume=515; citation_publication_date=2014; citation_pages=568-571; citation_doi=10.1038/nature13954; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors; citation_author=T Wang; citation_volume=9; citation_publication_date=2018; citation_pages=1532; citation_doi=10.1038/s41467-018-03915-4; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma; citation_author=RE Vilain; citation_volume=23; citation_publication_date=2017; citation_pages=5024-5033; citation_doi=10.1158/1078-0432.CCR-16-0698; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=The balance players of the adaptive immune system; citation_author=MH Andersen; citation_volume=78; citation_publication_date=2018; citation_pages=1379-1382; citation_doi=10.1158/0008-5472.CAN-17-3607; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Nat. Immunol.; citation_title=PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer; citation_author=B Diskin; citation_volume=21; citation_publication_date=2020; citation_pages=442-454; citation_doi=10.1038/s41590-020-0620-x; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Blood Cancer J.; citation_title=The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity; citation_author=SM Ahmad, IM Svane, MH Andersen; citation_volume=4; citation_publication_date=2014; citation_doi=10.1038/bcj.2014.50; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=Oncoimmunology; citation_title=PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine; citation_author=S Munir Ahmad; citation_volume=5; citation_publication_date=2016; citation_pages=e1202391; citation_doi=10.1080/2162402X.2016.1202391; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Cancer; citation_title=The blockade of immune checkpoints in cancer immunotherapy; citation_author=DM Pardoll; citation_volume=12; citation_publication_date=2012; citation_pages=252-264; citation_doi=10.1038/nrc3239; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=Response definition criteria for ELISPOT assays revisited; citation_author=Z Moodie; citation_volume=59; citation_publication_date=2010; citation_pages=1489-1501; citation_doi=10.1007/s00262-010-0875-4; citation_id=CR50">
    <meta name="citation_reference" content="citation_journal_title=Scand. J. Immunol.; citation_title=Characterization and comparison of ‘standard’ and ‘young’ tumor infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution; citation_author=M Donia; citation_volume=75; citation_publication_date=2011; citation_pages=157-167; citation_doi=10.1111/j.1365-3083.2011.02640.x; citation_id=CR51">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells; citation_author=W Hobo; citation_volume=116; citation_publication_date=2010; citation_pages=4501-4511; citation_doi=10.1182/blood-2010-04-278739; citation_id=CR52">
    <meta name="citation_reference" content="citation_journal_title=Breast Cancer Res. Treat.; citation_title=High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer; citation_author=Ö Met, E Balslev, H Flyger, IM Svane; citation_volume=125; citation_publication_date=2011; citation_pages=395-406; citation_doi=10.1007/s10549-010-0844-9; citation_id=CR53">
    <meta name="citation_reference" content="citation_journal_title=Curr. Protoc. Mol. Biol.; citation_title=High‐throughput real‐time quantitative reverse transcription PCR; citation_author=AL Bookout, CL Cummins, DJ Mangelsdorf, JM Pesola, MF Kramer; citation_volume=73; citation_publication_date=2006; citation_pages=15.8.1-15.8.28; citation_doi=10.1002/0471142727.mb1508s73; citation_id=CR54">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells; citation_author=HS Robins; citation_volume=114; citation_publication_date=2009; citation_pages=4099-4107; citation_doi=10.1182/blood-2009-04-217604; citation_id=CR55">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Using synthetic templates to design an unbiased multiplex PCR assay; citation_author=CS Carlson; citation_volume=4; citation_publication_date=2013; citation_pages=2680; citation_doi=10.1038/ncomms3680; citation_id=CR56">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol. Methods; citation_title=Ultra-sensitive detection of rare T cell clones; citation_author=H Robins; citation_volume=375; citation_publication_date=2012; citation_pages=14-19; citation_doi=10.1016/j.jim.2011.09.001; citation_id=CR57">
    <meta name="citation_reference" content="citation_journal_title=J. Virol.; citation_title=Dynamics of the cytotoxic T cell response to a model of acute viral infection; citation_author=WS DeWitt; citation_volume=89; citation_publication_date=2015; citation_pages=4517-4526; citation_doi=10.1128/JVI.03474-14; citation_id=CR58">
    <meta name="citation_reference" content="citation_journal_title=Ann. Appl. Stat.; citation_title=A simple forward selection procedure based on false discovery rate control; citation_author=Y Benjamini, Y Gavrilov; citation_volume=3; citation_publication_date=2009; citation_pages=179-198; citation_doi=10.1214/08-AOAS194; citation_id=CR59">
    <meta name="citation_author" content="Kjeldsen, Julie Westerlin">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Lorentzen, Cathrine Lund">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Martinenaite, Evelina">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author_institution" content="IO Biotech Aps, Copenhagen, Denmark">
    <meta name="citation_author" content="Ellebaek, Eva">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Donia, Marco">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Holmstroem, Rikke Boedker">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Klausen, Tobias Wirenfeldt">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Madsen, Cecilie Oelvang">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Ahmed, Shamaila Munir">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Weis-Banke, Stine Emilie">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Holmström, Morten Orebo">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Hendel, Helle Westergren">
    <meta name="citation_author_institution" content="Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author" content="Ehrnrooth, Eva">
    <meta name="citation_author_institution" content="IO Biotech Aps, Copenhagen, Denmark">
    <meta name="citation_author" content="Zocca, Mai-Britt">
    <meta name="citation_author_institution" content="IO Biotech Aps, Copenhagen, Denmark">
    <meta name="citation_author" content="Pedersen, Ayako Wakatsuki">
    <meta name="citation_author_institution" content="IO Biotech Aps, Copenhagen, Denmark">
    <meta name="citation_author" content="Andersen, Mads Hald">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="citation_author_institution" content="Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark">
    <meta name="citation_author" content="Svane, Inge Marie">
    <meta name="citation_author_institution" content="National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma">
    <meta name="twitter:description" content="Nature Medicine - A first-in-class immune-modulating IDO/PD-L1-targeting vaccine combined with nivolumab in a phase 1/2 trial achieved very promising clinical activity and long-lasting immune...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-021-01544-x">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma - Nature Medicine">
    <meta property="og:description" content="A first-in-class immune-modulating IDO/PD-L1-targeting vaccine combined with nivolumab in a phase 1/2 trial achieved very promising clinical activity and long-lasting immune responses in patients with advanced melanoma.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSIyMCIgaGVpZ2h0PSIyMCI+PHBhdGggZD0iTTcgMGExIDEgMCAxIDEgMCAySDIuNmMtLjM3MSAwLS42LjIwOS0uNi41djE1YzAgLjI5MS4yMjkuNS42LjVoMTQuOGMuMzcxIDAgLjYtLjIwOS42LS41VjEzYTEgMSAwIDAgMSAyIDB2NC41YzAgMS40MzgtMS4xNjIgMi41LTIuNiAyLjVIMi42QzEuMTYyIDIwIDAgMTguOTM4IDAgMTcuNXYtMTVDMCAxLjA2MiAxLjE2MiAwIDIuNiAwem02IDBoNmwuMDc1LjAwMy4xMjYuMDE3LjExMS4wMy4xMTEuMDQ0LjA5OC4wNTIuMDk2LjA2Ny4wOS4wOGExIDEgMCAwIDEgLjA5Ny4xMTJsLjA3MS4xMS4wNTQuMTE0LjAzNS4xMDUuMDMuMTQ4TDIwIDF2NmExIDEgMCAwIDEtMiAwVjMuNDE0bC02LjY5MyA2LjY5M2ExIDEgMCAwIDEtMS40MTQtMS40MTRMMTYuNTg0IDJIMTNhMSAxIDAgMCAxLS45OTMtLjg4M0wxMiAxYTEgMSAwIDAgMSAxLTEiLz48L3N2Zz4=");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 2px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 2px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: 1em}
.MathJax_MenuRadioCheck.RTL {right: 1em; left: auto}
.MathJax_MenuLabel {padding: 2px 2em 4px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #CCCCCC; margin: 4px 1px 0px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: Highlight; color: HighlightText}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style><style type="text/css">.MJX_Assistive_MathML {position: absolute!important; top: 0; left: 0; clip: rect(1px, 1px, 1px, 1px); padding: 1px 0 0 0!important; border: 0!important; height: 1px!important; width: 1px!important; overflow: hidden!important; display: block!important; -webkit-touch-callout: none; -webkit-user-select: none; -khtml-user-select: none; -moz-user-select: none; -ms-user-select: none; user-select: none}
.MJX_Assistive_MathML.MJX_Assistive_MathML_Block {width: 100%!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MJXp-script {font-size: .8em}
.MJXp-right {-webkit-transform-origin: right; -moz-transform-origin: right; -ms-transform-origin: right; -o-transform-origin: right; transform-origin: right}
.MJXp-bold {font-weight: bold}
.MJXp-italic {font-style: italic}
.MJXp-scr {font-family: MathJax_Script,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-frak {font-family: MathJax_Fraktur,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-sf {font-family: MathJax_SansSerif,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-cal {font-family: MathJax_Caligraphic,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-mono {font-family: MathJax_Typewriter,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-largeop {font-size: 150%}
.MJXp-largeop.MJXp-int {vertical-align: -.2em}
.MJXp-math {display: inline-block; line-height: 1.2; text-indent: 0; font-family: 'Times New Roman',Times,STIXGeneral,serif; white-space: nowrap; border-collapse: collapse}
.MJXp-display {display: block; text-align: center; margin: 1em 0}
.MJXp-math span {display: inline-block}
.MJXp-box {display: block!important; text-align: center}
.MJXp-box:after {content: " "}
.MJXp-rule {display: block!important; margin-top: .1em}
.MJXp-char {display: block!important}
.MJXp-mo {margin: 0 .15em}
.MJXp-mfrac {margin: 0 .125em; vertical-align: .25em}
.MJXp-denom {display: inline-table!important; width: 100%}
.MJXp-denom > * {display: table-row!important}
.MJXp-surd {vertical-align: top}
.MJXp-surd > * {display: block!important}
.MJXp-script-box > *  {display: table!important; height: 50%}
.MJXp-script-box > * > * {display: table-cell!important; vertical-align: top}
.MJXp-script-box > *:last-child > * {vertical-align: bottom}
.MJXp-script-box > * > * > * {display: block!important}
.MJXp-mphantom {visibility: hidden}
.MJXp-munderover, .MJXp-munder {display: inline-table!important}
.MJXp-over {display: inline-block!important; text-align: center}
.MJXp-over > * {display: block!important}
.MJXp-munderover > *, .MJXp-munder > * {display: table-row!important}
.MJXp-mtable {vertical-align: .25em; margin: 0 .125em}
.MJXp-mtable > * {display: inline-table!important; vertical-align: middle}
.MJXp-mtr {display: table-row!important}
.MJXp-mtd {display: table-cell!important; text-align: center; padding: .5em 0 0 .5em}
.MJXp-mtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-mlabeledtr {display: table-row!important}
.MJXp-mlabeledtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mlabeledtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-merror {background-color: #FFFF88; color: #CC0000; border: 1px solid #CC0000; padding: 1px 3px; font-style: normal; font-size: 90%}
.MJXp-scale0 {-webkit-transform: scaleX(.0); -moz-transform: scaleX(.0); -ms-transform: scaleX(.0); -o-transform: scaleX(.0); transform: scaleX(.0)}
.MJXp-scale1 {-webkit-transform: scaleX(.1); -moz-transform: scaleX(.1); -ms-transform: scaleX(.1); -o-transform: scaleX(.1); transform: scaleX(.1)}
.MJXp-scale2 {-webkit-transform: scaleX(.2); -moz-transform: scaleX(.2); -ms-transform: scaleX(.2); -o-transform: scaleX(.2); transform: scaleX(.2)}
.MJXp-scale3 {-webkit-transform: scaleX(.3); -moz-transform: scaleX(.3); -ms-transform: scaleX(.3); -o-transform: scaleX(.3); transform: scaleX(.3)}
.MJXp-scale4 {-webkit-transform: scaleX(.4); -moz-transform: scaleX(.4); -ms-transform: scaleX(.4); -o-transform: scaleX(.4); transform: scaleX(.4)}
.MJXp-scale5 {-webkit-transform: scaleX(.5); -moz-transform: scaleX(.5); -ms-transform: scaleX(.5); -o-transform: scaleX(.5); transform: scaleX(.5)}
.MJXp-scale6 {-webkit-transform: scaleX(.6); -moz-transform: scaleX(.6); -ms-transform: scaleX(.6); -o-transform: scaleX(.6); transform: scaleX(.6)}
.MJXp-scale7 {-webkit-transform: scaleX(.7); -moz-transform: scaleX(.7); -ms-transform: scaleX(.7); -o-transform: scaleX(.7); transform: scaleX(.7)}
.MJXp-scale8 {-webkit-transform: scaleX(.8); -moz-transform: scaleX(.8); -ms-transform: scaleX(.8); -o-transform: scaleX(.8); transform: scaleX(.8)}
.MJXp-scale9 {-webkit-transform: scaleX(.9); -moz-transform: scaleX(.9); -ms-transform: scaleX(.9); -o-transform: scaleX(.9); transform: scaleX(.9)}
.MathJax_PHTML .noError {vertical-align: ; font-size: 90%; text-align: left; color: black; padding: 1px 3px; border: 1px solid}
</style></head>
<body class="article-page"><div id="MathJax_Message" style="display: none;"></div><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-021-01544-x;doi=10.1038/s41591-021-01544-x;subjmeta=109,1634,1813,1941,2030,250,2779,308,575,590,631,67,692;kwrd=Melanoma,Peptide+vaccines,Phase+II+trials,Translational+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-933968079&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01544-x%26doi%3D10.1038/s41591-021-01544-x%26subjmeta%3D109,1634,1813,1941,2030,250,2779,308,575,590,631,67,692%26kwrd%3DMelanoma,Peptide+vaccines,Phase+II+trials,Translational+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=-933968079&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01544-x%26doi%3D10.1038/s41591-021-01544-x%26subjmeta%3D109,1634,1813,1941,2030,250,2779,308,575,590,631,67,692%26kwrd%3DMelanoma,Peptide+vaccines,Phase+II+trials,Translational+research"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-021-01544-x"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01544-x.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01544-x.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2021-12-09">09 December 2021</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma</h1>
                    <ul class="c-article-author-list c-article-author-list--short js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Julie_Westerlin-Kjeldsen-Aff1" data-author-popup="auth-Julie_Westerlin-Kjeldsen-Aff1" data-author-search="Kjeldsen, Julie Westerlin" data-track-context="researcher popup with no profile" data-track-index="1_17">Julie Westerlin Kjeldsen</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6201-1758"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6201-1758</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Cathrine_Lund-Lorentzen-Aff1" data-author-popup="auth-Cathrine_Lund-Lorentzen-Aff1" data-author-search="Lorentzen, Cathrine Lund" data-track-context="researcher popup with no profile" data-track-index="2_17">Cathrine Lund Lorentzen</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Evelina-Martinenaite-Aff1-Aff2" data-author-popup="auth-Evelina-Martinenaite-Aff1-Aff2" data-author-search="Martinenaite, Evelina" data-track-context="researcher popup with no profile" data-track-index="3_17">Evelina Martinenaite</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Eva-Ellebaek-Aff1" data-author-popup="auth-Eva-Ellebaek-Aff1" data-author-search="Ellebaek, Eva" data-track-context="researcher popup with no profile" data-track-index="4_17">Eva Ellebaek</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6748-9232"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6748-9232</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Marco-Donia-Aff1" data-author-popup="auth-Marco-Donia-Aff1" data-author-search="Donia, Marco" data-track-context="researcher popup with no profile" data-track-index="5_17">Marco Donia</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-4966-9752"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-4966-9752</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rikke_Boedker-Holmstroem-Aff1" data-author-popup="auth-Rikke_Boedker-Holmstroem-Aff1" data-author-search="Holmstroem, Rikke Boedker" data-track-context="researcher popup with no profile" data-track-index="6_17">Rikke Boedker Holmstroem</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-5476-9937"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-5476-9937</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Tobias_Wirenfeldt-Klausen-Aff1" data-author-popup="auth-Tobias_Wirenfeldt-Klausen-Aff1" data-author-search="Klausen, Tobias Wirenfeldt" data-track-context="researcher popup with no profile" data-track-index="7_17">Tobias Wirenfeldt Klausen</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Cecilie_Oelvang-Madsen-Aff1" data-author-popup="auth-Cecilie_Oelvang-Madsen-Aff1" data-author-search="Madsen, Cecilie Oelvang" data-track-context="researcher popup with no profile" data-track-index="8_17">Cecilie Oelvang Madsen</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Shamaila_Munir-Ahmed-Aff1" data-author-popup="auth-Shamaila_Munir-Ahmed-Aff1" data-author-search="Ahmed, Shamaila Munir" data-track-context="researcher popup with no profile" data-track-index="9_17">Shamaila Munir Ahmed</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Stine_Emilie-Weis_Banke-Aff1" data-author-popup="auth-Stine_Emilie-Weis_Banke-Aff1" data-author-search="Weis-Banke, Stine Emilie" data-track-context="researcher popup with no profile" data-track-index="10_17">Stine Emilie Weis-Banke</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-6037-494X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-6037-494X</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Morten_Orebo-Holmstr_m-Aff1" data-author-popup="auth-Morten_Orebo-Holmstr_m-Aff1" data-author-search="Holmström, Morten Orebo" data-track-context="researcher popup with no profile" data-track-index="11_17">Morten Orebo Holmström</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Helle_Westergren-Hendel-Aff3" data-author-popup="auth-Helle_Westergren-Hendel-Aff3" data-author-search="Hendel, Helle Westergren" data-track-context="researcher popup with no profile" data-track-index="12_17">Helle Westergren Hendel</a><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Eva-Ehrnrooth-Aff2" data-author-popup="auth-Eva-Ehrnrooth-Aff2" data-author-search="Ehrnrooth, Eva" data-track-context="researcher popup with no profile" data-track-index="13_17">Eva Ehrnrooth</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Mai_Britt-Zocca-Aff2" data-author-popup="auth-Mai_Britt-Zocca-Aff2" data-author-search="Zocca, Mai-Britt" data-track-context="researcher popup with no profile" data-track-index="14_17">Mai-Britt Zocca</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ayako_Wakatsuki-Pedersen-Aff2" data-author-popup="auth-Ayako_Wakatsuki-Pedersen-Aff2" data-author-search="Pedersen, Ayako Wakatsuki" data-track-context="researcher popup with no profile" data-track-index="15_17">Ayako Wakatsuki Pedersen</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Mads_Hald-Andersen-Aff1-Aff4" data-author-popup="auth-Mads_Hald-Andersen-Aff1-Aff4" data-author-search="Andersen, Mads Hald" data-track-context="researcher popup with no profile" data-track-index="16_17">Mads Hald Andersen</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff4" tabindex="-1">4</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 17 authors for this article" title="Show all 17 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Inge_Marie-Svane-Aff1" data-author-popup="auth-Inge_Marie-Svane-Aff1" data-author-search="Svane, Inge Marie" data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="17_17">Inge Marie Svane<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-9451-6037"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-9451-6037</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;27</b>,&nbsp;<span class="u-visually-hidden">pages </span>2212–2223 (<span data-test="article-publication-year">2021</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">27k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">131 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">152 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-021-01544-x/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            
                
                    <p class="u-mt-0">An <a href="https://doi.org/10.1038/s41591-022-01771-w" class="relation-link" data-track="click" data-track-action="view linked article" data-track-label="link">Author Correction</a> to this article was published on 08 March 2022</p>
                
            
        </div>
    

    
        <div class="u-mb-8 c-status-message c-status-message--boxed c-status-message--info">
            
                <span class="c-status-message__icon">
                    <svg class="u-icon" width="18" height="18" aria-hidden="true" focusable="false">
                        <use xlink:href="#icon-eds-i-info-filled-medium"></use>
                    </svg>
                </span>
            
            <p class="u-mt-0">This article has been <a href="#change-history">updated</a></p>
        </div>
    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-class immune-modulatory vaccine (IO102/IO103) against indoleamine 2,3-dioxygenase (IDO) and PD ligand 1 (PD-L1), targeting immunosuppressive cells and tumor cells expressing IDO and/or PD-L1 (IDO/PD-L1), combined with nivolumab. Thirty aPD1 therapy-naive patients with MM were treated in a phase 1/2 study (<a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a>, NCT03047928). The primary endpoint was feasibility and safety; the systemic toxicity profile was comparable to that of nivolumab monotherapy. Secondary endpoints were efficacy and immunogenicity; an objective response rate (ORR) of 80% (confidence interval (CI), 62.7–90.5%) was reached, with 43% (CI, 27.4–60.8%) complete responses. After a median follow-up of 22.9 months, the median progression-free survival (PFS) was 26 months (CI, 15.4–69 months). Median overall survival (OS) was not reached. Vaccine-specific responses assessed in vitro were detected in the blood of &gt;93% of patients during vaccination. Vaccine-reactive T cells comprised CD4<sup>+</sup> and CD8<sup>+</sup> T cells with activity against IDO- and PD-L1-expressing cancer and immune cells. T cell influx of peripherally expanded T cells into tumor sites was observed in responding patients, and general enrichment of IDO- and PD-L1-specific clones after treatment was documented. These clinical efficacy and favorable safety data support further validation in a larger randomized trial to confirm the clinical potential of this immunomodulating approach.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41586-020-2537-9/MediaObjects/41586_2020_2537_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41586-020-2537-9?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41586-020-2537-9">An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">29 July 2020</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-023-39196-9/MediaObjects/41467_2023_39196_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-023-39196-9?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41467-023-39196-9">A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">20 June 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-024-02851-9/MediaObjects/41591_2024_2851_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-024-02851-9?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41591-024-02851-9">A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">27 March 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749511057,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>Despite remarkable advances in the treatment of MM with immune checkpoint inhibitors (ICIs) targeting PD-1 and cytotoxic T lymphocyte antigen 4 (CTLA-4), around half of patients are resistant to ICI monotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20, 1239–1251 (2019)." href="/articles/s41591-021-01544-x#ref-CR1" id="ref-link-section-d74233406e652">1</a></sup>. The combination of anti-CTLA-4 (aCTLA-4) and aPD1 therapy is to date the most effective therapy resulting in a response rate of around 60%; however, 50% of the patients also develop severe adverse events<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Weber, J. S., Postow, M., Lao, C. D. &amp; Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21, 1230–1240 (2016)." href="/articles/s41591-021-01544-x#ref-CR2" id="ref-link-section-d74233406e656">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019)." href="/articles/s41591-021-01544-x#ref-CR3" id="ref-link-section-d74233406e659">3</a></sup>. Therefore, an equally effective but less toxic treatment is highly needed. Several approaches to enhance ICI efficacy are currently being investigated, such as other ICIs, T cell therapy with tumor-infiltrating T cells or innate immunity stimulators such as Toll-like receptor 9 agonists<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ascierto, P. A. et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann. Oncol. 28, v611–v612 (2017)." href="#ref-CR4" id="ref-link-section-d74233406e663">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Angeles, L. Warming ‘cold’ melanoma with TLR9 agonists. Cancer Discov. 8, 670 (2018)." href="#ref-CR5" id="ref-link-section-d74233406e663_1">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Mullinax, J. E. et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Front. Oncol. 8, 44 (2018)." href="/articles/s41591-021-01544-x#ref-CR6" id="ref-link-section-d74233406e666">6</a></sup>. Treating cancer patients with vaccines that stimulate a targeted immune response is another attractive approach, with very few side effects observed thus far in combination immunotherapy studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362 (2020)." href="/articles/s41591-021-01544-x#ref-CR7" id="ref-link-section-d74233406e670">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017)." href="/articles/s41591-021-01544-x#ref-CR8" id="ref-link-section-d74233406e673">8</a></sup>.</p><p>Immune-modulatory vaccines targeting tumoral immune escape mechanisms offer a new, generalizable strategy compared to patient-specific neoantigen cancer vaccines<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362 (2020)." href="/articles/s41591-021-01544-x#ref-CR7" id="ref-link-section-d74233406e680">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Andersen, M. H. Anti-cancer immunotherapy: breakthroughs and future strategies. Semin. Immunopathol. 41, 1–3 (2019)." href="/articles/s41591-021-01544-x#ref-CR9" id="ref-link-section-d74233406e683">9</a></sup>. The immune-modulatory vaccine strategy in this clinical trial is based on the finding of circulating cytotoxic T cells specific to IDO and PD-L1 in the blood of patients with cancer and, to a lesser extent, in healthy donors. IDO- and PD-L1-specific CD8<sup>+</sup> T cells can directly recognize and kill IDO<sup>+</sup> and/or PD-L1<sup>+</sup> tumor cells and likewise recognize and kill non-malignant cells that express their cognate targets. Furthermore, IDO- and PD-L1-specific CD4<sup>+</sup> T cells release pro-inflammatory cytokines in response to IDO- or PD-L1-expressing target cells. IDO and PD-L1 are expressed not only by melanoma cells but also by many other cell types in the tumor microenvironment (TME), which differentiates these antigens from traditional tumor antigens used in other studies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Munir, S., Andersen, G. H., Svane, I. M. &amp; Andersen, M. H. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells. Oncoimmunology 2, e23991 (2013)." href="#ref-CR10" id="ref-link-section-d74233406e696">10</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ahmad, S. M., Borch, T. H., Hansen, M. &amp; Andersen, M. H. PD-L1-specific T cells. Cancer Immunol. Immunother. 65, 797–804 (2016)." href="#ref-CR11" id="ref-link-section-d74233406e696_1">11</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Andersen, M. H. The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. Cancer Immunol. Immunother. 61, 1289–1297 (2012)." href="#ref-CR12" id="ref-link-section-d74233406e696_2">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sørensen, R. B. et al. Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res. 71, 2038–2044 (2011)." href="#ref-CR13" id="ref-link-section-d74233406e696_3">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ahmad, S. M., Larsen, S. K., Svane, I. M. &amp; Andersen, M. H. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 28, 236–238 (2014)." href="#ref-CR14" id="ref-link-section-d74233406e696_4">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Andersen, M. H. CD4 responses against IDO. Oncoimmunology 1, 1211–1212 (2012)." href="/articles/s41591-021-01544-x#ref-CR15" id="ref-link-section-d74233406e699">15</a></sup>. Activation of IDO/PD-L1-specific T cells by vaccination can therefore restrict the range of immunosuppressive signals mediated by immunosuppressive cells and thereby revert the TME from an immune hostile to an immune friendly environment. In animal models of cancer, vaccinations with IDO epitopes resulted in anti-tumor therapeutic effects that were correlated with reductions in IDO expression in myeloid cell populations within the TME<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Dey, S. et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J. Immunother. Cancer 8, e000605 (2020)." href="/articles/s41591-021-01544-x#ref-CR16" id="ref-link-section-d74233406e703">16</a></sup>. The IDO/PD-L1 immune-modulating vaccine may lead to a translatable strategy for improving the efficacy of aPD1 therapy through activation of specific T cells. We hypothesize that the IDO/PD-L1 vaccine attracts T cells into the tumor, which induces type 1 helper T (T<sub>H</sub>1) cell inflammation and reverts the TME into an immune-permissive site, thereby turning the tumor ‘hot’. This would also upregulate PD-L1 expression in cancer and immune cells, generating more susceptible targets to aPD1 therapy (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig6">1a</a>). This theory was confirmed in a mouse model in which aPD1 therapy and IDO vaccination show synergistic effects<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Dey, S. et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J. Immunother. Cancer 8, e000605 (2020)." href="/articles/s41591-021-01544-x#ref-CR16" id="ref-link-section-d74233406e712">16</a></sup>.</p><p>In this phase 1/2 clinical trial, MM1636, patients with MM received a combination of the IDO/PD-L1 (IO102/IO103) peptide vaccine with the adjuvant Montanide and the aPD1 antibody nivolumab. Patients were included in three cohorts: 30 aPD1 therapy-naive patients (cohort A), ten aPD1 therapy-refractory patients (cohort B, de novo resistance) and ten patients who progressed after aPD1 therapy (cohort C, acquired resistance). Here, we report results from cohort A.</p><p>The vaccine was given biweekly for the first six administrations and thereafter every 4th week. A maximum of 15 vaccines were administered. Nivolumab was given in parallel, biweekly (3 mg per kg) or every 4th week (6 mg per kg) for up to 2 years (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig6">1b</a>).</p><p>The primary objective was safety and feasibility. Secondary objectives were immunogenicity and clinical efficacy.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Patients and treatment</h3><p>Thirty patients were enrolled from December 2017 to June 2020. None of the 30 patients dropped out of the study; all received at least three cycles of therapy (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">1</a>). At the current database lock (5 October 2020), six patients were still on treatment in the trial.</p><p>Of the 24 patients who were not on trial treatment at data cutoff, two are still receiving nivolumab monotherapy (6 mg per kg every 4 weeks). Reasons for stopping treatment for the remaining 22 patients included disease progression (37%), toxicity (20%), maximum benefit or complete response (CR) confirmed on two consecutive scans (17%) or completing 2 years of treatment (7%).</p><p>For the 24 patients who were not on trial treatment at data cutoff, the mean number of vaccinations was 10.5 (range, 3–15 vaccinations). Thirteen of these 24 patients continued nivolumab (6 mg per kg, every 4 weeks) as a standard of care. Nine patients received subsequent therapy after progression (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">1</a>).</p><p>Baseline characteristics are shown in Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01544-x#Tab1">1</a>. The mean age was 70 years; 37% of patients had elevated lactate dehydrogenase (LDH) levels, 60% were stage M1c, 37% had <i>BRAF</i> mutations, and 43% were negative for PD-L1 (&lt;1%). A total of three patients (10%) had received prior ipilimumab therapy. No patients had brain metastasis (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">2</a>).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Baseline patient characteristics (<i>n</i> = 30)</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01544-x/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec4">Notable clinical responses to the combination therapy</h3><p>Thirty patients with MM were treated with the IDO/PD-L1 vaccine and nivolumab according to the trial protocol. By investigator review, the ORR reached 80% (CI, 62.7–90.5%), with 43% of patients (CI, 27.4–60.8%) achieving a CR and 37% (CI, 20.9–54.5%) reaching a partial response (PR) as the best overall response, while 20% experienced progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig1">1a</a>). Two of the patients with a PR did not have a confirmatory scan stating PR on two consecutive scans. Early onset of response was frequent, with 22 of 30 patients having an objective response at the first evaluation (after 12 weeks on treatment). Median times to PR and CR were 75 d (range, 54–256 d) and 327 d (range, 73–490 d), respectively (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig2">2a–c</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Clinical response."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Clinical response.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="622"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, Pie charts with percent ORR, CR, PR and PD according to RECIST 1.1 by investigator review of all patients (<i>n</i> = 30), PD-L1<sup>+</sup> patients (&gt;1%, (<i>n</i> = 17)) and PD-L1<sup>−</sup> patients (&lt;1%, <i>n</i> = 13)), respectively. Two-sided CIs (95%) were constructed using the Clopper–Pearson method. <b>b</b>, Treatment effect in MM1636 compared with a matched historical control group from the DAMMED database (<i>n</i> = 74). Patients in MM1636 (<i>n</i> = 29) were matched with the exact same combination variable according to age (≤70 years, &gt;70 years), sex, LDH levels (normal, elevated), M stage (M1a, M1b, M1c), <i>BRAF</i> status (wild type, mutated) and PD-L1 status (&lt;1%, ≥1%). Estimates for treatment effects were calculated by weighted logistic regression analyses and weighted Cox proportional hazard model. Bar height indicates the estimated response rate; tops of bars are centers for error bars. Odds ratios (OR), response rates and their corresponding 95% CIs were extracted from the regression model. All <i>P</i> values were two sided, and <i>P</i> values below 0.05 were considered statistically significant. <b>c</b>, Best change in the sum of target lesion size compared with that at baseline (<i>n</i> = 30). The horizontal line at −30 shows the threshold for defining an objective response in the absence of non-target disease progression or new lesions according to RECIST 1.1. Two patients with 100% reduction in target lesion size had non-target lesions present. White stars, six patients had normalization (&lt;10 mm) of fluor-18-deoxyglucose (FDG)-negative lymph nodes (at baseline, lymph nodes were &gt;1.5 cm and FDG<sup>+</sup>) and 100% reduction of non-lymph node lesions and are considered to have had a CR (green bar). Black star, one patient (MM29) was considered to have had a PR (blue bar), although he had not reached a −30% change in target lesion size. The patient had a single measurable 13-mm lung metastasis at baseline and multiple biopsy-verified cutaneous metastases on the left crus (not detectable by positron-emission tomography–computed tomography (PET–CT) at baseline). The best change in target lesion size was 10 mm, and a post-treatment biopsy from the cutaneous metastases showed no sign of malignancy. Thus, overall, the patient was classified as having a PR. <b>d</b>, Kaplan–Meier curve of the response duration in the 24 patients with an objective response. <b>e</b>, Kaplan–Meier curve of PFS in all 30 treated patients. <b>f</b>, Kaplan–Meier curve of OS in all 30 treated patients.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Clinical response."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Clinical response.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="1168"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>, Swimmer plot showing response duration and time to response according to RECIST 1.1 for all treated patients (<i>n</i> = 30). Triangles indicate first evidence of PR, while squares indicate first evidence of CR. Closed circles indicate time of progression. Arrows indicate ongoing responses. Patient MM18 died due to nivolumab-induced side effects. <b>b</b>, Spider plot showing response kinetics in all treated patients (<i>n</i> = 30). Red squares indicate time of progression. <b>c</b>, PET–CT images of patient MM42 before and after treatment (after 12 series of treatment) showing FDG metabolism in target lesions. SC, subcutaneous.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>The ORR among PD-L1<sup>+</sup> (&gt;1% (clone 28.8)) patients (<i>n</i> = 17) was 94.1% (CI, 73–99.7%) and 61.5% (CI, 35.5–82.3%) in PD-L1<sup>−</sup> patients (<i>n</i> = 13) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig1">1a</a>). Objective responses were observed in patients irrespective of human leukocyte antigen (HLA) genotype (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">2</a>).</p><p>Clinical response data were validated by blinded independent external review, in which an ORR of 76.6% (CI, 57.7–90.1%) was reported, with 53.3% of patients achieving a CR, 23.3% achieving a PR and 3.3% experiencing stable disease. Comparisons between investigator review and external review are outlined in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">3</a>.</p><p>To examine whether the very high response rate should be attributed to nivolumab or to the vaccine, we retrieved clinical response information from a matched historical control group using the Danish Metastatic Melanoma Database (DAMMED) from contemporaneously treated patients with stage 3–4 melanoma who received aPD1 monotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Ellebaek, E. et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 73, 101943 (2021)." href="/articles/s41591-021-01544-x#ref-CR17" id="ref-link-section-d74233406e1250">17</a></sup>. Patients were matched with the exact same combination variable according to age, sex, PD-L1 status, <i>BRAF</i> status, LDH level and M stage (those at stage M1d were excluded from the control group (no patients with brain metastasis)). Matched controls were identified for 29 patients, and the ORR of 79.3% (CI, 61.0–90.4%) observed in MM1636 was found to be significantly higher (<i>P</i> &lt; 0.0012) than that in the matched control group in which an ORR of 41.7% (CI, 31.0–53.3%) was reached. Furthermore, of the 29 patients in MM1636, a significantly (<i>P</i> &lt; 0.0017) higher percentage (41.4% (CI, 25.2–59.6%)) of patients achieved CR in MM1636 than that (12% (CI, 6.3–21.6%)) in the matched historical control group. ORR and complete response rate (CRR) in the matched historical control group were comparable to those of patients treated in randomized phase 3 pivotal trials with aPD1 monotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015)." href="/articles/s41591-021-01544-x#ref-CR18" id="ref-link-section-d74233406e1263">18</a></sup> (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig1">1b</a>).</p><h3 class="c-article__sub-heading" id="Sec5">The treatment leads to prolonged PFS</h3><p>At data cutoff, the median duration of response had not been reached, with 87% of all responding patients being free from progression at 12 months (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig1">1d</a>).</p><p>Patients were followed for up to 35 months with a median follow-up time of 22.9 months (CI, 14.9–26.2 months). OS and PFS were calculated from the first day of treatment to death or progression or to the date of the last follow-up (5 October 2020).</p><p>The median PFS (mPFS) for all treated patients was 26 months (CI, 15.4–69 months) and was not reached for responding patients (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig1">1e</a>). The median OS was not reached at the data cutoff. OS at 12 months was 81.6% (CI, 61.6–92%) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig1">1f</a>). One patient (MM18) with a CR died from nivolumab-related severe adverse events; the remaining patients died because of metastatic melanoma. For comparison, the mPFS was 8.3 months (CI, 5.5 months–NR (not reached)) in the matched historical control group (<i>n</i> = 74), while the median OS was 23.2 months (CI, 23.2 months–NR). (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig7">2a,b</a>).</p><h3 class="c-article__sub-heading" id="Sec6">The combination of the IDO/PD-L1 vaccine and nivolumab was safe</h3><p>Treatment-related adverse events are listed for all 30 patients in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">4</a>. Common treatment-related grade 1–2 toxicities were fatigue (47%), rash (47%), arthralgia (30%), diarrhea (23%), nausea (23%), dry skin (20%), pruritus (20%), infusion reaction (17%), xerostomia (17%) and myalgia (17%).</p><p>Four patients (13%) experienced grade 3–4 adverse events: one patient with a grade 3 maculopapular rash (MM01), one patient with grade 3 adrenal insufficiency (MM06) and one patient with grade 3 arthralgia (MM22).</p><p>Patient MM18 died from urosepsis with multi-organ failure and severe hyponatremia. This patient had experienced multiple immune-related adverse events with grade 3 colitis, grade 2 pneumonitis, grade 3 arthralgia, grade 2 vasculitis and grade 2 nivolumab infusion-related allergic reaction. Additionally, patient MM18 had symptoms of myocarditis at the time of death with highly elevated cardiac troponin I levels. Bedside echocardiography showed an ejection fraction of 15%, which at baseline was 60%, but an autopsy was not conducted, and myocarditis was never confirmed pathologically.</p><p>Patient MM06 had received first-line treatment with ipilimumab before entering the trial and was on substitution corticosteroids at the time of inclusion. Adrenal insufficiency was aggravated by an erysipelas infection with high fever, reaching grade 3 in Common Terminology Criteria for Adverse Events and resolving quickly after appropriate antibiotic therapy was initiated.</p><p>As expected, local side effects were common with 77% of the patients who developed injection site reactions. These reactions were classified as granulomas (63%), redness (20%), pain (13%) and pruritus (13%) at the injection site. All local reactions were grade 1–2, most likely related to the Montanide adjuvant and typically transient. However, two patients (MM07 and MM20) decided to discontinue vaccination after eight and 11 injections, respectively, due to granulomas, tenderness and pain that limited instrumental activities of daily living but continued to receive nivolumab (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig7">2c</a>).</p><h3 class="c-article__sub-heading" id="Sec7">Vaccine-specific responses in blood were frequently detected</h3><p>First, all 30 patients were assessed for the presence of vaccine-specific responses in peripheral blood mononuclear cells (PBMCs) before, on and after vaccination using a modified interferon (IFN)-γ enzyme-linked immune absorbent spot (ELISPOT) assay. This assay is known to expand antigen-specific memory cells and to improve the detection and the correlative power of ELISPOT during treatment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Godard, B. et al. Optimization of an Elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Hum. Immunol. 65, 1307–1318 (2004)." href="#ref-CR19" id="ref-link-section-d74233406e1336">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Meier, A. et al. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol. Immunother. 54, 219–228 (2005)." href="#ref-CR20" id="ref-link-section-d74233406e1336_1">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Calarota, S. A. et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J. Immunol. 180, 5907–5915 (2008)." href="/articles/s41591-021-01544-x#ref-CR21" id="ref-link-section-d74233406e1339">21</a></sup>.</p><p>Prevaccine IDO-specific responses were detectable in ten (33%) patients, while prevaccine PD-L1-specific responses were detectable in eight patients (27%); overlapping (specific to both IDO and PD-L1) prevaccine responses were present in four (13.3%) patients. During vaccination, an increase of IDO-specific T cells or PD-L1-specific T cells in the blood was observed in 28 (93%) and 26 (86%) patients, respectively. In total, 93% of patients had an increase in either PD-L1- or IDO-specific responses on vaccination (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig3">3a</a>), with a significant (<i>P</i> &lt; 0.0001) median increase from baseline to the post-vaccine response demonstrated for both IDO and PD-L1 (at different time points on treatment), confirming that vaccine-specific immune responses were induced in patients regardless of clinical response (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig3">3b,c</a>). Immune responses fluctuated in the blood over time (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig8">3a</a>). An increase in IDO- and PD-L1-specific responses in the peripheral blood was also detectable directly ex vivo across the different clinical response groups (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig9">4</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Vaccine-specific responses in blood."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Vaccine-specific responses in blood.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="786"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, IDO- and PD-L1-specific T cell responses in PBMCs at baseline and on vaccination as measured by the IFN-γ ELISPOT assay (<i>n</i> = 30). *Responses were calculated as the difference between the average numbers of spots in wells stimulated with IDO or PD-L1 peptide (triplicates) and those from the corresponding control (DMSO), and statistical analyses of ELISPOT responses were performed using a distribution-free resampling method (Moodie et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489–1501 (2010)." href="/articles/s41591-021-01544-x#ref-CR50" id="ref-link-section-d74233406e1379">50</a></sup>). DR (double response), response was not statistically confirmed due to replicate number, but the number of spots in peptide wells was two times higher than that in control wells (DMSO). NS, no significant response and no DR. For a detailed overview of responses at serial time points on vaccination, see Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig9">4a</a>. <b>b</b>, IDO- and PD-L1-specific T cell response in PBMCs in all treated patients measured by the IFN-γ ELISPOT assay at baseline and on vaccination. On-vaccination responses were selected from the ‘best’ ELISPOT response at different time points for each patient (series 3, 6, 12, 18 or 24) during vaccination (<i>n</i> = 30). Wilcoxon matched-pairs signed-rank test was used to compare responses to IDO or PD-L1 peptides in the vaccine between baseline and later time points. <b>c</b>, Representative example of ELISPOT wells with response in patient MM23 in serial PBMCs before and on treatment. <b>d</b>, IDO-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were isolated and expanded from PBMCs stimulated in vitro with the IDO peptide and a low dose of IL-2 for 14–15 d before sorting using the Miltenyi Cytokine Secretion Assay—Cell Enrichment and Detection kit. To assess their cytolytic potential, IDO-specific T cells were stimulated with IDO peptide, and expression of CD107a, IFN-γ and TNF-α was assessed by flow cytometry (the example is from patient MM14).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Sustained vaccine-specific responses were observed 3 and 6 months after the last vaccine, indicating induction of memory responses in nine patients with response to clinical treatment who surpassed follow-up at data lock (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig8">3b</a>). Importantly, PD-L1- and IDO-specific responses were observed irrespective of HLA genotype (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">5</a>).</p><p>To verify the functionality of vaccine-induced T cells, IDO- or PD-L1-specific T cells were isolated and in vitro expanded from PBMCs of five patients. Phenotypic characterization by flow cytometry revealed that the isolated vaccine-specific T cells consisted of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Also, both IDO- and PD-L1-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells showed pro-inflammatory properties, as they expressed the cytolytic marker CD107a and secreted the cytokines IFN-γ and tumor necrosis factor (TNF)-α (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig3">3d</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig11">6a–d</a>). Interestingly, we were also able to detect vaccine-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses in peripheral blood ex vivo (Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig9">4</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig10">5</a>). We observed a significant increase in the overall percentage of CD107a, CD137 and TNF-α expression in response to peptide stimulation in on- or post-treatment PBMC samples compared to that at baseline, further confirming the expansion and the diverse signature of vaccine-specific T cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig10">5</a>).</p><h3 class="c-article__sub-heading" id="Sec8">Vaccine-specific responses detected in the skin at the vaccination site</h3><p>To investigate whether vaccine-specific T cells have the potential to migrate to peripheral tissue, delayed-type hypersensitivity (DTH) tests were performed after six cycles of treatment on 15 patients to assess the presence of vaccine-reactive T cells in the skin. Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">6</a> display an overview of skin-infiltrating lymphocyte (SKIL) cultures.</p><p>We detected IDO-specific T cells in the skin of six of ten patients and PD-L1-specific T cells in nine of 11 patients (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig12">7a</a>). Intracellular cytokine staining was performed on SKILs from five patients after stimulation with either PD-L1 or IDO peptide. Here, we detected mainly CD4<sup>+</sup> peptide-reactive T cells that secreted TNF-α and upregulated CD107a, and a minor fraction also secreted IFN-γ. In one patient, we detected CD8<sup>+</sup> PD-L1-reactive T cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig12">7b–d</a>).</p><h3 class="c-article__sub-heading" id="Sec9">Vaccine-induced T cells specifically recognize target cells</h3><p>To confirm the functionality of vaccine-expanded T cells, vaccine-specific T cell clones (clonal purity was confirmed by T cell receptor (TCR) sequencing) were isolated and expanded from patient PBMCs (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig13">8e</a>). We showed that PD-L1-specific T cells were able to recognize PD-L1<sup>+</sup> autologous tumor cells in a PD-L1 expression-dependent manner if the cancer cells also expressed HLA-II (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig4">4a,b</a>). Similarly, an HLA-DR-restricted IDO-specific CD4<sup>+</sup> T cell clone was able to recognize an HLA-DR-matched IDO-expressing model cell line, MonoMac1, in an IDO-expression-dependent manner (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig4">4e–g</a>). As previously described, IDO- and PD-L1-specific T cells’ mode of action is not limited to targeting only cancer cells. We were able to show that vaccine-specific T cell clones also reacted against PD-L1- and IDO-expressing autologous immune cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig4">4c,h</a>). To provide myeloid cells with a tumor-associated phenotype we treated isolated CD14<sup>+</sup> myeloid cells with tumor conditioned medium (TCM) derived from an established autologous tumor cell line. We observed that such TCM-treated CD14<sup>+</sup> cells had increased expression of PD-L1 and IDO and were effectively recognized by autologous PD-L1- and IDO-specific CD4<sup>+</sup> T cell clones (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig4">4c,d,h,i</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="PD-L1- and IDO-specific T cells from vaccinated patients react against PD-L1- and IDO-expressing target cells."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: PD-L1- and IDO-specific T cells from vaccinated patients react against PD-L1- and IDO-expressing target cells.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="769"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>, Left, PD-L1-specific T cell culture (MM1636.05) reactivity against PD-L1 peptide or autologous tumor cells in the IFN-γ ELISPOT assay. Tumor cells were either not treated or pretreated with 200 U ml<sup>−1</sup> IFN-γ for 48 h before the assay. Effector:target (E:T) ratio of 10:1 was used. Right, PD-L1 and HLA-II surface expression on melanoma cells with (green) or without (yellow) pretreatment with IFN-γ compared to an isotype control (gray) as assessed by flow cytometry. <b>b</b>, Left, PD-L1-specific T cell (MM1636.05) reactivity in the IFN-γ ELISPOT assay against autologous tumor cells pretreated with IFN-γ (500 U ml<sup>−1</sup>) and transfected with mock or PD-L1 small interfering (si)RNA 24 h after transfection. E:T ratio, 10:1. Right, PD-L1 surface expression on melanoma tumor cells (MM1636.05) assessed by flow cytometry 24 h after transfection with mock (blue) or PD-L1 (red) siRNA compared to the isotype control (gray). <b>c</b>, Reactivity of the CD4<sup>+</sup> PD-L1-specific T cell clone (MM1636.14) against PD-L1 peptide or autologous CD14<sup>+</sup> cells; E:T ratio, 10:1. CD14<sup>+</sup> cells were isolated using magnetic bead sorting and used as targets in an ELISPOT assay directly or after pretreatment for 2 d with TCM derived from the autologous tumor cell line. <b>d</b>, Quantitative PCR with reverse transcription (RT–qPCR) analysis of <i>PD-L1</i> (<i>CD274</i>) expression in sorted CD14<sup>+</sup> cells before and after treatment with autologous TCM for 48 h. <b>e</b>, Reactivity of the IDO-specific CD4<sup>+</sup> T cell clone (MM1636.23) against IDO peptide combined with HLA-DR (L243)-, HLA-DQ (SPV-L3)- or HLA-DP (B7/21)-blocking antibodies (aHLA-DR, aHLA-DQ and aHLA-DP) in an intracellular staining assay (ICS) for IFN-γ and TNF-α production. T cells were incubated with individual blocking antibodies (2 μg ml<sup>−1</sup>) for 30 min before adding IDO peptide. <b>f</b>, Reactivity of the IDO-specific CD4<sup>+</sup> T cell clone (MM1636.23) against the HLA-DR-matched IDO-expressing cell line MonoMac1 transfected with mock or IDO siRNA in an ICS assay, E.T ratio, 4:1. siRNA transfection was performed 48 h before the experiment. <b>g</b>, RT–qPCR analysis of <i>IDO1</i> expression in MonoMac1 cells 48 h after siRNA transfection. <b>h</b>, Reactivity of the CD4<sup>+</sup> IDO-specific T cell clone (MM1636.14) against IDO peptide or autologous CD14<sup>+</sup> cells; E:T ratio, 20:1. CD14<sup>+</sup> cells were isolated using magnetic bead sorting and used as targets in an ELISPOT assay directly or after pretreatment with TCM derived from the autologous tumor cell line. <b>i</b>, RT–qPCR analysis of <i>IDO1</i> expression in sorted CD14<sup>+</sup> cells before and after treatment with autologous TCM for 48 h. Bars in RT–qPCR data (<b>d</b>,<b>g</b>,<b>i</b>) represent the mean of three (<b>d</b>,<b>i</b>) or six (<b>g</b>) technical replicates ±s.d.; <i>P</i> values were determined by two-tailed parametric <i>t</i>-tests. ELISPOT counts (<b>a</b>,<b>b</b>,<b>c</b>,<b>h</b>) represent the mean value of three technical replicates ±s.e.m.; response <i>P</i> values were determined using the distribution-free resampling (DFR) method. TNTC, too numerous to count.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec10">T cell clones in blood and tumors</h3><p>To track the role of treatment-induced T cell responses, TCR sequencing of the complementarity-determining region 3 (CDR3) was performed on five patients in peripheral blood (baseline and cycles 3, 6 and 12) and paired biopsies. These five patients (MM01, MM02, MM08, MM09 and MM13) were selected due to the availability of material and to investigate a balanced patient group with both responders and non-responders. Due to a limited number of available paired biopsies (either as a consequence of patient refusal or unexpectedly rapid and substantial clinical responses), statistical analysis could not be applied. Details on clinical response are shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig2">2a</a>. Additionally, PBMCs (on treatment) or SKILs were stimulated with the IDO/PD-L1 peptides, and then cytokine-producing T cells were sorted to track vaccine-induced T cells both in the periphery and at the tumor site.</p><p>To identify enriched IDO/PD-L1-specific T cell clones, TCR rearrangements in sorted IDO/PD-L1-specific clones and TCR rearrangements in sorted IDO/PD-L1-specific T cell samples were compared to sequences from baseline PBMC samples for each patient. Clonal expansion of vaccine-specific TCR rearrangements from samples on vaccination were then tracked using a differential abundance framework. Cumulative IDO/PD-L1-specific T cell frequencies were tracked in post-treatment samples.</p><p>We found no relation between clinical response and the enrichment of vaccine-specific clones, but an increase in IDO/PD-L1-specific T cell clones was observed at different time points in the periphery in all five patients (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig8">3c</a>).</p><p>We next investigated overall changes in the T cell repertoire in the blood. A modest increase in the peripheral T cell fraction was observed in the three responding patients at cycle 3, while the two non-responding patients had a clear decrease in T cell fraction (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig13">8a</a>). We thereafter investigated TCR clonality and TCR repertoire richness, exploring the proportion of abundant clones and the number of unique rearrangements, respectively. A decreasing peripheral Simpson clonality and increasing TCR repertoire richness was observed in responding patients at cycle 3, which might indicate tumor trafficking upon treatment. The opposite pattern was observed in non-responding patients (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig13">8b,c</a>).</p><p>Peripherally expanded clones were associated with tumors and persisted until cycle 12 (latest time point analyzed). The largest peripheral expansion was observed at cycle 3, with the most significant increase observed in patient MM01 (CR). Responding patients had a larger fraction of peripherally expanded clones that were also found in tumors compared to that of non-responders. By tracking peripherally expanded clones detected at the tumor site, we observed that patient MM01 had a substantial increase after treatment, indicating tumor trafficking of peripheral expanded clones (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig13">8d</a>).</p><h3 class="c-article__sub-heading" id="Sec11">Influx at the tumor site of vaccine-enriched T cell clones</h3><p>Given the observation of increased T cell fraction and enrichment of IDO- and PD-L1-specific clones in the blood after treatment, we investigated whether the same trend was observed at the tumor site.</p><p>Both TCR sequencing and immunohistochemistry (IHC) of paired biopsies from the five patients described above showed an increase in the T cell fraction with an influx of CD3<sup>+</sup> and CD8<sup>+</sup> T cells after treatment in the three responding patients (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig5">5a–c</a>). IHC was not possible for patient MM09 due to tissue loss.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Changes in the TME after treatment. Number of CD3+ and CD8+ T cells, TCR fraction, TCR clonality, TCR repertoire, biopsy expanded TCR clones and enrichment of IDO- and PD-L1-specific T cells at the tumor site."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Changes in the TME after treatment. Number of CD3<sup>+</sup> and CD8<sup>+</sup> T cells, TCR fraction, TCR clonality, TCR repertoire, biopsy expanded TCR clones and enrichment of IDO- and PD-L1-specific T cells at the tumor site.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="553"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>a</b>, Number of CD3<sup>+</sup> and CD8<sup>+</sup> T cells per mm<sup>2</sup> (sum in the validated area) at the tumor site detected by IHC of paired biopsies from four patients. <b>b</b>, Example of IHC of CD3<sup>+</sup> and CD8<sup>+</sup> T cells at the tumor site before and after treatment (cells per mm<sup>2</sup>) in one patient (MM01). <b>c</b>, T cell fraction at the tumor site at baseline and cycle 6 by TCR sequencing. The T cell fraction was calculated by taking the total number of T cell templates and dividing by the total number of nucleated cells. <b>d</b>, Tracking of vaccine-associated clones at baseline and cycle 6 in tumor biopsies. Cumulative frequencies of IDO and PD-L1 vaccine-specific TCR rearrangements are represented. <b>e</b>,<b>f</b>, TCR clonality and TCR repertoire richness in five patients at the tumor site at baseline and cycle 6. Simpson clonality measures how evenly TCR sequences are distributed among a set of T cells, where 0 indicates an even distribution of frequencies and 1 indicates an asymmetric distribution in which a few clones dominate. TCR repertoire richness reports the mean number of unique rearrangements. <b>g</b>, Bar chart representing baseline expanded biopsy clones from five patients (colored bars) and the detection of biopsy expanded clones also found in the blood at baseline and series 3, 6 and 12 (white and gray bars) by TCR sequencing.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01544-x/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>We thereafter investigated whether some of the IDO/PD-L1 vaccine-linked T cells were present at the tumor site. Vaccine-associated clones were tracked as the combined frequency of IDO- and PD-L1-specific T cell rearrangements. In biopsies, the frequencies at cycle 6 were compared to those at baseline and showed an increase in vaccine-specific T cells in four of five patients, irrespective of clinical response (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig5">5d</a>). TCR sequencing of PD-L1-specific SKILs (a more specific culture than IDO/PD-L1-specific isolations derived from PBMCs on vaccination) and paired biopsies showed that two of the top five PD-L1-specific SKIL clones were present at the tumor site both before and after treatment (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig12">7e,f</a>).</p><p>With a focus on the more abundant T cell clones, we investigated overall TCR clonality at the tumor site before and after treatment. In addition, we explored the number of unique TCR rearrangements, dissecting the lower-frequency clones. Patient MM01 had a significant increase in TCR clonality and a decrease in repertoire richness at the tumor site after therapy, indicating a focused tumor repertoire response of selected clones. All three responding patients had a decrease in TCR repertoire richness, which again might indicate a focused tumor response (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig5">5e,f</a>).</p><p>Deeper analyses showed that the T cell clones that expanded at the tumor site after therapy were also present in the blood at baseline and increased significantly after treatment in four of five patients. The highest proportion was detected early at cycle 3. These data again support trafficking of peripherally expanded clones to the tumor site and could indicate that the T cell response to treatment is derived from pre-existing peripherally tumor-associated T cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig5">5g</a>).</p><h3 class="c-article__sub-heading" id="Sec12">Signs of treatment-induced inflammation in the TME</h3><p>To dissect changes in the TME induced by T cell influx upon treatment in responding patients, RNA gene expression analyses using the nCounter PanCancer Immune Profiling Panel from NanoString were performed on paired biopsies from two responding patients (MM01 and MM13). Expression of genes related to adaptive immunity such as T cell activation, effector functions (genes encoding IFN-γ, TNF-α, IL-15 and IL-18) and cytotoxicity was increased in post-treatment biopsies (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig14">9a,b</a>). Also, expression of genes related to checkpoint inhibitors such as those encoding T cell immunoglobulin and mucin-domain containing-3 (TIM-3), IDO, PD-L1, PD-L2, PD-1 and CTLA-4 increased after treatment, indicating activation of immune cells in the TME (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig14">9c</a>).</p><p>Additionally, IHC of paired biopsies from four patients (MM01, MM02, MM05 and MM13) showed an upregulation of PD-L1, IDO, MHC-I and MHC-II on tumor cells, indicating a treatment-induced pro-inflammatory response in the three responding patients, except for a decrease in MHC-II expression in patient MM13. By contrast, the non-responding patient MM02 had a reduction in T cell numbers present in the tumor after treatment and no expression of PD-L1, IDO or MHC-II and, interestingly, total loss of MHC-I, demonstrating tumor immune escape (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig15">10a</a>).</p><p>CD8<sup>+</sup> T cells and their distance (µm) to PD-L1-expressing cells in baseline biopsies from five patients was investigated by IHC. Except for patient MM13 (PR), distance and clinical responses were associated: the two responders had reduced distance (&lt;20 µm) between cells expressing these markers compared to non-responding patients (&gt;80 µm). This observation indicates that responding patients not only have a higher intratumoral infiltration of CD8<sup>+</sup> T cells, but that these cells can surround and attack PD-L1-expressing immune cells and tumor cells (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig15">10b</a>).</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec13-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec13">Discussion</h2><div class="c-article-section__content" id="Sec13-content"><p>In this clinical trial, MM1636, 30 patients with metastatic melanoma were treated with a first-in-class immunomodulatory IDO/PD-L1-targeting peptide vaccine combined with nivolumab. The treatment led to an unprecedented high ORR of 80%, with 43% of patients reaching a CR, and a striking mPFS of 26 months (95% CI, 15.4–69 months) was reached. The vaccine represents a new treatment strategy to activate specific T cells that target cells contributing to immune suppression (including tumor cells), positively modulating the TME by inducing local inflammation. Indeed, we show that vaccine-specific T cells isolated and expanded from vaccinated patients recognize not only tumor cells in a target- and HLA-restricted manner but also myeloid cells polarized toward a tumor-associated phenotype. Hence, myeloid cells become targets for vaccine-activated T cells when they have a tumor-associated phenotype in the TME. These phenomena may further induce checkpoint molecules and rewire the TME toward an increasingly aPD1-permissive state.</p><p>A drawback of our study is the single-center nonrandomized setup. Comparison between trials or between patients in trials and real-world patients is problematic due to multiple factors, such as period of conduction and other therapies available at the different periods of time. Nevertheless, the rate of investigator-assessed ORR in the phase 3 trial CheckMate 067 was 43.7% in the nivolumab monotherapy group and 57% in the nivolumab and ipilimumab group. CRs occurred in 8.9% and 11.5% of patients, respectively<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015)." href="/articles/s41591-021-01544-x#ref-CR18" id="ref-link-section-d74233406e1815">18</a></sup>. The mPFS of 26 months (95% CI, 15.4–69 months) in this trial is more than twice as long as that for patients treated with nivolumab and ipilimumab in CheckMate 067, for which an mPFS of 11.5 months (95% CI, 8.7–19.3 months) was reached.</p><p>Patient baseline characteristics were in general comparable to those of patients with MM who have been treated in CheckMate 067, although patients in MM1636 were older (mean age, 70 years) and a larger fraction were positive for PD-L1 (57%)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019)." href="/articles/s41591-021-01544-x#ref-CR3" id="ref-link-section-d74233406e1822">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015)." href="/articles/s41591-021-01544-x#ref-CR18" id="ref-link-section-d74233406e1825">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017)." href="/articles/s41591-021-01544-x#ref-CR22" id="ref-link-section-d74233406e1828">22</a></sup>. Among patients with PD-L1-negative tumors in MM1636, an ORR of 61.5% was still reached, which would be expected to be around 33% for first-line nivolumab monotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015)." href="/articles/s41591-021-01544-x#ref-CR23" id="ref-link-section-d74233406e1832">23</a></sup>. Some studies suggest that older patients might have a tendency to respond better to aPD1 therapy; however, this is still debated<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Iii, C. H. K. et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347–5356 (2019)." href="#ref-CR24" id="ref-link-section-d74233406e1836">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bastholt, L. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. Eur. J. Cancer 119, 122–131 (2019)." href="#ref-CR25" id="ref-link-section-d74233406e1836_1">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Yan, X., Tian, X., Wu, Z. &amp; Han, W. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. Front. Oncol. 10, 1671 (2020)." href="#ref-CR26" id="ref-link-section-d74233406e1836_2">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Huang, X. Z. et al. Efficacy of immune checkpoint inhibitors and age in cancer patients. Immunotherapy 12, 587–603 (2020)." href="/articles/s41591-021-01544-x#ref-CR27" id="ref-link-section-d74233406e1839">27</a></sup>.</p><p>To address potential trial bias and the nonrandomized setup, patients in MM1636 were matched for age, performance status, sex, M stage, LDH level, PD-L1 status and <i>BRAF</i> status with a historical control group from the DAMMED, who were treated contemporarily (2015–2019) with aPD1 monotherapy as standard of care<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Ellebaek, E. et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 73, 101943 (2021)." href="/articles/s41591-021-01544-x#ref-CR17" id="ref-link-section-d74233406e1849">17</a></sup>. We found a significantly higher ORR and CRR in MM1636 compared to those of matched patients, who had an ORR of 43% and a CRR of 13%, comparable to patients treated in CheckMate 067. Restrictions of the synthetic control group are of course that it is partially historic and patient selection outside matching criteria cannot be ruled out<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Khozin, S., Blumenthal, G. M. &amp; Pazdur, R. Real-world data for clinical evidence generation in oncology. J. Natl Cancer Inst. 109, 1359–1360 (2017)." href="/articles/s41591-021-01544-x#ref-CR28" id="ref-link-section-d74233406e1853">28</a></sup>.</p><p>Numerous contemporary clinical trials are exploring the combination of aPD1 therapy with other immunomodulating agents for advanced melanoma.</p><p>Talimogene laherparepvec, an oncolytic virus, is approved by the Food and Drug Administration and the European Medicines Agency to treat advanced melanoma. A small phase 1b trial with 21 patients (MASTERKEY-265) combined talimogene laherparepvec and pembrolizumab to treat patients with advanced unresectable melanoma and reached an ORR of 62% and a CR of 33%<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017)." href="/articles/s41591-021-01544-x#ref-CR29" id="ref-link-section-d74233406e1864">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Long, G. et al. 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB–IVM1c melanoma. J. Immunother. Cancer 8, A261 (2020)." href="/articles/s41591-021-01544-x#ref-CR30" id="ref-link-section-d74233406e1867">30</a></sup>. Seventy-one percent of the patients in this trial had an M stage below M1c; this number was 40% in our trial. Furthermore, mainly patients with an M stage below M1c responded to treatment, which was not the case in MM1636. Results from a large randomized phase 3 trial are awaited (KEYNOTE-034).</p><p>Epacadostat, an IDO inhibitor, was tested in combination with pembrolizumab in a nonrandomized phase 2 trial in 40 aPD1 treatment-naive patients with MM with promising results, reaching an ORR of 62%. Unfortunately, the phase 3 trial showed no indication that epacadostat provided improvement in PFS and OS<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083–1097 (2019)." href="/articles/s41591-021-01544-x#ref-CR31" id="ref-link-section-d74233406e1874">31</a></sup>. Limitations of the phase 3 trial were the sparse information on pharmacodynamics as well as biomarker evaluation to improve the design. The IDO/PD-L1 vaccine is different from epacadostat, as it is not an IDO inhibitor but targets IDO- and PD-L1-expressing cells. Similar vaccines administered as monotherapy induced objective responses in lung cancer and basal cell carcinoma, while epacadostat as monotherapy in 52 patients resulted in no responses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Iversen, T. Z. et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin. Cancer Res. 20, 221–232 (2014)." href="/articles/s41591-021-01544-x#ref-CR32" id="ref-link-section-d74233406e1878">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Kjeldsen, J. W. et al. Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study—a brief research report. Front. Immunol. 9, 2145 (2018)." href="/articles/s41591-021-01544-x#ref-CR33" id="ref-link-section-d74233406e1881">33</a></sup>.</p><p>Sahin et al. recently published encouraging data from a first-in-human trial, in which a vaccine containing liposomal RNA targeting four unmutated tumor-associated antigens (NY-ESO-1, MAGE-A3, tyrosinase and TPTE) was administered alone or in combination with nivolumab in patients with advanced melanoma. Responses were observed in both the monotherapy group as well as the combination group in checkpoint inhibitor-experienced patients, suggesting the efficacy of non-mutant shared tumor antigen vaccines<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107–112 (2020)." href="/articles/s41591-021-01544-x#ref-CR34" id="ref-link-section-d74233406e1888">34</a></sup>.</p><p>The overall safety and tolerability findings are comparable to those of aPD1 monotherapy. Injection site reactions were exclusive to the vaccine. However, these side effects were transient and mild in most patients and most likely due to the adjuvant Montanide. IDO- and PD-L1-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells exist among peripheral blood lymphocytes in healthy donors<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sørensen, R. B. et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117, 2200–2210 (2011)." href="#ref-CR35" id="ref-link-section-d74233406e1899">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Søorensen, R. B. et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS ONE 4, e6910 (2009)." href="#ref-CR36" id="ref-link-section-d74233406e1899_1">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Munir, S. et al. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS ONE 7, e34568 (2012)." href="#ref-CR37" id="ref-link-section-d74233406e1899_2">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Munir, S. et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 73, 1764–1776 (2013)." href="/articles/s41591-021-01544-x#ref-CR38" id="ref-link-section-d74233406e1902">38</a></sup> and expand in response to pro-inflammatory stimuli<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Sørensen, R. B. et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117, 2200–2210 (2011)." href="/articles/s41591-021-01544-x#ref-CR35" id="ref-link-section-d74233406e1906">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Andersen, M. H. The targeting of tumor-associated macrophages by vaccination. Cell Stress 3, 139–140 (2019)." href="/articles/s41591-021-01544-x#ref-CR39" id="ref-link-section-d74233406e1909">39</a></sup>. Furthermore, both IDO and PD-L1 are induced in cells as a counter response to the inflammatory response. This provides a mechanism that ensures immune homeostasis, which keeps IDO/PD-L1-specific T cells in check; therefore, the risk of triggering autoimmune-related adverse events by vaccination appears to be minimal. This was confirmed in the first clinical trials of IDO and PD-L1 vaccination (<a href="https://clinicaltrials.gov/ct2/show/NCT01543464">NCT01543464</a> (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Kjeldsen, J. W. et al. Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study—a brief research report. Front. Immunol. 9, 2145 (2018)." href="/articles/s41591-021-01544-x#ref-CR33" id="ref-link-section-d74233406e1921">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin. Cancer Res. 22, 3734–3745 (2016)." href="/articles/s41591-021-01544-x#ref-CR40" id="ref-link-section-d74233406e1924">40</a></sup>) and <a href="https://clinicaltrials.gov/ct2/show/NCT03042793">NCT03042793</a> (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Jørgensen, N. G. et al. Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: a phase I first-in-human trial. Front. Immunol. 11, 595035 (2020)." href="/articles/s41591-021-01544-x#ref-CR41" id="ref-link-section-d74233406e1935">41</a></sup>)).</p><p>The spontaneous (baseline) immune response to the vaccines observed in the current study is in agreement with our previous observation in various patients with cancer<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sørensen, R. B. et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117, 2200–2210 (2011)." href="#ref-CR35" id="ref-link-section-d74233406e1942">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Søorensen, R. B. et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS ONE 4, e6910 (2009)." href="#ref-CR36" id="ref-link-section-d74233406e1942_1">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Munir, S. et al. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS ONE 7, e34568 (2012)." href="#ref-CR37" id="ref-link-section-d74233406e1942_2">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Munir, S. et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 73, 1764–1776 (2013)." href="/articles/s41591-021-01544-x#ref-CR38" id="ref-link-section-d74233406e1945">38</a></sup>. Numerous vaccine-induced changes in the blood and at the tumor site were observed. Peripheral IDO- and/or PD-L1-specific T cells were detected in vitro in a modified ELISPOT in over 93% of patients on vaccination, unrelated to patient HLA type. Immune responses were persistent in patients who surpassed follow-up at data cutoff and were still detectable up to 6 months after the last vaccine, suggesting induction of memory T cells. We did not observe a correlation between vaccine-induced responses in blood and clinical responses. However, the detection of a highly significant increase in vaccine-specific T cell numbers after vaccination in almost all patients together with the very low number of patients with PD makes it difficult to expect such a correlation, especially because other aspects should be taken into account (for example, the loss of class I expression on tumors cells in patient MM02 with PD after vaccination). Frequencies of peripheral T cells induced against PD-L1 were overall higher than those against IDO. Importantly, however, we also observed that it was not the same patients who responded strongly to both IDO and PD-L1, nor did patients react with a similar response pattern to the two antigens; that is, different time points of response were observed. This suggests that each component of the vaccine plays different roles in the ongoing immune response in patients. The goal of IDO/PD-L1 vaccination was to modulate the TME to increase responsiveness to aPD1 therapy, as we have observed in animal models, in which immune conversion is demonstrated in the TME with an increased influx of T cells. Targeting both IDO and PD-L1 together enables synergy, as the TME is known to use different immune escape mechanisms and IDO and PD-L1 are often overexpressed by different cellular compartments. Ex vivo ELISPOT and flow cytometry assays confirmed the induction of immune response toward both epitopes and the higher immunogenicity of the PD-L1 epitope, although because of lower sensitivity failed to detect some of the responses. TCR sequencing of five patients confirmed enrichment of IDO/PD-L1-specific T cell clones in the blood at different time points after treatment. Furthermore, an increase in enriched IDO/PD-L1-specific clones was observed in four of five patients at the tumor site after treatment, irrespective of clinical response.</p><p>Phenotypic characterization showed that vaccine-specific T cells, which were expanded in vitro with interleukin (IL)-2 from the blood of vaccinated individuals, were both CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells. This was confirmed by ex vivo phenotype description of vaccine-activated T cells. Vaccine-specific T cells expressed CD107a and CD137 and produced IFN-γ and TNF-α upon stimulation with the cognate target, indicating their cytolytic capacity.</p><p>Overall, the data from immune monitoring supports the importance of both antigens in the generation of the frequent clinical responses in the study.</p><p>Despite a limited number of paired biopsies (due to either patient refusal or the fact that a large fraction of responding patients had no assessable tumors after six cycles), we observed trends indicating treatment-induced general T cell influx in responding patients. It was shown that proliferation of CD8<sup>+</sup> T cells in the tumor after aPD1 treatment is associated with radiographic reduction in tumor size<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)." href="/articles/s41591-021-01544-x#ref-CR42" id="ref-link-section-d74233406e1965">42</a></sup>. Additionally, we showed that a large proportion of expanded peripheral TCR clones were associated with tumors and the most considerable amount of clonal expansion was observed early, at cycle 3. For the patient with a CR included in the TCR sequencing analyses (MM01), the number of peripheral expanded clones present at the tumor site increased after treatment compared to that at baseline, indicating tumor trafficking of peripheral expanded clones.</p><p>Gene expression analyses (two paired biopsies) and IHC (five paired biopsies) further demonstrated that the combination treatment induced a pro-inflammatory TME in responding patients with signs of T cell activation and cytotoxicity and increased cytokine activity. This may lead to further upregulation of IDO, PD-L1, MHC-I and MHC-II on tumor cells, leading to more treatment targets. It was shown that, following vaccination with a cancer vaccine, PD-L1 expression is increased on tumor cells due to recruitment of tumor-specific T cells and upregulation of adaptive immune resistance pathways in the TME<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Wang, T. et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat. Commun. 9, 1532 (2018)." href="/articles/s41591-021-01544-x#ref-CR43" id="ref-link-section-d74233406e1972">43</a></sup>. Treatment with nivolumab monotherapy enhances PD-L1 expression, and it is therefore problematic to discriminate the effect of the vaccine as compared to that of nivolumab<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Vilain, R. E. et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. Clin. Cancer Res. 23, 5024–5033 (2017)." href="/articles/s41591-021-01544-x#ref-CR44" id="ref-link-section-d74233406e1976">44</a></sup>.</p><p>IDO- and PD-L1-specific pro-inflammatory effector T cells were hypothesized to counteract the functions of IDO- and PD-L1-expressing immune-suppressive cells as a means to keep the immune balance between immune activation and inhibition<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Andersen, M. H. The balance players of the adaptive immune system. Cancer Res. 78, 1379–1382 (2018)." href="/articles/s41591-021-01544-x#ref-CR45" id="ref-link-section-d74233406e1983">45</a></sup>. However, because the expression of these molecules is induced as a counter-regulatory response to inflammatory mediators such as IFNs, they can also be expressed by, for example, activated myeloid cells or T cells. Thus, activation of PD-L1-specific T cells may result in depletion of activated T cells in the tumor and other sites. Importantly, it was recently described that PD-L1<sup>+</sup> T cells mainly have tolerogenic effects on tumor immunity and exert tumor-promoting properties, suggesting that targeting this immune population is indeed also beneficial<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat. Immunol. 21, 442–454 (2020)." href="/articles/s41591-021-01544-x#ref-CR46" id="ref-link-section-d74233406e1989">46</a></sup>. We have previously investigated the effect of activating PD-L1-specific T cells in vitro and in vivo and found that, overall, they supported the effector phase of an immune response by removing PD-L1-expressing regulatory immune cells that inhibit PD-1<sup>+</sup> effector T cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Ahmad, S. M., Svane, I. M. &amp; Andersen, M. H. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J. 4, e230 (2014)." href="/articles/s41591-021-01544-x#ref-CR47" id="ref-link-section-d74233406e1995">47</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Munir Ahmad, S. et al. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology 5, e1202391 (2016)." href="/articles/s41591-021-01544-x#ref-CR48" id="ref-link-section-d74233406e1998">48</a></sup>. The major role of the PD-1 pathway is believed to be the regulation of effector T cell responses. Thus, this protective pathway is more important after activation, rather than at the initial T cell-activation stage<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012)." href="/articles/s41591-021-01544-x#ref-CR49" id="ref-link-section-d74233406e2003">49</a></sup>. Accordingly, the presence of PD-L1-specific T cells during the activation phase of an immune response may not increase or support a pro-inflammatory immune response due to the expression of PD-L1 on potent antigen-presenting cells or on the T cells themselves<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Ahmad, S. M., Larsen, S. K., Svane, I. M. &amp; Andersen, M. H. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 28, 236–238 (2014)." href="/articles/s41591-021-01544-x#ref-CR14" id="ref-link-section-d74233406e2007">14</a></sup>. Thus, the overall effects of PD-L1-specific T cells may vary depending on the expression of both PD-1 and PD-L1, that is, due to the microenvironment and the state of the immune response.</p><p>In conclusion, here we report an impressive response rate, CR rate and mPFS for a first-in-class immune-modulating vaccine combined with nivolumab. This may be a first step toward a new treatment strategy for patients with MM. Limitations are the low number of patients treated at a single institution and the lack of a randomized design with aPD1 monotherapy as comparator. Studies in aPD1 therapy-resistant or -refractory melanoma are ongoing as well as biomarker analysis for selecting patients at a higher likelihood to benefit from the combination versus aPD1 monotherapy. A larger randomized trial will be essential to validate these findings and determine the specific contribution of the vaccine to clinical responses and changes in the TME. In December 2020, the Food and Drug Administration granted breakthrough therapy designation for the IO102/IO103 vaccine combined with aPD1 therapy in metastatic melanoma based on data from the MM1636 trial.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec14-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec14">Methods</h2><div class="c-article-section__content" id="Sec14-content"><h3 class="c-article__sub-heading" id="Sec15">Trial design and treatment plan</h3><p>MM1636 is an investigator-initiated, nonrandomized, open-label, single-center phase 1/2 study. All patients were treated at the Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark. The study was conducted according to the Declaration of Helsinki and Good Clinical Practice (GCP) and monitored by the GCP unit in Copenhagen, Denmark. The protocol was approved by the ethical committee of the Capital region of Denmark (H-17000988), the Danish Medical Agencies (2017011073) and the Capital Region of Denmark Data Unit (P-2019-172). The study was registered at <a href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</a> under the identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03047928">NCT03047928</a> and at the EudraCT (no. 2016-0004527-23).</p><p>This study initially aimed to include 30 aPD1 treatment-naive patients with MM. An amendment with the addition of two other cohorts with ten patients in each cohort was made to evaluate immune responses and clinical efficacy in aPD1 therapy-resistant patients (cohort B, de novo resistance and cohort C, acquired resistance) for a total of 50 patients. The amendment with cohorts B and C was approved at the inclusion of 18 patients in cohort A. The trial is still including patients in cohorts B and C. This article reports results from cohort A.</p><p>The first six patients were treated as for phase 1, evaluating for safety and tolerability before the remaining 24 patients were included in phase 2.</p><p>The IDO/PD-L1 vaccine was administered subcutaneously biweekly for the first 10 weeks and thereafter every 4 weeks for approximately 9 months. A maximum of 15 vaccines were administered. Nivolumab was administered according to the approved label (3 mg per kg biweekly) for 24 cycles. The 15th vaccine was administered together with the 24th nivolumab cycle of 3 mg per kg, and responding patients thereafter continued nivolumab monotherapy every 4th week (6 mg per kg) as a standard of care after investigator assessment. Treatment with nivolumab was discontinued at the maximum benefit (assessed by the investigator), after a maximum of 2 years of therapy, at progression or due to severe adverse events (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01544-x#Fig6">1b</a>, treatment plan).</p><h3 class="c-article__sub-heading" id="Sec16">Vaccine composition</h3><p>Each vaccine was composed of 100 µg IO102, a 21-amino-acid peptide (DTLLKALLEIASCLEKALQVF) from IDO, and 100 µg IO103, a 19-amino-acid peptide (FMTYWHLLNAFTVTVPKDL) from the signal peptide of PD-L1 (PolyPeptide Laboratories). Peptides were dissolved separately in 50 µl DMSO, filtered for sterility and frozen at −20 °C (NUNC CyroTubes CryoLine System Internal Thread, Sigma-Aldrich). At &lt;24 h before administration, peptides were thawed. The PD-L1 peptide was diluted in 400 µl sterile water and, immediately before injection, mixed with the IDO peptide solution and 500 µl Montanide ISA-51 (SEPPIC) to achieve a total volume of 1 ml.</p><h3 class="c-article__sub-heading" id="Sec17">Patients</h3><p>Patients above 18 years of age with locally advanced or stage 4 melanoma according to the AJCC (seventh edition), at least one measurable lesion according to RECIST 1.1 and an ECOG PS of 0–1 were eligible. The main exclusion criteria were prior treatment with aPD1 therapy, CNS metastases &gt;1 cm, severe comorbidities and active autoimmune disease. Enrollment was not restricted to PD-L1 status, but it was known before inclusion. Patients were included after informed consent.</p><p>Patients MM42 and MM20 have confirmed their approval of PET–CT images and clinical images that have been included in the article.</p><h3 class="c-article__sub-heading" id="Sec18">Key study assessments</h3><p>Safety and tolerability were evaluated based on changes in clinical laboratory analyses and reported adverse events. Adverse events were assessed according to Common Terminology Criteria for Adverse Events (version 5.0) and were graded from 1 to 5 for all treated patients up to 6 months after the last dose of the IDO/PD-L1 vaccine.</p><p>Clinical efficacy was assessed using FDG PET–CT scans before treatment and every 3rd month until progression. Objective responses were categorized into CR, PR, stable disease or PD according to RECIST version 1.1.</p><p>Clinical data were collected at CCIT-DK in the eCRF program OpenClinica version 1.0 and in Microsoft Excel version 2002 on a secure server.</p><p>Blood samples for immunologic analyses were collected before treatment, before the third cycle, after the sixth, 12th, 18th and 24th cycles (on vaccination) and 3 and 6 months after the last vaccine.</p><p>Two to three tumor needle biopsies (1.2 mm) were collected at baseline and after six cycles from the same tumor site, when accessible, to evaluate immune responses at the tumor site.</p><p>DTH skin tests were performed and punch biopsies were taken from the DTH area after cycle 6 for the evaluation of SKILs reactive to PD-L1 and IDO (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">1</a>, treatment plan).</p><h3 class="c-article__sub-heading" id="Sec19">Statistical analysis of clinical outcome</h3><p>Survival curves were computed in GraphPad Prism software version 9.0.0 according to Kaplan–Meier method. Median follow-up time of enrollment was calculated using the reverse Kaplan–Meier method, also in GraphPad Prism software version 9.0.0.</p><p>For binary outcomes, 95% two-sided CIs were constructed using the Clopper–Pearson method, also in GraphPad version 9.0.0.</p><p>An independent board of certified and experienced oncoradiologists performed an external review to evaluate clinical response to address the potential bias of investigator site review. The external review took place at Rigshospitalet, Copenhagen University Hospital. This hospital did not participate in the MM1636 trial, and the external reviewer had no prior knowledge about the clinical trial or the trial therapy. Only PET–CT images were accessed, and arrows indicating target or non-target lesions appeared on baseline images as the only additional information.</p><p>To address potential trial bias regarding treatment effect, we matched patients in MM1636 with patients from the DAMMED, a population-based database that retrospectively collects data on patients with metastatic melanoma in Denmark. Here, data from 938 patients treated with aPD1 monotherapy contemporaneously (January 2015–October 2019) were extracted. Two hundred and eighteen of these patients were eligible for comparison and matching (all parameters available) (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">1</a>), and 74 patients from the DAMMED were found to match. Patients were matched for age (≤70 years, &gt;70 years), sex, LDH levels (normal, elevated), M stage (M1a, M1b, M1c), <i>BRAF</i> status (wild type, mutated) and PD-L1 status (&lt;1%, ≥1%). An exact matching algorithm was used in which patients in MM1636 were matched with patients from the DAMMED with the same combination of variables. Twenty-nine patients from MM1636 were matched with exact combinations of the six variables. One patient could not be matched. To secure balance of the calculations, control patients were weighted according to the number of patients for each MM1636 patient. Estimates for treatment effects were calculated by weighted logistic regression analyses and weighted Cox proportional hazard model. The R package ‘Matchlt’ was used for matching patients.</p><p>As the method chosen for matching control patients to protocol patients, a weighted binary logistic regression model was used for comparing response rates in the two matched cohorts. Odds ratios and response rates, including their corresponding 95% CIs, were extracted from the regression models. All <i>P</i> values were two sided, and <i>P</i> values below 0.05 were considered statistically significant. SAS version 9.4M5 was used for the weighted logistic regression models.</p><h3 class="c-article__sub-heading" id="Sec20">Processing of peripheral blood mononuclear cells</h3><p>Peripheral blood was collected from all patients in heparinized tubes and was processed within 4 h. In brief, PBMCs were isolated using Lymphoprep (Medinor) separation. PBMCs were counted on a Sysmex XP-300 analyzer and frozen in Human AB Serum (Sigma-Aldrich, H4522-100ML) with 10% DMSO using controlled-rate freezing (CoolCell, BioCision) in a −80 °C freezer and were moved the next day to a freezer at −140 °C until further processing.</p><h3 class="c-article__sub-heading" id="Sec21">Needle biopsies at baseline and after the sixth vaccine</h3><p>Two to three needle biopsies (1.2 mm) were taken at baseline and after the sixth cycle of treatment when assessable from the same tumor lesion.</p><p>One fragment was fixed with formalin and embedded in paraffin (FFPE); one to two fragments were used for expanding tumor-infiltrating T cells and establishing autologous tumor cell lines.</p><h3 class="c-article__sub-heading" id="Sec22">Delayed-type hypersensitivity and generation of skin-infiltrating lymphocytes</h3><p>After six cycles of treatment, we performed intradermal injections of vaccine components without adjuvant and one control injection containing DMSO without peptide. Patients were injected with either a mixture of both IDO and PD-L1 peptides at all three injection sites or PD-L1 peptide, IDO peptide or a mixture of the two at the injection sites, respectively (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">6</a>). Eight hours after injection, punch biopsies were resected from the three sites where the peptide was injected and transported immediately to the laboratory and cut into fragments of 1–2 mm<sup>3</sup>.</p><p>SKILs were expanded to establish ‘young SKILs’ in CM medium consisting of RPMI 1640 with GlutaMAX, 25 mM HEPES, pH 7.2 (Gibco, 72400-021), IL-2 (100 or 6,000 IU ml<sup>−1</sup>) (Proleukin Novartis, 004184), 10% heat-inactivated Human AB Serum (Sigma-Aldrich, H4522-100ML), 100 U ml<sup>−1</sup> penicillin, 1.25 µg ml<sup>−1</sup> Fungizone (Bristol Myers Squibb, 49182) and 100 µg ml<sup>−1</sup> streptomycin (Gibco, 15140-122). Half of the medium was replaced three times per week.</p><p>Young SKILs from samples derived from IDO peptide, PD-L1 peptide and the mixture injection sites were further expanded in a small-scale version of the 14-d rapid expansion protocol as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Donia, M. et al. Characterization and comparison of ‘standard’ and ‘young’ tumor infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand. J. Immunol. 75, 157–167 (2011)." href="/articles/s41591-021-01544-x#ref-CR51" id="ref-link-section-d74233406e2178">51</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec23">Quantification of specific T cells in blood by ELISPOT</h3><p>For enumeration of vaccine-specific T cells in the peripheral blood, PBMCs from patients were stimulated with IDO or PD-L1 peptide in the presence of a low dose of IL-2 (120 U ml<sup>−1</sup>) for 7–13 d before being used in IFN-γ ELISPOT assays with 2.5–3.2 × 10<sup>5</sup> cells per well.</p><p>Briefly, cells were placed in a 96-well PVDF membrane-bottomed ELISPOT plate (MultiScreen MSIPN4W50, Millipore) precoated with IFN-γ-capture antibody (clone 1-D1K, Mabtech). Diluted IDO or PD-L1 peptide stocks in DMSO were added at 5 µM; an equivalent amount of DMSO was added to control wells. PBMCs from each patient were set up in duplicate or triplicate for peptide and control stimulations. Cells were incubated in ELISPOT plates in the presence of the peptide for 16–18 h, after which they were washed off, and biotinylated secondary antibody (anti-human IFN-γ mAB, clone 7-B6-1, Mabtech) was added. After 2 h of incubation, unbound secondary antibody was washed off, and streptavidin-conjugated alkaline phosphatase (Mabtech) was added for 1 h. Next, unbound streptavidin-conjugated enzyme was washed off, and the assay was developed by adding BCIP/NBT substrate (Mabtech). ELISPOT plates were analyzed on the CTL ImmunoSpot S6 Ultimate V analyzer using ImmunoSpot software version 5.1. Responses were calculated as the difference between the average numbers of spots in wells stimulated with IDO or PD-L1 peptide and those from corresponding control wells.</p><p>For detection of IDO and PD-L1 peptide responses ex vivo, PBMCs were thawed and rested overnight in medium containing DNase I (1 μg ml<sup>−1</sup>, Sigma-Aldrich, 11284932001) before being used in IFN-γ ELISPOT assays as described above. A total of 6–9 × 10<sup>5</sup> PBMCs per well were seeded. Statistical analysis of all ELISPOT responses was performed using the DFR method as described by Moodie et al. using RStudio software (RStudio Team, 2016, <a href="http://www.rstudio.com/">http://www.rstudio.com/</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489–1501 (2010)." href="/articles/s41591-021-01544-x#ref-CR50" id="ref-link-section-d74233406e2211">50</a></sup>.</p><p>Vaccine-specific ELISPOT responses were defined as true if the difference between the spot count in control and peptide-stimulated wells was statistically significant according to DFR statistical analysis or, for samples performed in duplicate, if the spot count in peptide-stimulated wells was at least 2× the spot count in control wells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489–1501 (2010)." href="/articles/s41591-021-01544-x#ref-CR50" id="ref-link-section-d74233406e2218">50</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec24">Cancer cell lines and tumor conditioned medium</h3><p>Autologous melanoma cell lines were established from needle biopsies. Briefly, biopsies were chopped into small fragments and seeded in 24-well cultures in RPMI 1640 with GlutaMAX, 25 mM HEPES, pH 7.2 (Gibco, 72400-021), 10% heat-inactivated FBS (Life Technologies, 10500064), 100 U ml<sup>−1</sup> penicillin, 1.25 µg ml<sup>−1</sup> Fungizone (Bristol Myers Squibb, 49182) and 100 µg ml<sup>−1</sup> streptomycin (Gibco, 15140-122). Established adherent melanoma tumor cell lines were cryopreserved at −140 °C in freezing medium containing FBS with 10% DMSO. PD-L1 and HLA-II expression on established tumor cell lines was assessed by flow cytometry staining with anti-PD-L1–PE-Cy7 (1:23 dilution, clone M1h1 (RUO), BD, 558017) and anti-HLA-II–FITC (1:23 dilution, clone Tu39 (RUO), BD, 555558) antibodies.</p><p>To obtain TCM, established tumor cell lines were cultured in 175-cm<sup>2</sup> Nunc cell culture flasks until 80–90% confluency was reached. The culture medium was then replaced with 20 ml fresh X-VIVO 15 with Gentamicin and Phenol Red (Lonza, BE02-060Q), medium with 5% heat-inactivated Human AB Serum (Sigma-Aldrich, H4522-100ML). After 24 h of incubation, TCM was collected and centrifuged to remove any resuspended cells, after which TCM was aliquoted, frozen and stored at −80 °C.</p><p>The acute monocytic leukemia cell line MonoMac1 was obtained from the DSMZ—German Collection of Microorganisms and Cell Cultures (ACC 252) and cultured in RPMI 1640 with GlutaMAX, 25 mM HEPES, pH 7.2 (Gibco, 72400-021) and 10% heat-inactivated FBS.</p><h3 class="c-article__sub-heading" id="Sec25">Isolation of autologous myeloid cells</h3><p>Autologous CD14<sup>+</sup> cells were sorted from freshly thawed PBMCs using a magnetic bead-separation kit (Miltenyi Biotec, 130-050-201) according to the manufacturer’s instructions. Isolated CD14<sup>+</sup> cells were used as targets in the IFN-γ ELISPOT assay directly after sorting or differentiated in vitro into tumor-associated macrophages by culturing with 1 ml fresh X-VIVO 15 medium with Gentamicin and Phenol Red (Lonza, BE02-060Q) and 5% heat-inactivated Human AB Serum, supplemented with 1 ml autologous TCM in 24-well plates for 2 d.</p><h3 class="c-article__sub-heading" id="Sec26">Quantification of vaccine-specific T cells from DTH biopsy sites by ELISPOT</h3><p>SKILs expanded in vitro were rested in medium without IL-2 overnight before being used in the IFN-γ ELISPOT assay as described above to evaluate reactivity of skin-infiltrating T cells.</p><h3 class="c-article__sub-heading" id="Sec27">Generation of IDO- and PD-L1-specific T cell cultures from PBMCs or SKILs</h3><p>IDO- or PD-L1-specific T cells were isolated from peptide-stimulated in vitro PBMC cultures on days 14–15 after stimulation or from SKIL cultures expanded in vitro. For specific T cell isolation, PBMCs or SKILs were stimulated with IDO or PD-L1 peptide, and cytokine-producing T cells were sorted using the IFN-γ or TNF-α Secretion Assay—Cell Enrichment and Detection kit (Miltenyi Biotec).</p><h3 class="c-article__sub-heading" id="Sec28">Cytokine-production profile of PD-L1- and IDO-specific T cells by intracellular staining</h3><p>To assess the T cell cytokine-production profile, isolated and expanded IDO- and PD-L1-specific T cell cultures were stimulated for 5 h with peptide at 5 μM in a 96-well plate. One hour after the start of the incubation, anti-CD107a–PE (1:133 dilution, clone H4A3, BD Biosciences, 555801) antibody and BD GolgiPlug (1:1,000 dilution, BD Biosciences) were added. After a 5-h incubation, cells were stained using fluorescently labeled surface marker antibodies: anti-CD4–PerCP (1:5 dilution, clone SK3, 345770), anti-CD8–FITC (1:5 dilution, clone SK1, 345772) and anti-CD3–APC-H7 (1:20 dilution, clone SK7, 560275) (all from BD Biosciences). Dead cells were stained using FVS510 (1:250 dilution, BD Biosciences, 564406), followed by overnight fixation and permeabilization using eBioscience Fixation/Permeabilization buffers (00-5123-43, 00-5223-56) according to the manufacturer’s instructions. Cells were then stained intracellularly in eBioscience permeabilization buffer (00-8333-56) with anti-IFN-γ–APC (1:20 dilution, clone 25723.11, BD Biosciences, 341117) and anti-TNF-α–BV421 (1:100 dilution, clone Mab11, BD Biosciences, 562783) antibodies. Samples were analyzed on the FACSCanto II (BD Biosciences) using BD FACSDiva software version 8.0.2. The gating strategy is shown in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">3a</a>. For assessing the reactivity against IDO expressing MonoMac1 cells, the appropriate amount of cancer cells was added to the IDO-specific T cells to obtain an effector:target ratio of 4:1 in the 96-well plate and T cell cytokine production was tested after 5 h of co-culture as described above. For HLA-blocking experiments, HLA-blocking antibodies (2 μg ml<sup>−1</sup>) were added directly into wells 30 min before the addition of peptide. Blocking antibodies used were HLA-DR (1:500 dilution, clone L243, Abcam, ab136320), HLA-DQ (1:500 dilution, clone SPV-L3, Abcam, ab23632) and HLA-DP (1:500 dilution, clone B7/21, Abcam, ab20897).</p><p>To assess ex vivo T cell reactivity to IDO and PD-L1 peptides in patient PBMCs, cells were thawed and rested for 1–2 d in medium containing DNase I (1 μg ml<sup>−1</sup>, Sigma-Aldrich, 11284932001). PBMCs were then stimulated with peptide at 5 μM in a 96-well plate for 8 h. An hour after the addition of peptide, anti-CD107a–BV421 (3:50 dilution, clone H4A3, BD Biosciences, 328626) antibody and BD GolgiPlug (1:1,000 dilution, BD Biosciences) were added. Surface and intracellular staining was performed as described above. Antibodies used for surface staining were anti-CD3–PE-CF594 (0.8:30 dilution, clone UCHT1, BD Biosciences, 562280), anti-CD4–BV711 (1:30 dilution, clone SK3, BD Biosciences, 563028) and anti-CD8–Qdot605 (1:150 dilution, clone 3B5, Thermo Fisher, Q10009). Antibodies used for intracellular staining were anti-CD137–PE (1:20 dilution, clone 4B4-1 (RUO), BD Biosciences, 555956), anti-IFN-γ–PE-Cy7 (1.5:20 dilution, clone B27, BD Biosciences, 557643) and anti-TNF-α–APC (1:20 dilution, clone Mab11, BD Biosciences, 554514). Samples were acquired on the NovoCyte Quanteon (ACEA Biosciences) and analyzed using NovoExpress software version 1.4.1. To assess vaccine-specific T cell responses, background values observed in unstimulated PBMC samples were subtracted from values observed in peptide-stimulated conditions. Positive response value threshold was set at a difference of 0.2% from the background values. Based on this response cutoff, only TNF-α, CD107a and CD137 responses were detected in this assay. Statistical analysis comparing baseline with on-treatment or post-treatment cytokine profiles was performed using two-sided Wilcoxon matched-pairs signed-rank test. The gating strategy is shown in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM1">3b</a>.</p><h3 class="c-article__sub-heading" id="Sec29">siRNA-mediated <i>PD-L1</i> and <i>IDO1</i> silencing</h3><p>A stealth siRNA duplex for targeted silencing of <i>PD-L1</i> (Invitrogen)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Hobo, W. et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood 116, 4501–4511 (2010)." href="/articles/s41591-021-01544-x#ref-CR52" id="ref-link-section-d74233406e2312">52</a></sup>, a custom silencer select siRNA for targeted silencing of <i>IDO1</i> (Ambion) and the recommended silencer select negative control (Ambion) siRNA for mock transfection were used.</p><p>The stealth PD-L1 siRNA duplex consisted of the sense sequence 5′-CCUACUGGCAUU-UGCUGAACGCAUU-3′ and the antisense sequence 5′-AAUGCGUUCAGCAAAUGCCAGUAGG-3′. The three silencer IDO siRNA duplexes used were siRNA1 (sense sequence, 5′-ACAUCUGCCUGAUCUCAUATT-3′; antisense sequence, 5′-UAUGAGAUCAGGCAGAUGUTT-3′), siRNA2 (sense sequence, 5′-CCACGAUCAUGUGAACCCATT-3′; antisense sequence, 5′-UGGGUUCACAUGAUCG-UGGAT-3′) and siRNA3 (sense sequence, 5′-CGAUCAUGUGAACCCAAAATT-3′; antisense sequence, 5′-UUUUGGGUUCACAUGAUCGTG-3′). For <i>PD-L1</i> or <i>IDO1</i> silencing, cancer cells were electroporated with 0.025 nmol of each siRNA duplex as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Met, Ö., Balslev, E., Flyger, H. &amp; Svane, I. M. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res. Treat. 125, 395–406 (2011)." href="/articles/s41591-021-01544-x#ref-CR53" id="ref-link-section-d74233406e2328">53</a></sup>. For <i>PD-L1</i>-silencing experiments, cancer cells were treated with IFN-γ (500 U ml<sup>−1</sup>, PeproTech) 1 h after electroporation. Electroporated cells were used as target cells in ELISPOT and ICS assays 24 h or 48 h after siRNA electroporation.</p><h3 class="c-article__sub-heading" id="Sec30">RT–qPCR</h3><p>Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen, 74134) following the manufacturer’s instructions. RNA concentration was quantified using a NanoDrop 2000 (Thermo Fisher Scientific), and a total of 1,000 ng RNA was reverse transcribed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814) using 1,000 ng input RNA for transcription. Real-time qPCR analyses were performed using the TaqMan Gene Expression Assay on a Roche LightCycler 480 instrument. RT–qPCR assays were performed with a minimum of three technical replicates and analyzed using the ΔCt method as described in Bookout et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="Bookout, A. L., Cummins, C. L., Mangelsdorf, D. J., Pesola, J. M. &amp; Kramer, M. F. High‐throughput real‐time quantitative reverse transcription PCR. Curr. Protoc. Mol. Biol. 73, 15.8.1–15.8.28 (2006)." href="/articles/s41591-021-01544-x#ref-CR54" id="ref-link-section-d74233406e2345">54</a></sup> with normalization of <i>IDO1</i> expression (primer ID, Hs00984148_m1) or <i>PD-L1</i> expression (primer ID, Hs001125296_m1) to the expression level of the housekeeping gene <i>POLR2A</i> (primer ID, Hs00172187_m1) and the control sample (mock). For low-concentration samples with no amplification, Ct was set to 40. Controls without reverse transcriptase were used as controls for specific amplifications. <i>P</i> values were determined using two-tailed parametric <i>t</i>-tests.</p><h3 class="c-article__sub-heading" id="Sec31">
                           <i>BRAF</i>-mutational status and PD-L1 status at baseline in all patients</h3><p>A library of historical FFPE biopsies were assessable for all patients and analyzed locally at Herlev and Gentofte University Hospital by experienced pathologists for <i>BRAF</i> status and PD-L1 expression on tumor cells.</p><p>The <i>BRAF</i> analysis was carried out with real-time PCR using the EntroGen BRAF Mutation Analysis Kit II (BRAFX-RT64, CE-IVD) to specifically detect mutations corresponding to V600D, V600E and V600K in the BRAF protein.</p><p>PD-L1 status was assessed using the monoclonal rabbit anti-PD-L1 antibody (clone 28.8, PD-L1 IHC 28-8 pharmDx) in FFPE biopsies following the manufacturer’s instructions. Patients were considered positive for PD-L1 with expression levels ≥1% and negative for PD-L1 with expression levels &lt;1%.</p><h3 class="c-article__sub-heading" id="Sec32">Human leukocyte antigen type</h3><p>Blood samples from all 30 patients were genotyped for class I (HLA-A, HLA-B, HLA-C) and three class II types (HLA-DRB1, HLA-DQA1, HLA-DQB1) using LinkSēq HLA Typing Kits (Thermo Fisher, 1580C). These test kits are based on real-time PCR using allele-specific exponential amplification (sequence-specific primers) followed by melting curve analyses.</p><h3 class="c-article__sub-heading" id="Sec33">Immunohistochemistry simplex: Immunoscore CR</h3><p>IHC staining was performed using a qualified Ventana Benchmark XT with four different steps: (1) antigen retrieval; (2) staining with the following primary antibodies: anti-CD3 antibody (clone HDX2; provider, HalioDx; HD-FG-000013; 10931065/10636667; concentration, 0.25 µg ml<sup>−1</sup>), anti-CD8 antibody (clone HDX3; provider, HalioDx; HD-FG-000019; 10931069/10337710/10639301; concentration, 0.5 µg ml<sup>−1</sup>), anti-IDO monoclonal antibody (clone VINC3IDO; provider, Thermo Fisher Scientific; 14-9750-82; E25003-101; concentration, 0.05 µg ml<sup>−1</sup>), anti-HLA class 1 ABC antibody (clone, EMR8-5; provider, Abcam; ab70328; GR3248333/GR3186494; concentration, 0.5 µg ml<sup>−1</sup>), anti-HLA-DR/DP/DQ/DX antibody (clone CR3/43; provider, Santa Cruz; sc-53302; L1714; concentration, 1 µg ml<sup>−1</sup>) and anti-PD-L1 antibody (clone HDX3; provider, HalioDx; HD-FG-000035; 106312810/106312816; concentration, 3.3 µg ml<sup>−1</sup>); (3) detection with a secondary antibody using the ultraView Universal DAB Detection kit; and (4) counterstaining using Hematoxylin &amp; Bluing Reagent (staining of cellular nuclei). Control slides were systematically included in each staining run to permit quality control of the obtained measurements. Following coverslipping, slides were scanned with the NanoZoomer-XR to generate digital images (20×).</p><p>Two consecutive slides were specifically used to perform Immunoscore CR TL staining of CD3<sup>+</sup> and CD8<sup>+</sup> cells.</p><h3 class="c-article__sub-heading" id="Sec34">Digital pathology of T lymphocytes</h3><p>The digital pathology for Immunoscore CR TL allowed the quantification of positive cells (in cells per mm<sup>2</sup>) into the core tumor and invasive margin if present. Each sample was analyzed using the HalioDx Digital Pathology Platform.</p><h3 class="c-article__sub-heading" id="Sec35">Digital pathology and pathologist analysis of IDO</h3><p>Digital pathology for IDO allowed the quantification of stained area (in mm<sup>2</sup>) into the whole tumor. Each sample was analyzed using the HalioDx Digital Pathology Platform.</p><p>Analysis of IDO<sup>+</sup> cells was performed by a pathologist. Results were expressed as <i>an H</i> score from 0 to 300. The score is obtained by the formula 3 × percentage of cells with strong staining + 2 × percentage of cells with moderate staining + percentage of cells with weak staining.</p><h3 class="c-article__sub-heading" id="Sec36">Digital pathologist analysis of MHC-I and MHC-II</h3><p>Analysis of MHC-I<sup>+</sup> and MHC-II<sup>+</sup> cells was performed by a pathologist. Results are expressed as a percentage of positive tumor cells and a percentage of positive cells in the stroma.</p><h3 class="c-article__sub-heading" id="Sec37">Digital pathology Immunoscore immune checkpoint (CD8<sup>+</sup> and PD-L1<sup>+</sup>)</h3><p>The Immunoscore CR IC test allowed the quantification of CD8<sup>++</sup> cell density in the whole tumor and a CD8<sup>+</sup>-centered proximity index (which corresponds to the percentage of CD8<sup>++</sup> cells that have at least one PD-L1<sup>+</sup> cell in the neighborhood) at different cutoff distances (20 µm, 40 µm, 60 µm and 80 µm).</p><h3 class="c-article__sub-heading" id="Sec38">Pathologist analysis of PD-L1</h3><p>A pathologist performed analysis of PD-L1<sup>+</sup> cells. Positivity of a viable tumor cell was considered when partial or complete cell membrane staining was observed (more than 10% of the tumor cell membrane). Results were expressed as a percentage.</p><h3 class="c-article__sub-heading" id="Sec39">NanoString RNA profiling and Immunosign</h3><p>RNA was extracted from FFPE tissues using Qiagen RNeasy FFPE extraction kits (Qiagen). Annotations from the pathologist performing H&amp;E staining were used to guide removal of normal tissue from the slides by macrodissection before nucleic acid extraction, which occurred after tissue deparaffinization and lysis. Each extracted RNA sample was independently quantified using a NanoDrop spectrophotometer (NanoDrop Technologies) and qualified (Agilent Bioanalyzer). Degradation was quantified as the percentage of RNA fragments smaller than 300 bp using the RNA 6000 Nano kit (Agilent Bioanalyzer). Good sample quality was defined as less than 50% of RNA fragments being 50–300 bp in size.</p><p>RNA expression profiling was performed using the nCounter PanCancer Immune Profiling Panel from NanoString (NanoString Technologies). The PanCancer Immune Profiling Panel contains 776 probes and is supplemented with six genes to complete HalioDx Immunosign targets.</p><p>Hybridization was performed according to the manufacturer’s instructions. Hybridized probes were then purified and immobilized on a streptavidin-coated cartridge using the nCounter Prep Station (NanoString Technologies). Data collection was carried out on the nCounter Digital Analyzer (NanoString Technologies) following the manufacturer’s instructions to count individual fluorescent barcodes and quantify target RNA molecules present in each sample. For each assay, a scan of 490 fields of view was performed.</p><p>Raw data from the NanoString nCounter were processed using NanoString recommendations.</p><p>Quality control enables to retain data of good quality with a binding density that ranges between 0.05 and 2.25. The linearity of positive controls was checked using the <i>R</i><sup>2</sup> value of regression between the counts and the concentrations of positive controls. Samples that showed <i>R</i><sup>2</sup> &lt; 0.75 were flagged and removed from the analysis. The background was removed using a thresholding method at the mean + 2 s.d. of negative controls. Raw counts were normalized using a positive normalization factor. Samples showing positive normalization factors outside the range of 0.3–3 were removed from the analysis. A second normalization was performed using the housekeeping gene normalization factor. Only the most stable housekeeping genes were selected for this normalization step using the variance-versus-mean relationship. All samples showing a normalization factor outside the range of 0.1–10 were removed from the analysis. All statistical analyses were performed on normalized counts using R software (version 2.6.2, 2019-12-12).</p><h3 class="c-article__sub-heading" id="Sec40">T cell receptor variable β chain sequencing</h3><p>To track longitudinal immune responses to therapy, genomic DNA was extracted from longitudinal pre- and post-treatment PBMCs (five patients), pre- and post-treatment biopsies (five patients) (both FFPE and treated with RNAlater) and IDO- and PD-L1-specific T cell cultures from PBMCs (five patients) or SKILs (one patient). Three clonal (two IDO- and one PD-L1-) specific cultures were also sequenced to confirm clonal purity of cultures.</p><p>DNA from PBMCs or RNAlater-treated biopsies was extracted with the DNeasy Blood and Tissue kit (Qiagen, 69504), DNA from sorted IDO and PD-L1-specific T cells from either PBMCs or SKILs was extracted using the QIAamp DNA Micro kit (Qiagen, 565304), and DNA from PFFE biopsies was extracted using the Maxwell RSC DNA FFPE kit (Promega, AS1450).</p><p>Immunosequencing of the CDR3 regions of human TCRβ chains was performed using the immunoSEQÒ Assay (Adaptive Biotechnologies). Extracted genomic DNA was amplified in a bias-controlled multiplex PCR, followed by high-throughput sequencing. Sequences were collapsed and filtered to identify and quantitate the absolute abundance of each unique TCRβ CDR3 region for further analysis as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Robins, H. S. et al. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells. Blood 114, 4099–4107 (2009)." href="#ref-CR55" id="ref-link-section-d74233406e2541">55</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013)." href="#ref-CR56" id="ref-link-section-d74233406e2541_1">56</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="Robins, H. et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14–19 (2012)." href="/articles/s41591-021-01544-x#ref-CR57" id="ref-link-section-d74233406e2544">57</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec41">Statistical analyses of TCRβ sequencing results</h3><p>Two quantitative components of diversity were compared across samples in this study. First, Simpson clonality was calculated on productive rearrangements by <span class="mathjax-tex">\(\sqrt {\mathop {\sum}\nolimits_{i = 1}^R {p_i^2} }\)</span>, where <i>R</i> is the total number of rearrangements and <sub><i>pi</i></sub> is the productive frequency of rearrangement <i>i</i>. Values of Simpson clonality range from 0 to 1 and measure how evenly receptor sequences (rearrangements) are distributed among a set of T cells. Clonality values approaching 0 indicate a very even distribution of frequencies, whereas values approaching 1 indicate an increasingly asymmetric distribution in which a few clones are present at high frequencies.</p><p>Second, sample richness was calculated as the number of unique productive rearrangements in a sample after computationally downsampling to a common number of T cells to control for variation in sample depth or T cell fraction. Repertoires were randomly sampled without replacement five times, and we report the mean number of unique rearrangements.</p><p>The T cell fraction was calculated by taking the total number of T cell templates and dividing by the total number of nucleated cells. The total number of nucleated cells was derived from reference genes using the immunoSEQ Analyzer version 3.</p><p>To identify enriched vaccine clones in each patient, rearrangement frequencies in their baseline PBMCs and each IDO/PD-L1-sorted T cell sample were compared using a binomial distribution framework as previously described<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="DeWitt, W. S. et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 89, 4517–4526 (2015)." href="/articles/s41591-021-01544-x#ref-CR58" id="ref-link-section-d74233406e2636">58</a></sup>. In brief, for each clone, we performed a two-sided test to determine whether frequencies were the same in the patient’s periphery and a PD-L1- or IDO-specific T cell sample. The Benjamini–Hochberg procedure was used to control the false discovery rate at 0.01 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Benjamini, Y. &amp; Gavrilov, Y. A simple forward selection procedure based on false discovery rate control. Ann. Appl. Stat. 3, 179–198 (2009)." href="/articles/s41591-021-01544-x#ref-CR59" id="ref-link-section-d74233406e2640">59</a></sup>). Clonal expansion in post-treatment samples was similarly assessed using this differential abundance framework, but an IDO/PD-L1-specific T cell sample was replaced with a post-treatment series sample. In biopsies, the six series frequencies were compared to those of baseline tissue. Lastly, vaccine-associated clones were tracked in each PBMC and tissue sample by summing the frequency of each rearrangement enriched in either PD-L1- or IDO-specific T cells. All statistical analyses were performed in R version 3.6.1.</p><h3 class="c-article__sub-heading" id="Sec42">Reporting Summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01544-x#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>This clinical trial was registered at <a href="https://www.clinicaltrials.gov/">https://www.clinicaltrials.gov/</a> before patient enrollment (clinical trial identifier <a href="https://clinicaltrials.gov/ct2/show/NCT03047928">NCT03047928</a>). Each vaccine was composed of 100 µg IO102, a 21-amino-acid peptide (DTLLKALLEIASCLEKALQVF) from the IDO peptide, and 100 µg IO103, a 19-amino-acid peptide (FMTYWHLLNAFTVTVPKDL) from the signal peptide of PD-L1. TCR sequencing data are available from Adaptive Biotechnologies. Upon request, the CCIT-DK office will provide a username and a password to access the designated data within approximately 2–4 weeks (<a href="https://www.herlevhospital.dk/ccit-denmark/find-us/Sider/Contact-information.aspx">https://www.herlevhospital.dk/ccit-denmark/find-us/Sider/Contact-information.aspx</a>). All requests for the remaining data including raw data and analyzed data and materials will, within a reasonable time frame, be reviewed by the CCIT-DK office (<a href="https://www.herlevhospital.dk/ccit-denmark/find-us/Sider/Contact-information.aspx">https://www.herlevhospital.dk/ccit-denmark/find-us/Sider/Contact-information.aspx</a>) to verify whether the request is subject to any intellectual property or obligations. Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a material-transfer agreement. The following database was used in the study: <a href="https://research.regionh.dk/da/publications/the-danish-metastatic-melanoma-database-dammed(32749d99-095f-4cae-b5de-769bae27f01e).html">https://research.regionh.dk/da/publications/the-danish-metastatic-melanoma-database-dammed(32749d99-095f-4cae-b5de-769bae27f01e).html</a>.</p>
            </div></div></section><section data-title="Change history"><div class="c-article-section" id="change-history-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="change-history">Change history</h2><div class="c-article-section__content" id="change-history-content"><ul class="c-article-change-list"><li class="c-article-change-list__item u-mb-24" id="chg1"><ins datetime="2022-03-08"><h3 class="c-article-change-list__heading u-h3 u-pr-8 u-display-inline">08 March 2022</h3><div class="c-article-change-list__details"><p>A Correction to this paper has been published: <a href="https://doi.org/10.1038/s41591-022-01771-w">https://doi.org/10.1038/s41591-022-01771-w</a></p></div></ins></li></ul></div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncol.</i> <b>20</b>, 1239–1251 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(19)30388-2" data-track-item_id="10.1016/S1470-2045(19)30388-2" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2819%2930388-2" aria-label="Article reference 1" data-doi="10.1016/S1470-2045(19)30388-2">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsVeltb7K" aria-label="CAS reference 1">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31345627" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma%20%28KEYNOTE-006%29%3A%20post-hoc%205-year%20results%20from%20an%20open-label%2C%20multicentre%2C%20randomised%2C%20controlled%2C%20phase%203%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2819%2930388-2&amp;volume=20&amp;pages=1239-1251&amp;publication_year=2019&amp;author=Robert%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Weber, J. S., Postow, M., Lao, C. D. &amp; Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. <i>Oncologist</i> <b>21</b>, 1230–1240 (2016).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>381</b>, 1535–1546 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1910836" data-track-item_id="10.1056/NEJMoa1910836" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1910836" aria-label="Article reference 3" data-doi="10.1056/NEJMoa1910836">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitVShs7jF" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31562797" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Five-year%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1910836&amp;volume=381&amp;pages=1535-1546&amp;publication_year=2019&amp;author=Larkin%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Ascierto, P. A. et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. <i>Ann. Oncol.</i> <b>28</b>, v611–v612 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdx440.011" data-track-item_id="10.1093/annonc/mdx440.011" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdx440.011" aria-label="Article reference 4" data-doi="10.1093/annonc/mdx440.011">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20BMS-986016%2C%20a%20monoclonal%20antibody%20that%20targets%20lymphocyte%20activation%20gene-3%20%28LAG-3%29%2C%20in%20combination%20with%20nivolumab%20in%20pts%20with%20melanoma%20who%20progressed%20during%20prior%20anti-PD-1%2FPD-L1%20therapy%20%28mel%20prior%20IO%29%20in%20all-comer%20and%20biomarker-enriched%20populations&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx440.011&amp;volume=28&amp;pages=v611-v612&amp;publication_year=2017&amp;author=Ascierto%2CPA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Angeles, L. Warming ‘cold’ melanoma with TLR9 agonists. <i>Cancer Discov.</i> <b>8</b>, 670 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-ND2018-004" data-track-item_id="10.1158/2159-8290.CD-ND2018-004" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-ND2018-004" aria-label="Article reference 5" data-doi="10.1158/2159-8290.CD-ND2018-004">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Warming%20%E2%80%98cold%E2%80%99%20melanoma%20with%20TLR9%20agonists&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-ND2018-004&amp;volume=8&amp;publication_year=2018&amp;author=Angeles%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Mullinax, J. E. et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. <i>Front. Oncol.</i> <b>8</b>, 44 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fonc.2018.00044" data-track-item_id="10.3389/fonc.2018.00044" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffonc.2018.00044" aria-label="Article reference 6" data-doi="10.3389/fonc.2018.00044">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29552542" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840208" aria-label="PubMed Central reference 6">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Combination%20of%20ipilimumab%20and%20adoptive%20cell%20therapy%20with%20tumor-infiltrating%20lymphocytes%20for%20patients%20with%20metastatic%20melanoma&amp;journal=Front.%20Oncol.&amp;doi=10.3389%2Ffonc.2018.00044&amp;volume=8&amp;publication_year=2018&amp;author=Mullinax%2CJE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. <i>Cell</i> <b>183</b>, 347–362 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2020.08.053" data-track-item_id="10.1016/j.cell.2020.08.053" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2020.08.053" aria-label="Article reference 7" data-doi="10.1016/j.cell.2020.08.053">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitF2jtLfJ" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33064988" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20Ib%20trial%20of%20personalized%20neoantigen%20therapy%20plus%20anti-PD-1%20in%20patients%20with%20advanced%20melanoma%2C%20non-small%20cell%20lung%20cancer%2C%20or%20bladder%20cancer&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;volume=183&amp;pages=347-362&amp;publication_year=2020&amp;author=Ott%2CPA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> <b>547</b>, 217–221 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature22991" data-track-item_id="10.1038/nature22991" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature22991" aria-label="Article reference 8" data-doi="10.1038/nature22991">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFaqt7rO" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28678778" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577644" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20immunogenic%20personal%20neoantigen%20vaccine%20for%20patients%20with%20melanoma&amp;journal=Nature&amp;doi=10.1038%2Fnature22991&amp;volume=547&amp;pages=217-221&amp;publication_year=2017&amp;author=Ott%2CPA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Andersen, M. H. Anti-cancer immunotherapy: breakthroughs and future strategies. <i>Semin. Immunopathol.</i> <b>41</b>, 1–3 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00281-018-0711-z" data-track-item_id="10.1007/s00281-018-0711-z" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00281-018-0711-z" aria-label="Article reference 9" data-doi="10.1007/s00281-018-0711-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30242450" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-cancer%20immunotherapy%3A%20breakthroughs%20and%20future%20strategies&amp;journal=Semin.%20Immunopathol.&amp;doi=10.1007%2Fs00281-018-0711-z&amp;volume=41&amp;pages=1-3&amp;publication_year=2019&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Munir, S., Andersen, G. H., Svane, I. M. &amp; Andersen, M. H. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4<sup>+</sup> T cells. <i>Oncoimmunology</i> <b>2</b>, e23991 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4161/onci.23991" data-track-item_id="10.4161/onci.23991" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4161%2Fonci.23991" aria-label="Article reference 10" data-doi="10.4161/onci.23991">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23734334" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654604" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20checkpoint%20regulator%20PD-L1%20is%20a%20specific%20target%20for%20naturally%20occurring%20CD4%2B%20T%20cells&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.23991&amp;volume=2&amp;publication_year=2013&amp;author=Munir%2CS&amp;author=Andersen%2CGH&amp;author=Svane%2CIM&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Ahmad, S. M., Borch, T. H., Hansen, M. &amp; Andersen, M. H. PD-L1-specific T cells. <i>Cancer Immunol. Immunother.</i> <b>65</b>, 797–804 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-015-1783-4" data-track-item_id="10.1007/s00262-015-1783-4" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-015-1783-4" aria-label="Article reference 11" data-doi="10.1007/s00262-015-1783-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XksFGrtQ%3D%3D" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26724936" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1-specific%20T%20cells&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-015-1783-4&amp;volume=65&amp;pages=797-804&amp;publication_year=2016&amp;author=Ahmad%2CSM&amp;author=Borch%2CTH&amp;author=Hansen%2CM&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Andersen, M. H. The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. <i>Cancer Immunol. Immunother.</i> <b>61</b>, 1289–1297 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-012-1234-4" data-track-item_id="10.1007/s00262-012-1234-4" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-012-1234-4" aria-label="Article reference 12" data-doi="10.1007/s00262-012-1234-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVOhtL7L" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22388712" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401509" aria-label="PubMed Central reference 12">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20specific%20targeting%20of%20immune%20regulation%3A%20T-cell%20responses%20against%20indoleamine%202%2C3-dioxygenase&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-012-1234-4&amp;volume=61&amp;pages=1289-1297&amp;publication_year=2012&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Sørensen, R. B. et al. Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2. <i>Cancer Res.</i> <b>71</b>, 2038–2044 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-10-3403" data-track-item_id="10.1158/0008-5472.CAN-10-3403" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-10-3403" aria-label="Article reference 13" data-doi="10.1158/0008-5472.CAN-10-3403">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21406395" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Spontaneous%20cytotoxic%20T-cell%20reactivity%20against%20indoleamine%202%2C3-dioxygenase-2&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-10-3403&amp;volume=71&amp;pages=2038-2044&amp;publication_year=2011&amp;author=S%C3%B8rensen%2CRB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Ahmad, S. M., Larsen, S. K., Svane, I. M. &amp; Andersen, M. H. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. <i>Leukemia</i> <b>28</b>, 236–238 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/leu.2013.261" data-track-item_id="10.1038/leu.2013.261" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fleu.2013.261" aria-label="Article reference 14" data-doi="10.1038/leu.2013.261">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsF2ntrrN" aria-label="CAS reference 14">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24091833" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Harnessing%20PD-L1-specific%20cytotoxic%20T%20cells%20for%20anti-leukemia%20immunotherapy%20to%20defeat%20mechanisms%20of%20immune%20escape%20mediated%20by%20the%20PD-1%20pathway&amp;journal=Leukemia&amp;doi=10.1038%2Fleu.2013.261&amp;volume=28&amp;pages=236-238&amp;publication_year=2014&amp;author=Ahmad%2CSM&amp;author=Larsen%2CSK&amp;author=Svane%2CIM&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Andersen, M. H. CD4 responses against IDO. <i>Oncoimmunology</i> <b>1</b>, 1211–1212 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4161/onci.20780" data-track-item_id="10.4161/onci.20780" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4161%2Fonci.20780" aria-label="Article reference 15" data-doi="10.4161/onci.20780">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23170283" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494649" aria-label="PubMed Central reference 15">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=CD4%20responses%20against%20IDO&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.20780&amp;volume=1&amp;pages=1211-1212&amp;publication_year=2012&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Dey, S. et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. <i>J. Immunother. Cancer</i> <b>8</b>, e000605 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/jitc-2020-000605" data-track-item_id="10.1136/jitc-2020-000605" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Fjitc-2020-000605" aria-label="Article reference 16" data-doi="10.1136/jitc-2020-000605">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32690770" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373332" aria-label="PubMed Central reference 16">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Peptide%20vaccination%20directed%20against%20IDO1-expressing%20immune%20cells%20elicits%20CD8%2B%20and%20CD4%2B%20T-cell-mediated%20antitumor%20immunity%20and%20enhanced%20anti-PD1%20responses&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1136%2Fjitc-2020-000605&amp;volume=8&amp;publication_year=2020&amp;author=Dey%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Ellebaek, E. et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiol</i>. <b>73</b>, 101943 (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. <i>N. Engl. J. Med.</i> <b>373</b>, 23–34 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1504030" data-track-item_id="10.1056/NEJMoa1504030" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1504030" aria-label="Article reference 18" data-doi="10.1056/NEJMoa1504030">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26027431" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905" aria-label="PubMed Central reference 18">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20nivolumab%20and%20ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1504030&amp;volume=373&amp;pages=23-34&amp;publication_year=2015&amp;author=Larkin%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Godard, B. et al. Optimization of an Elispot assay to detect cytomegalovirus-specific CD8<sup>+</sup> T lymphocytes. <i>Hum. Immunol.</i> <b>65</b>, 1307–1318 (2004).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.humimm.2004.06.006" data-track-item_id="10.1016/j.humimm.2004.06.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.humimm.2004.06.006" aria-label="Article reference 19" data-doi="10.1016/j.humimm.2004.06.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2cXhtVSksb%2FE" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15556681" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Optimization%20of%20an%20Elispot%20assay%20to%20detect%20cytomegalovirus-specific%20CD8%2B%20T%20lymphocytes&amp;journal=Hum.%20Immunol.&amp;doi=10.1016%2Fj.humimm.2004.06.006&amp;volume=65&amp;pages=1307-1318&amp;publication_year=2004&amp;author=Godard%2CB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Meier, A. et al. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. <i>Cancer Immunol. Immunother.</i> <b>54</b>, 219–228 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-004-0578-9" data-track-item_id="10.1007/s00262-004-0578-9" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-004-0578-9" aria-label="Article reference 20" data-doi="10.1007/s00262-004-0578-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXjs1agtw%3D%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15580499" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Spontaneous%20T-cell%20responses%20against%20peptides%20derived%20from%20the%20Taxol%20resistance-associated%20gene-3%20%28TRAG-3%29%20protein%20in%20cancer%20patients&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-004-0578-9&amp;volume=54&amp;pages=219-228&amp;publication_year=2005&amp;author=Meier%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Calarota, S. A. et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. <i>J. Immunol.</i> <b>180</b>, 5907–5915 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4049/jimmunol.180.9.5907" data-track-item_id="10.4049/jimmunol.180.9.5907" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4049%2Fjimmunol.180.9.5907" aria-label="Article reference 21" data-doi="10.4049/jimmunol.180.9.5907">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXkvVCjs78%3D" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18424710" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=HIV-1-specific%20T%20cell%20precursors%20with%20high%20proliferative%20capacity%20correlate%20with%20low%20viremia%20and%20high%20CD4%20counts%20in%20untreated%20individuals&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.180.9.5907&amp;volume=180&amp;pages=5907-5915&amp;publication_year=2008&amp;author=Calarota%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>377</b>, 1345–1356 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1709684" data-track-item_id="10.1056/NEJMoa1709684" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1709684" aria-label="Article reference 22" data-doi="10.1056/NEJMoa1709684">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1Git73I" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28889792" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778" aria-label="PubMed Central reference 22">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709684&amp;volume=377&amp;pages=1345-1356&amp;publication_year=2017&amp;author=Wolchok%2CJD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Robert, C. et al. Nivolumab in previously untreated melanoma without <i>BRAF</i> mutation. <i>N. Engl. J. Med.</i> <b>372</b>, 320–330 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1412082" data-track-item_id="10.1056/NEJMoa1412082" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1412082" aria-label="Article reference 23" data-doi="10.1056/NEJMoa1412082">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXisFGqsLg%3D" aria-label="CAS reference 23">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25399552" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20in%20previously%20untreated%20melanoma%20without%20BRAF%20mutation&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1412082&amp;volume=372&amp;pages=320-330&amp;publication_year=2015&amp;author=Robert%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Iii, C. H. K. et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. <i>Clin. Cancer Res.</i> <b>24</b>, 5347–5356 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Age%20correlates%20with%20response%20to%20anti-PD1%2C%20reflecting%20age-related%20differences%20in%20intratumoral%20effector%20and%20regulatory%20T-cell%20populations&amp;journal=Clin.%20Cancer%20Res.&amp;volume=24&amp;pages=5347-5356&amp;publication_year=2019&amp;author=Iii%2CCHK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Bastholt, L. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>Eur. J. Cancer</i> <b>119</b>, 122–131 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2019.06.022" data-track-item_id="10.1016/j.ejca.2019.06.022" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2019.06.022" aria-label="Article reference 25" data-doi="10.1016/j.ejca.2019.06.022">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFertrnI" aria-label="CAS reference 25">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31442816" aria-label="PubMed reference 25">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Age%20favoured%20overall%20survival%20in%20a%20large%20population-based%20Danish%20patient%20cohort%20treated%20with%20anti-PD1%20immune%20checkpoint%20inhibitor%20for%20metastatic%20melanoma&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2019.06.022&amp;volume=119&amp;pages=122-131&amp;publication_year=2019&amp;author=Bastholt%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Yan, X., Tian, X., Wu, Z. &amp; Han, W. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. <i>Front. Oncol</i>. <b>10</b>, 1671 (2020).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Huang, X. Z. et al. Efficacy of immune checkpoint inhibitors and age in cancer patients. <i>Immunotherapy</i> <b>12</b>, 587–603 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.2217/imt-2019-0124" data-track-item_id="10.2217/imt-2019-0124" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.2217%2Fimt-2019-0124" aria-label="Article reference 27" data-doi="10.2217/imt-2019-0124">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32378444" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20immune%20checkpoint%20inhibitors%20and%20age%20in%20cancer%20patients&amp;journal=Immunotherapy&amp;doi=10.2217%2Fimt-2019-0124&amp;volume=12&amp;pages=587-603&amp;publication_year=2020&amp;author=Huang%2CXZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Khozin, S., Blumenthal, G. M. &amp; Pazdur, R. Real-world data for clinical evidence generation in oncology. <i>J. Natl Cancer Inst.</i> <b>109</b>, 1359–1360 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/jnci/djx187" data-track-item_id="10.1093/jnci/djx187" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fjnci%2Fdjx187" aria-label="Article reference 28" data-doi="10.1093/jnci/djx187">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Real-world%20data%20for%20clinical%20evidence%20generation%20in%20oncology&amp;journal=J.%20Natl%20Cancer%20Inst.&amp;doi=10.1093%2Fjnci%2Fdjx187&amp;volume=109&amp;pages=1359-1360&amp;publication_year=2017&amp;author=Khozin%2CS&amp;author=Blumenthal%2CGM&amp;author=Pazdur%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. <i>Cell</i> <b>170</b>, 1109–1119 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.cell.2017.08.027" data-track-item_id="10.1016/j.cell.2017.08.027" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.cell.2017.08.027" aria-label="Article reference 29" data-doi="10.1016/j.cell.2017.08.027">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVOhu7rJ" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28886381" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034392" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Oncolytic%20virotherapy%20promotes%20intratumoral%20T%20cell%20infiltration%20and%20improves%20anti-PD-1%20immunotherapy&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.08.027&amp;volume=170&amp;pages=1109-1119&amp;publication_year=2017&amp;author=Ribas%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Long, G. et al. 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB–IVM1c melanoma. <i>J. Immunother. Cancer</i> <b>8</b>, A261 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=429%20Long-term%20analysis%20of%20MASTERKEY-265%20phase%201b%20trial%20of%20talimogene%20laherparepvec%20%28T-VEC%29%20plus%20pembrolizumab%20in%20patients%20with%20unresectable%20stage%20IIIB%E2%80%93IVM1c%20melanoma&amp;journal=J.%20Immunother.%20Cancer&amp;volume=8&amp;publication_year=2020&amp;author=Long%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncol.</i> <b>20</b>, 1083–1097 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(19)30274-8" data-track-item_id="10.1016/S1470-2045(19)30274-8" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2819%2930274-8" aria-label="Article reference 31" data-doi="10.1016/S1470-2045(19)30274-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtF2kurbM" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31221619" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Epacadostat%20plus%20pembrolizumab%20versus%20placebo%20plus%20pembrolizumab%20in%20patients%20with%20unresectable%20or%20metastatic%20melanoma%20%28ECHO-301%2FKEYNOTE-252%29%3A%20a%20phase%203%2C%20randomised%2C%20double-blind%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;volume=20&amp;pages=1083-1097&amp;publication_year=2019&amp;author=Long%2CGV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Iversen, T. Z. et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. <i>Clin. Cancer Res.</i> <b>20</b>, 221–232 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-13-1560" data-track-item_id="10.1158/1078-0432.CCR-13-1560" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-13-1560" aria-label="Article reference 32" data-doi="10.1158/1078-0432.CCR-13-1560">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXislKksA%3D%3D" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24218513" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-lasting%20disease%20stabilization%20in%20the%20absence%20of%20toxicity%20in%20metastatic%20lung%20cancer%20patients%20vaccinated%20with%20an%20epitope%20derived%20from%20indoleamine%202%2C3%20dioxygenase&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-13-1560&amp;volume=20&amp;pages=221-232&amp;publication_year=2014&amp;author=Iversen%2CTZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Kjeldsen, J. W. et al. Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study—a brief research report. <i>Front. Immunol.</i> <b>9</b>, 2145 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2018.02145" data-track-item_id="10.3389/fimmu.2018.02145" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2018.02145" aria-label="Article reference 33" data-doi="10.3389/fimmu.2018.02145">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30283461" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157336" aria-label="PubMed Central reference 33">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Durable%20clinical%20responses%20and%20long-term%20follow-up%20of%20stage%20III%E2%80%93IV%20non-small-cell%20lung%20cancer%20%28NSCLC%29%20patients%20treated%20with%20IDO%20peptide%20vaccine%20in%20a%20phase%20I%20study%E2%80%94a%20brief%20research%20report&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2018.02145&amp;volume=9&amp;publication_year=2018&amp;author=Kjeldsen%2CJW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> <b>585</b>, 107–112 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41586-020-2537-9" data-track-item_id="10.1038/s41586-020-2537-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-020-2537-9" aria-label="Article reference 34" data-doi="10.1038/s41586-020-2537-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVygtLvK" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32728218" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=An%20RNA%20vaccine%20drives%20immunity%20in%20checkpoint-inhibitor-treated%20melanoma&amp;journal=Nature&amp;doi=10.1038%2Fs41586-020-2537-9&amp;volume=585&amp;pages=107-112&amp;publication_year=2020&amp;author=Sahin%2CU">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Sørensen, R. B. et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. <i>Blood</i> <b>117</b>, 2200–2210 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2010-06-288498" data-track-item_id="10.1182/blood-2010-06-288498" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2010-06-288498" aria-label="Article reference 35" data-doi="10.1182/blood-2010-06-288498">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21079151" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062329" aria-label="PubMed Central reference 35">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Indoleamine%202%2C3-dioxygenase%20specific%2C%20cytotoxic%20T%20cells%20as%20immune%20regulators&amp;journal=Blood&amp;doi=10.1182%2Fblood-2010-06-288498&amp;volume=117&amp;pages=2200-2210&amp;publication_year=2011&amp;author=S%C3%B8rensen%2CRB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Søorensen, R. B. et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> <b>4</b>, e6910 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0006910" data-track-item_id="10.1371/journal.pone.0006910" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0006910" aria-label="Article reference 36" data-doi="10.1371/journal.pone.0006910">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20system%20strikes%20back%3A%20cellular%20immune%20responses%20against%20indoleamine%202%2C3-dioxygenase&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0006910&amp;volume=4&amp;publication_year=2009&amp;author=S%C3%B8orensen%2CRB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Munir, S. et al. Natural CD4<sup>+</sup> T-cell responses against indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> <b>7</b>, e34568 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0034568" data-track-item_id="10.1371/journal.pone.0034568" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0034568" aria-label="Article reference 37" data-doi="10.1371/journal.pone.0034568">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38Xmslaiurc%3D" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22539948" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335144" aria-label="PubMed Central reference 37">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Natural%20CD4%2B%20T-cell%20responses%20against%20indoleamine%202%2C3-dioxygenase&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0034568&amp;volume=7&amp;publication_year=2012&amp;author=Munir%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Munir, S. et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. <i>Cancer Res.</i> <b>73</b>, 1764–1776 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-12-3507" data-track-item_id="10.1158/0008-5472.CAN-12-3507" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-12-3507" aria-label="Article reference 38" data-doi="10.1158/0008-5472.CAN-12-3507">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXktVGisrs%3D" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23328583" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=HLA-restricted%20CTL%20that%20are%20specific%20for%20the%20immune%20checkpoint%20ligand%20PD-L1%20occur%20with%20high%20frequency%20in%20cancer%20patients&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-12-3507&amp;volume=73&amp;pages=1764-1776&amp;publication_year=2013&amp;author=Munir%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Andersen, M. H. The targeting of tumor-associated macrophages by vaccination. <i>Cell Stress</i> <b>3</b>, 139–140 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.15698/cst2019.05.185" data-track-item_id="10.15698/cst2019.05.185" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.15698%2Fcst2019.05.185" aria-label="Article reference 39" data-doi="10.15698/cst2019.05.185">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVCjsrfE" aria-label="CAS reference 39">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31225509" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551857" aria-label="PubMed Central reference 39">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20targeting%20of%20tumor-associated%20macrophages%20by%20vaccination&amp;journal=Cell%20Stress&amp;doi=10.15698%2Fcst2019.05.185&amp;volume=3&amp;pages=139-140&amp;publication_year=2019&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. <i>Clin. Cancer Res.</i> <b>22</b>, 3734–3745 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-15-1879" data-track-item_id="10.1158/1078-0432.CCR-15-1879" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-15-1879" aria-label="Article reference 40" data-doi="10.1158/1078-0432.CCR-15-1879">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xht1yhtb3L" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27006492" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-lasting%20complete%20responses%20in%20patients%20with%20metastatic%20melanoma%20after%20adoptive%20cell%20therapy%20with%20tumor-infiltrating%20lymphocytes%20and%20an%20attenuated%20IL2%20regimen&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-15-1879&amp;volume=22&amp;pages=3734-3745&amp;publication_year=2016&amp;author=Andersen%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Jørgensen, N. G. et al. Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: a phase I first-in-human trial. <i>Front. Immunol.</i> <b>11</b>, 595035 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3389/fimmu.2020.595035" data-track-item_id="10.3389/fimmu.2020.595035" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3389%2Ffimmu.2020.595035" aria-label="Article reference 41" data-doi="10.3389/fimmu.2020.595035">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33240282" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680803" aria-label="PubMed Central reference 41">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Peptide%20vaccination%20against%20PD-L1%20with%20IO103%20a%20novel%20immune%20modulatory%20vaccine%20in%20multiple%20myeloma%3A%20a%20phase%20I%20first-in-human%20trial&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2020.595035&amp;volume=11&amp;publication_year=2020&amp;author=J%C3%B8rgensen%2CNG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> <b>515</b>, 568–571 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nature13954" data-track-item_id="10.1038/nature13954" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnature13954" aria-label="Article reference 42" data-doi="10.1038/nature13954">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFanu7jL" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25428505" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-1%20blockade%20induces%20responses%20by%20inhibiting%20adaptive%20immune%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fnature13954&amp;volume=515&amp;pages=568-571&amp;publication_year=2014&amp;author=Tumeh%2CPC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Wang, T. et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. <i>Nat. Commun.</i> <b>9</b>, 1532 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-018-03915-4" data-track-item_id="10.1038/s41467-018-03915-4" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-018-03915-4" aria-label="Article reference 43" data-doi="10.1038/s41467-018-03915-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29670088" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906566" aria-label="PubMed Central reference 43">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20cancer%20vaccine-mediated%20postoperative%20immunotherapy%20for%20recurrent%20and%20metastatic%20tumors&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-018-03915-4&amp;volume=9&amp;publication_year=2018&amp;author=Wang%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Vilain, R. E. et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. <i>Clin. Cancer Res.</i> <b>23</b>, 5024–5033 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-16-0698" data-track-item_id="10.1158/1078-0432.CCR-16-0698" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-16-0698" aria-label="Article reference 44" data-doi="10.1158/1078-0432.CCR-16-0698">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVCit7nN" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28512174" aria-label="PubMed reference 44">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Dynamic%20changes%20in%20PD-L1%20expression%20and%20immune%20infiltrates%20early%20during%20treatment%20predict%20response%20to%20PD-1%20blockade%20in%20melanoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-0698&amp;volume=23&amp;pages=5024-5033&amp;publication_year=2017&amp;author=Vilain%2CRE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Andersen, M. H. The balance players of the adaptive immune system. <i>Cancer Res.</i> <b>78</b>, 1379–1382 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/0008-5472.CAN-17-3607" data-track-item_id="10.1158/0008-5472.CAN-17-3607" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F0008-5472.CAN-17-3607" aria-label="Article reference 45" data-doi="10.1158/0008-5472.CAN-17-3607">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXks1yls7s%3D" aria-label="CAS reference 45">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29440147" aria-label="PubMed reference 45">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20balance%20players%20of%20the%20adaptive%20immune%20system&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-17-3607&amp;volume=78&amp;pages=1379-1382&amp;publication_year=2018&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. <i>Nat. Immunol.</i> <b>21</b>, 442–454 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41590-020-0620-x" data-track-item_id="10.1038/s41590-020-0620-x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41590-020-0620-x" aria-label="Article reference 46" data-doi="10.1038/s41590-020-0620-x">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXksFeqtr8%3D" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32152508" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1%20engagement%20on%20T%20cells%20promotes%20self-tolerance%20and%20suppression%20of%20neighboring%20macrophages%20and%20effector%20T%20cells%20in%20cancer&amp;journal=Nat.%20Immunol.&amp;doi=10.1038%2Fs41590-020-0620-x&amp;volume=21&amp;pages=442-454&amp;publication_year=2020&amp;author=Diskin%2CB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Ahmad, S. M., Svane, I. M. &amp; Andersen, M. H. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. <i>Blood Cancer J.</i> <b>4</b>, e230 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/bcj.2014.50" data-track-item_id="10.1038/bcj.2014.50" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fbcj.2014.50" aria-label="Article reference 47" data-doi="10.1038/bcj.2014.50">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC2cbktlGnsQ%3D%3D" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25036801" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219446" aria-label="PubMed Central reference 47">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20stimulation%20of%20PD-L1-specific%20cytotoxic%20T%20lymphocytes%20can%20both%20directly%20and%20indirectly%20enhance%20antileukemic%20immunity&amp;journal=Blood%20Cancer%20J.&amp;doi=10.1038%2Fbcj.2014.50&amp;volume=4&amp;publication_year=2014&amp;author=Ahmad%2CSM&amp;author=Svane%2CIM&amp;author=Andersen%2CMH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Munir Ahmad, S. et al. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. <i>Oncoimmunology</i> <b>5</b>, e1202391 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1080/2162402X.2016.1202391" data-track-item_id="10.1080/2162402X.2016.1202391" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1080%2F2162402X.2016.1202391" aria-label="Article reference 48" data-doi="10.1080/2162402X.2016.1202391">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27622072" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007957" aria-label="PubMed Central reference 48">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1%20peptide%20co-stimulation%20increases%20immunogenicity%20of%20a%20dendritic%20cell-based%20cancer%20vaccine&amp;journal=Oncoimmunology&amp;doi=10.1080%2F2162402X.2016.1202391&amp;volume=5&amp;publication_year=2016&amp;author=Munir%20Ahmad%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. <i>Nat. Rev. Cancer</i> <b>12</b>, 252–264 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrc3239" data-track-item_id="10.1038/nrc3239" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrc3239" aria-label="Article reference 49" data-doi="10.1038/nrc3239">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XksVegtrw%3D" aria-label="CAS reference 49">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22437870" aria-label="PubMed reference 49">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023" aria-label="PubMed Central reference 49">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20blockade%20of%20immune%20checkpoints%20in%20cancer%20immunotherapy&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc3239&amp;volume=12&amp;pages=252-264&amp;publication_year=2012&amp;author=Pardoll%2CDM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. <i>Cancer Immunol. Immunother.</i> <b>59</b>, 1489–1501 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-010-0875-4" data-track-item_id="10.1007/s00262-010-0875-4" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-010-0875-4" aria-label="Article reference 50" data-doi="10.1007/s00262-010-0875-4">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC3cnps1Gmtw%3D%3D" aria-label="CAS reference 50">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20549207" aria-label="PubMed reference 50">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909425" aria-label="PubMed Central reference 50">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Response%20definition%20criteria%20for%20ELISPOT%20assays%20revisited&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-010-0875-4&amp;volume=59&amp;pages=1489-1501&amp;publication_year=2010&amp;author=Moodie%2CZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Donia, M. et al. Characterization and comparison of ‘standard’ and ‘young’ tumor infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. <i>Scand. J. Immunol.</i> <b>75</b>, 157–167 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/j.1365-3083.2011.02640.x" data-track-item_id="10.1111/j.1365-3083.2011.02640.x" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fj.1365-3083.2011.02640.x" aria-label="Article reference 51" data-doi="10.1111/j.1365-3083.2011.02640.x">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20and%20comparison%20of%20%E2%80%98standard%E2%80%99%20and%20%E2%80%98young%E2%80%99%20tumor%20infiltrating%20lymphocytes%20for%20adoptive%20cell%20therapy%20at%20a%20Danish%20translational%20research%20institution&amp;journal=Scand.%20J.%20Immunol.&amp;doi=10.1111%2Fj.1365-3083.2011.02640.x&amp;volume=75&amp;pages=157-167&amp;publication_year=2011&amp;author=Donia%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Hobo, W. et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8<sup>+</sup> T cells. <i>Blood</i> <b>116</b>, 4501–4511 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2010-04-278739" data-track-item_id="10.1182/blood-2010-04-278739" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2010-04-278739" aria-label="Article reference 52" data-doi="10.1182/blood-2010-04-278739">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFGgtbvM" aria-label="CAS reference 52">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20682852" aria-label="PubMed reference 52">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=siRNA%20silencing%20of%20PD-L1%20and%20PD-L2%20on%20dendritic%20cells%20augments%20expansion%20and%20function%20of%20minor%20histocompatibility%20antigen-specific%20CD8%2B%20T%20cells&amp;journal=Blood&amp;doi=10.1182%2Fblood-2010-04-278739&amp;volume=116&amp;pages=4501-4511&amp;publication_year=2010&amp;author=Hobo%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Met, Ö., Balslev, E., Flyger, H. &amp; Svane, I. M. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. <i>Breast Cancer Res. Treat.</i> <b>125</b>, 395–406 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s10549-010-0844-9" data-track-item_id="10.1007/s10549-010-0844-9" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s10549-010-0844-9" aria-label="Article reference 53" data-doi="10.1007/s10549-010-0844-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFCqt73J" aria-label="CAS reference 53">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20336365" aria-label="PubMed reference 53">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=High%20immunogenic%20potential%20of%20p53%20mRNA-transfected%20dendritic%20cells%20in%20patients%20with%20primary%20breast%20cancer&amp;journal=Breast%20Cancer%20Res.%20Treat.&amp;doi=10.1007%2Fs10549-010-0844-9&amp;volume=125&amp;pages=395-406&amp;publication_year=2011&amp;author=Met%2C%C3%96&amp;author=Balslev%2CE&amp;author=Flyger%2CH&amp;author=Svane%2CIM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Bookout, A. L., Cummins, C. L., Mangelsdorf, D. J., Pesola, J. M. &amp; Kramer, M. F. High‐throughput real‐time quantitative reverse transcription PCR. <i>Curr. Protoc. Mol. Biol.</i> <b>73</b>, 15.8.1–15.8.28 (2006).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/0471142727.mb1508s73" data-track-item_id="10.1002/0471142727.mb1508s73" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2F0471142727.mb1508s73" aria-label="Article reference 54" data-doi="10.1002/0471142727.mb1508s73">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=High%E2%80%90throughput%20real%E2%80%90time%20quantitative%20reverse%20transcription%20PCR&amp;journal=Curr.%20Protoc.%20Mol.%20Biol.&amp;doi=10.1002%2F0471142727.mb1508s73&amp;volume=73&amp;pages=15.8.1-15.8.28&amp;publication_year=2006&amp;author=Bookout%2CAL&amp;author=Cummins%2CCL&amp;author=Mangelsdorf%2CDJ&amp;author=Pesola%2CJM&amp;author=Kramer%2CMF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Robins, H. S. et al. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells. <i>Blood</i> <b>114</b>, 4099–4107 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2009-04-217604" data-track-item_id="10.1182/blood-2009-04-217604" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2009-04-217604" aria-label="Article reference 55" data-doi="10.1182/blood-2009-04-217604">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsVGku7vN" aria-label="CAS reference 55">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19706884" aria-label="PubMed reference 55">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774550" aria-label="PubMed Central reference 55">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20assessment%20of%20T-cell%20receptor%20%CE%B2-chain%20diversity%20in%20%CE%B1%CE%B2%20T%20cells&amp;journal=Blood&amp;doi=10.1182%2Fblood-2009-04-217604&amp;volume=114&amp;pages=4099-4107&amp;publication_year=2009&amp;author=Robins%2CHS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. <i>Nat. Commun.</i> <b>4</b>, 2680 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms3680" data-track-item_id="10.1038/ncomms3680" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms3680" aria-label="Article reference 56" data-doi="10.1038/ncomms3680">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24157944" aria-label="PubMed reference 56">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Using%20synthetic%20templates%20to%20design%20an%20unbiased%20multiplex%20PCR%20assay&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms3680&amp;volume=4&amp;publication_year=2013&amp;author=Carlson%2CCS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">Robins, H. et al. Ultra-sensitive detection of rare T cell clones. <i>J. Immunol. Methods</i> <b>375</b>, 14–19 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.jim.2011.09.001" data-track-item_id="10.1016/j.jim.2011.09.001" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.jim.2011.09.001" aria-label="Article reference 57" data-doi="10.1016/j.jim.2011.09.001">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XlsV2hsA%3D%3D" aria-label="CAS reference 57">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21945395" aria-label="PubMed reference 57">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Ultra-sensitive%20detection%20of%20rare%20T%20cell%20clones&amp;journal=J.%20Immunol.%20Methods&amp;doi=10.1016%2Fj.jim.2011.09.001&amp;volume=375&amp;pages=14-19&amp;publication_year=2012&amp;author=Robins%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">DeWitt, W. S. et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. <i>J. Virol.</i> <b>89</b>, 4517–4526 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1128/JVI.03474-14" data-track-item_id="10.1128/JVI.03474-14" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1128%2FJVI.03474-14" aria-label="Article reference 58" data-doi="10.1128/JVI.03474-14">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXlvVWlsb4%3D" aria-label="CAS reference 58">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25653453" aria-label="PubMed reference 58">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442358" aria-label="PubMed Central reference 58">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Dynamics%20of%20the%20cytotoxic%20T%20cell%20response%20to%20a%20model%20of%20acute%20viral%20infection&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.03474-14&amp;volume=89&amp;pages=4517-4526&amp;publication_year=2015&amp;author=DeWitt%2CWS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">Benjamini, Y. &amp; Gavrilov, Y. A simple forward selection procedure based on false discovery rate control. <i>Ann. Appl. Stat.</i> <b>3</b>, 179–198 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1214/08-AOAS194" data-track-item_id="10.1214/08-AOAS194" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1214%2F08-AOAS194" aria-label="Article reference 59" data-doi="10.1214/08-AOAS194">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20simple%20forward%20selection%20procedure%20based%20on%20false%20discovery%20rate%20control&amp;journal=Ann.%20Appl.%20Stat.&amp;doi=10.1214%2F08-AOAS194&amp;volume=3&amp;pages=179-198&amp;publication_year=2009&amp;author=Benjamini%2CY&amp;author=Gavrilov%2CY">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01544-x?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>We thank all patients and their relatives for being a part of the trial. We thank Ö. Met, M. Jonassen, S. Ullitz Færch, B. Saxild, S. Wendt and C. Grønhøj for technical support. We thank M. Cumberbatch for input with translational analysis. We thank the nurses at clinic 5 and the head of the Oncology Department at Herlev and Gentofte Hospital, L. Sengeløv. The study was funded through a research funding agreement between IO Biotech and the CCIT-DK, Herlev Hospital and the Oncology Department at Herlev Hospital.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark</p><p class="c-article-author-affiliation__authors-list">Julie Westerlin Kjeldsen,&nbsp;Cathrine Lund Lorentzen,&nbsp;Evelina Martinenaite,&nbsp;Eva Ellebaek,&nbsp;Marco Donia,&nbsp;Rikke Boedker Holmstroem,&nbsp;Tobias Wirenfeldt Klausen,&nbsp;Cecilie Oelvang Madsen,&nbsp;Shamaila Munir Ahmed,&nbsp;Stine Emilie Weis-Banke,&nbsp;Morten Orebo Holmström,&nbsp;Mads Hald Andersen&nbsp;&amp;&nbsp;Inge Marie Svane</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">IO Biotech Aps, Copenhagen, Denmark</p><p class="c-article-author-affiliation__authors-list">Evelina Martinenaite,&nbsp;Eva Ehrnrooth,&nbsp;Mai-Britt Zocca&nbsp;&amp;&nbsp;Ayako Wakatsuki Pedersen</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Herlev, Denmark</p><p class="c-article-author-affiliation__authors-list">Helle Westergren Hendel</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark</p><p class="c-article-author-affiliation__authors-list">Mads Hald Andersen</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Julie_Westerlin-Kjeldsen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Julie Westerlin Kjeldsen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Julie%20Westerlin%20Kjeldsen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Julie%20Westerlin%20Kjeldsen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Julie%20Westerlin%20Kjeldsen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Cathrine_Lund-Lorentzen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Cathrine Lund Lorentzen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Cathrine%20Lund%20Lorentzen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Cathrine%20Lund%20Lorentzen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Cathrine%20Lund%20Lorentzen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Evelina-Martinenaite-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Evelina Martinenaite</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Evelina%20Martinenaite" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Evelina%20Martinenaite" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Evelina%20Martinenaite%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Eva-Ellebaek-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Eva Ellebaek</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Eva%20Ellebaek" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Eva%20Ellebaek" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Eva%20Ellebaek%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marco-Donia-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Marco Donia</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marco%20Donia" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marco%20Donia" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marco%20Donia%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rikke_Boedker-Holmstroem-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Rikke Boedker Holmstroem</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rikke%20Boedker%20Holmstroem" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rikke%20Boedker%20Holmstroem" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rikke%20Boedker%20Holmstroem%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Tobias_Wirenfeldt-Klausen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Tobias Wirenfeldt Klausen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Tobias%20Wirenfeldt%20Klausen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Tobias%20Wirenfeldt%20Klausen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Tobias%20Wirenfeldt%20Klausen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Cecilie_Oelvang-Madsen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Cecilie Oelvang Madsen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Cecilie%20Oelvang%20Madsen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Cecilie%20Oelvang%20Madsen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Cecilie%20Oelvang%20Madsen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Shamaila_Munir-Ahmed-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Shamaila Munir Ahmed</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Shamaila%20Munir%20Ahmed" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Shamaila%20Munir%20Ahmed" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Shamaila%20Munir%20Ahmed%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Stine_Emilie-Weis_Banke-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Stine Emilie Weis-Banke</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Stine%20Emilie%20Weis-Banke" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Stine%20Emilie%20Weis-Banke" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Stine%20Emilie%20Weis-Banke%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Morten_Orebo-Holmstr_m-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Morten Orebo Holmström</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Morten%20Orebo%20Holmstr%C3%B6m" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Morten%20Orebo%20Holmstr%C3%B6m" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Morten%20Orebo%20Holmstr%C3%B6m%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Helle_Westergren-Hendel-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Helle Westergren Hendel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Helle%20Westergren%20Hendel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Helle%20Westergren%20Hendel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Helle%20Westergren%20Hendel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Eva-Ehrnrooth-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Eva Ehrnrooth</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Eva%20Ehrnrooth" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Eva%20Ehrnrooth" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Eva%20Ehrnrooth%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Mai_Britt-Zocca-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Mai-Britt Zocca</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Mai-Britt%20Zocca" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Mai-Britt%20Zocca" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Mai-Britt%20Zocca%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ayako_Wakatsuki-Pedersen-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Ayako Wakatsuki Pedersen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ayako%20Wakatsuki%20Pedersen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ayako%20Wakatsuki%20Pedersen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ayako%20Wakatsuki%20Pedersen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Mads_Hald-Andersen-Aff1-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Mads Hald Andersen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Mads%20Hald%20Andersen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Mads%20Hald%20Andersen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Mads%20Hald%20Andersen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Inge_Marie-Svane-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Inge Marie Svane</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Inge%20Marie%20Svane" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Inge%20Marie%20Svane" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Inge%20Marie%20Svane%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>I.M.S. and M.H.A. conceived the study. J.W.K. wrote the protocol with input from I.M.S., M.H.A. and M.-B.Z. J.W.K. and C.L.L. were responsible for patient treatment and patient care with help from R.B.H. and consulting from I.M.S., E. Ellebaek and M.D. I.M.S., E. Ellebaek and M.D. were responsible for patient recruitment. J.W.K. and C.L.L. were responsible for coordinating trial procedures and collecting data and samples. J.W.K. and C.L.L. were clinical investigators, and I.M.S. was a sponsor. J.W.K. and C.L.L. analyzed and interpreted clinical data with support from I.M.S. and E. Ehrnrooth. T.W.K. performed statistical analyses. H.W.H. helped with clinical imaging. J.W.K., E.M., C.O.M., S.M.A., S.E.W.-B., M.O.H. and A.W.P. analyzed and interpreted translational data with support from M.H.A. and I.M.S. Funding was acquired by I.M.S., M.H.A. and M.-B.Z. J.W.K. wrote the manuscript with input from I.M.S., M.H.A., E.M. and A.W.P. All authors reviewed the manuscript, interpreted data and approved the final version.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:inge.marie.svane@regionh.dk">Inge Marie Svane</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar3">Competing interests</h3>
                <p>M.H.A. is named as an inventor on various patent applications relating to therapeutic uses of IDO and PD-L1 peptides. These patent applications are assigned to the company IO Biotech, which is developing immune-modulating cancer treatments. M.H.A. is a founder, shareholder and advisor for IO Biotech. I.M.S. is a cofounder, shareholder and advisor for IO Biotech. I.M.S. has an advisory board relationship with or lectured for Roche, Novartis, MSD, Celgene, Incyte, TILT Bio, Pfizer and BMS AstraZeneca and has received limited grants for translational research from BMS, Roche and Novartis. M.-B.Z. is the CEO, founder and shareholder at IO Biotech. E.M., A.W.P. and E. Ehrnrooth are employees at IO Biotech. E. Ellebaek has received honoraria from BMS, Pierre Fabre, Roche and Kyowa Kirin and travel support from MSD. M.D. has received honoraria from Genzyme, MSD, BMS, Roche and Novartis and travel support from Novartis, MSD, BMS, Roche and Pfizer. The remaining authors declare that they have no conflict of interest.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Peer review information</b> <i>Nature Medicine</i> thanks George Coukos, Michael Schell and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Javier Carmona was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.</p><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec44-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec44">Extended data</h2><div class="c-article-section__content" id="Sec44-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 mode of action and treatment " href="/articles/s41591-021-01544-x/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig6_ESM.jpg">Extended Data Fig. 1 Mode of Action and treatment plan.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> Anticipated mechanism of action of the combination therapy of an IDO/PD-L1 derived peptide vaccine and nivolumab (anti-PD1). 1) The IDO/PD-L1 peptide vaccine is administered subcutaneously (s.c) and nivolumab is administered intravenous (IV). 2) The vaccines peptides are phagocytosed by an antigen presenting cell and presented to IDO and PD-L1 specific T cells, which are activated. 3) The activated T cells migrates to the tumor site where they attack both immune-suppressive cells and tumour cells expressing IDO and/or PD-L1 leading to cytokine production and a pro-inflammatory tumour microenvironment. 4/5) Enhanced tumour killing by both IDO/PD-L1 specific T cells and tumor specific cytotoxic T cells due to PD-1 blockade. Created with BioRender.com <b>b)</b> Treatment plan. After written informed content patients were screened. Before treatment start a baseline PET/CT scan was performed, baseline blood sample for research use and if assessable a baseline needle biopsy. Patients were treated with the IDO/PD-L1 peptide vaccine subcutaneously biweekly for the first 6 injections and thereafter every fourth week for a maximum of 15 vaccines. Nivolumab was administered in parallel biweekly (3mg/kg) up to 24 series. If patients needed subsequent nivolumab after ended vaccination regiment they were treated with 6 mg/kg every fourth week up to two years. Needle biopsy and delayed type hypersensitivity (DTH) was performed after 6 series of treatment if assessable. PET/CT scans was performed every third month.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 progression free survival and" href="/articles/s41591-021-01544-x/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig7_ESM.jpg">Extended Data Fig. 2 Progression free survival and overall survival in matched historical control group and vaccine injection site reaction.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>) Kaplan-Meier curve of progression free survival with corresponding 95% confidence intervals in the matched historical control group (n=74). Patients were matched on BRAF-status, PD-L1-status, age, gender, M-stage and LDH level). <b>b)</b> Kaplan-Meier curve of overall survival with corresponding 95% confidence intervals in the matched historical control group (n=74). <b>c)</b> Images of injection site reaction in patient MM20 (CR) after 11 vaccination show redness, rash and granuloma at injection site.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 vaccine specific responses in" href="/articles/s41591-021-01544-x/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig8_ESM.jpg">Extended Data Fig. 3 Vaccine specific responses in blood.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> Heatmap of specific (background has been subtracted) IDO and PD-L1 responses in PBMCs at baseline, series 3, 6, 12, 18 and 24 measured by in vitro IFN-γ Elispot assay show fluctuations in the blood during treatment (n=30). <b>b)</b> Heatmap of specific (background has been subtracted) IDO and PD-L1 responses in PBMCs at baseline and 3 and 6 months after last vaccine measured by in vitro IFN- γ Elispot assay (n=30). 2.5–3.2x10<sup>5</sup> cells per well were used. <b>c)</b> Vaccine associated clones were tracked in the blood by summing the frequency of each rearrangement enriched in either IDO or PD-L1 T cells.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 ex vivo vaccine specific resp" href="/articles/s41591-021-01544-x/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig9_ESM.jpg">Extended Data Fig. 4 Ex vivo vaccine specific responses in blood.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Heatmaps of detected specific (background has been subtracted) IDO (a) and PD-L1 (b) responses in PBMCs at baseline and on/after treatment as measured by IFNγ ELISPOT (n=25). C) Example of well images of ex vivo ELISPOT wells for three different patients (n=3). 6-9x10<sup>5</sup> cells per well were used.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 cd4 and cd8 vaccine specific " href="/articles/s41591-021-01544-x/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig10_ESM.jpg">Extended Data Fig. 5 CD4 and CD8 vaccine specific T cell responses in blood.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Top: heatmaps of IDO specific CD4 (left) and CD8 (right) T cell responses in PBMCs at baseline and on/post treatment. Bottom: heatmaps of PD-L1 specific CD4 (left) and CD8 (right) T cell responses. Responses quantified by flow cytometry by an increased expression of CD107α, CD137 and TNFα after 8h peptide stimulation. Values represent specific responses after background values have been subtracted (n=21). Statistical analysis were performed using two-sided Wilcoxon matched-paired rank test.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 pro-inflammatory profiles of " href="/articles/s41591-021-01544-x/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig11_ESM.jpg">Extended Data Fig. 6 Pro-inflammatory profiles of sorted CD4 and CD8 T cells from blood.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a/b/c/d)</b> Percentage of in vitro stimulated and sorted PD-L1 and IDO specific CD4 and CD8 T cells secreting cytokines.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 vaccine specific responses in" href="/articles/s41591-021-01544-x/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig12_ESM.jpg">Extended Data Fig. 7 Vaccine specific responses in skin.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> IDO and PD-L1 specific T cell responses in SKILs after 6 series of treatment measured by IFN-γ Elispot assay (n=13). SKILs were grown from DTH injection with either IDO peptide, PD-L1 peptide or a mix as presented by different blue colours. * Responses were calculated as the difference between average numbers of spots in wells stimulated with IDO or PD-L1 peptide (triplicates) and corresponding control (DMSO) and statistical analyses of Elispot responses were performed using distribution-free resampling method (Moodie et al.). DR: Not statistically confirmed response due to replicate number but number of spots in peptide wells are two times higher than control wells (DMSO). NS: No significant response and no DR. <b>b/c/d)</b> Percentage of cytokine secreting/CD107a+ CD4+ and CD8+ IDO and PD-L1 specific T cells in response to in vitro peptide stimulation by flow cytometry. <b>e)</b> Skin infiltrating PD-L1 specific T cell clones also found in biopsy in patient MM01. TCR sequencing was performed on a PD-L1 specific T cell culture generated from DTH area on the lower back injected with PD-L1 peptide on patient MM01. Bars show the frequency of top 25 clones in the culture with which indicates a high Simpson clonality of 0.43. <b>f)</b> Tracking the frequency of the top five skin infiltrating PD-L1 specific clones in tumour before and after treatment.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 t cell changes in blood after" href="/articles/s41591-021-01544-x/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig13_ESM.jpg">Extended Data Fig. 8 T cell changes in blood after treatment. T cell fraction, TCR clonality and repertoire richness in blood and peripherally expanded TCR clones in both responding and non-responding patients.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> T cell fraction in peripheral blood of five patients at baseline, series 3, 6 and 12 by TCR sequencing. T cell fraction was calculated by taking the total number of T cell templates and dividing by the total number of nucleated cells (n=5.) <b>b)</b> TCR clonality in peripheral blood of five patients at baseline, series 3, 6 and 12 by TCR sequencing (n=5). Simpson clonality measures how evenly TCR sequences are distributed amongst a set of T cells where 0 indicate even distribution of frequencies and 1 indicate an asymmetric distribution where a few clones dominate. <b>c)</b> TCR repertoire richness in peripheral blood of five patients at baseline, series 3, 6 and 12 by TCR sequencing (n=5). TCR repertoire richness report the mean number of unique rearrangements. <b>d)</b> Bar-chart chart representing dynamics of the expanded T cell clones. Coloured bars represent peripherally expanded clones in five patients at series 3, series 6 and series 12 as compared to the baseline PBMC samples (n=5). Light gray bar represents peripherally expanded clones that are present in baseline biopsy samples while dark gray bar represents peripherally expanded clones that are present in the post-treatment biopsy (after 6 series). <b>e)</b> Frequency of the dominant TCR β chain in clonal PD-L1 and IDO specific cultures as determined by CDR3 sequencing.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 profiling of genes relevant t" href="/articles/s41591-021-01544-x/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig14_ESM.jpg">Extended Data Fig. 9 Profiling of genes relevant to T cell activation, cytokines and exhaustion markers on pre- and post-treatment biopsies in two patients.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> RNA expression profiling of genes related to T cell activation was performed using NanoString nCounter (n=2). <b>b)</b> RNA expression profiling of genes related to cytokine activity was performed using NanoString nCounter (n=2). <b>c)</b> RNA expression profiling of genes related to checkpoint inhibitors was performed using NanoString nCounter (n=2).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig15"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 10 treatment induced upregulati" href="/articles/s41591-021-01544-x/figures/15" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig15_ESM.jpg">Extended Data Fig. 10 Treatment induced upregulation of PD-L1, IDO, MHC I and MHC II and distance between CD8 T cells and PD-L1 expressing cells.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a)</b> IHC on 4 paired biopsies stained for CD3 and CD8 T cells, PD-L1, MHC I and MHC II on tumor cells/mm<sup>2</sup> (sum in the validated area) and IDO H-score (from 0 to 300). H-score is the expression of IDO on both immune and tumor cells: The score is obtained by the formula: 3 x percentage of cells with a strong staining + 2 x percentage of cells with a moderate staining + percentage of cells with a weak staining (n=4). <b>b)</b> Distance in µm between CD8+ T cells and PD-L1+ stained cells on five baseline biopsies detected by IHC (n=5).</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec45-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec45">Supplementary information</h2><div class="c-article-section__content" id="Sec45-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Figs. 1–3 and Tables 1–6</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=A%20phase%201%2F2%20trial%20of%20an%20immune-modulatory%20vaccine%20against%20IDO%2FPD-L1%20in%20combination%20with%20nivolumab%20in%20metastatic%20melanoma&amp;author=Julie%20Westerlin%20Kjeldsen%20et%20al&amp;contentID=10.1038%2Fs41591-021-01544-x&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2021-12-09&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-021-01544-x" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-021-01544-x" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Kjeldsen, J.W., Lorentzen, C.L., Martinenaite, E. <i>et al.</i> A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
                    <i>Nat Med</i> <b>27</b>, 2212–2223 (2021). https://doi.org/10.1038/s41591-021-01544-x</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01544-x?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-02-19">19 February 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-09-20">20 September 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-12-09">09 December 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-12">December 2021</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-021-01544-x</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/melanoma" data-track="click" data-track-action="view subject" data-track-label="link">Melanoma</a></li><li class="c-article-subject-list__subject"><a href="/subjects/peptide-vaccines" data-track="click" data-track-action="view subject" data-track-label="link">Peptide vaccines</a></li><li class="c-article-subject-list__subject"><a href="/subjects/phase-ii-trials" data-track="click" data-track-action="view subject" data-track-label="link">Phase II trials</a></li><li class="c-article-subject-list__subject"><a href="/subjects/translational-research" data-track="click" data-track-action="view subject" data-track-label="link">Translational research</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Harnessing amino acid pathways to influence myeloid cell function in tumor immunity" href="https://doi.org/10.1186/s10020-025-01099-4">
                                        Harnessing amino acid pathways to influence myeloid cell function in tumor immunity
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Jiongli Pan</li><li>Yi Lin</li><li>Xueli Bai</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Molecular Medicine</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines" href="https://doi.org/10.1038/s41423-024-01249-4">
                                        Sequential STING and CD40 agonism drives massive expansion of tumor-specific T cells in liposomal peptide vaccines
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Dmitrij Ostroumov</li><li>Naomi Benne</li><li>Thomas Christian Wirth</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Cellular &amp; Molecular Immunology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study" href="https://doi.org/10.1007/s00262-025-03969-6">
                                        Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Else Marit Inderberg</li><li>Nand Singh</li><li>Karianne Risberg Handeland</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Cancer Immunology, Immunotherapy</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Cooperative Hedgehog/GLI and JAK/STAT signaling drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer" href="https://doi.org/10.1186/s12964-025-02101-6">
                                        Cooperative Hedgehog/GLI and JAK/STAT signaling drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Dominik P. Elmer</li><li>Georg Stockmaier</li><li>Fritz Aberger</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Cell Communication and Signaling</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition" href="https://doi.org/10.1186/s13045-024-01634-6">
                                        Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Antonino Glaviano</li><li>Hannah Si-Hui Lau</li><li>Alan Prem Kumar</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Journal of Hematology &amp; Oncology</i> (2025)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01544-x.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: 409.45px;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec13" class="c-reading-companion__section-item"><a href="#Sec13" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec14" class="c-reading-companion__section-item"><a href="#Sec14" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-change-history" class="c-reading-companion__section-item"><a href="#change-history" data-track="click" data-track-action="section anchor" data-track-label="link:Change history">Change history</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec44" class="c-reading-companion__section-item"><a href="#Sec44" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec45" class="c-reading-companion__section-item"><a href="#Sec45" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-021-01544-x;doi=10.1038/s41591-021-01544-x;subjmeta=109,1634,1813,1941,2030,250,2779,308,575,590,631,67,692;kwrd=Melanoma,Peptide+vaccines,Phase+II+trials,Translational+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=576186503&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01544-x%26doi%3D10.1038/s41591-021-01544-x%26subjmeta%3D109,1634,1813,1941,2030,250,2779,308,575,590,631,67,692%26kwrd%3DMelanoma,Peptide+vaccines,Phase+II+trials,Translational+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=576186503&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01544-x%26doi%3D10.1038/s41591-021-01544-x%26subjmeta%3D109,1634,1813,1941,2030,250,2779,308,575,590,631,67,692%26kwrd%3DMelanoma,Peptide+vaccines,Phase+II+trials,Translational+research"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Clinical response.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Clinical response.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: Vaccine-specific responses in blood.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: PD-L1- and IDO-specific T cells from vaccinated patients react against PD-L1- and IDO-expressing target cells.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Fig. 5: Changes in the TME after treatment. Number of CD3<sup>+</sup> and CD8<sup>+</sup> T cells, TCR fraction, TCR clonality, TCR repertoire, biopsy expanded TCR clones and enrichment of IDO- and PD-L1-specific T cells at the tumor site.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig5_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig5_HTML.png" alt="figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 1 Mode of Action and treatment plan.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 2 Progression free survival and overall survival in matched historical control group and vaccine injection site reaction.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 3 Vaccine specific responses in blood.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 4 Ex vivo vaccine specific responses in blood.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 5 CD4 and CD8 vaccine specific T cell responses in blood.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 6 Pro-inflammatory profiles of sorted CD4 and CD8 T cells from blood.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 7 Vaccine specific responses in skin.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 8 T cell changes in blood after treatment. T cell fraction, TCR clonality and repertoire richness in blood and peripherally expanded TCR clones in both responding and non-responding patients.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 9 Profiling of genes relevant to T cell activation, cytokines and exhaustion markers on pre- and post-treatment biopsies in two patients.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig15">Extended Data Fig. 10 Treatment induced upregulation of PD-L1, IDO, MHC I and MHC II and distance between CD8 T cells and PD-L1 expressing cells.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig15_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01544-x/MediaObjects/41591_2021_1544_Fig15_ESM.jpg" alt="extended data figure 15" aria-describedby="rc-Fig15"></picture><p class="c-reading-companion__figure-links"><a href="#Fig15" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01544-x/figures/15" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncol.</i> <b>20</b>, 1239–1251 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2819%2930388-2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(19)30388-2" data-track-item_id="10.1016/S1470-2045(19)30388-2">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsVeltb7K" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31345627" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pembrolizumab%20versus%20ipilimumab%20in%20advanced%20melanoma%20%28KEYNOTE-006%29%3A%20post-hoc%205-year%20results%20from%20an%20open-label%2C%20multicentre%2C%20randomised%2C%20controlled%2C%20phase%203%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2819%2930388-2&amp;volume=20&amp;pages=1239-1251&amp;publication_year=2019&amp;author=Robert%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Weber, J. S., Postow, M., Lao, C. D. &amp; Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. <i>Oncologist</i> <b>21</b>, 1230–1240 (2016).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>381</b>, 1535–1546 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1910836" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1910836" data-track-item_id="10.1056/NEJMoa1910836">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitVShs7jF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31562797" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Five-year%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1910836&amp;volume=381&amp;pages=1535-1546&amp;publication_year=2019&amp;author=Larkin%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Ascierto, P. A. et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. <i>Ann. Oncol.</i> <b>28</b>, v611–v612 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdx440.011" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdx440.011" data-track-item_id="10.1093/annonc/mdx440.011">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20BMS-986016%2C%20a%20monoclonal%20antibody%20that%20targets%20lymphocyte%20activation%20gene-3%20%28LAG-3%29%2C%20in%20combination%20with%20nivolumab%20in%20pts%20with%20melanoma%20who%20progressed%20during%20prior%20anti-PD-1%2FPD-L1%20therapy%20%28mel%20prior%20IO%29%20in%20all-comer%20and%20biomarker-enriched%20populations&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdx440.011&amp;volume=28&amp;pages=v611-v612&amp;publication_year=2017&amp;author=Ascierto%2CPA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Angeles, L. Warming ‘cold’ melanoma with TLR9 agonists. <i>Cancer Discov.</i> <b>8</b>, 670 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-ND2018-004" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-ND2018-004" data-track-item_id="10.1158/2159-8290.CD-ND2018-004">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Warming%20%E2%80%98cold%E2%80%99%20melanoma%20with%20TLR9%20agonists&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-ND2018-004&amp;volume=8&amp;publication_year=2018&amp;author=Angeles%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Mullinax, J. E. et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. <i>Front. Oncol.</i> <b>8</b>, 44 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffonc.2018.00044" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fonc.2018.00044" data-track-item_id="10.3389/fonc.2018.00044">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29552542" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840208" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Combination%20of%20ipilimumab%20and%20adoptive%20cell%20therapy%20with%20tumor-infiltrating%20lymphocytes%20for%20patients%20with%20metastatic%20melanoma&amp;journal=Front.%20Oncol.&amp;doi=10.3389%2Ffonc.2018.00044&amp;volume=8&amp;publication_year=2018&amp;author=Mullinax%2CJE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. <i>Cell</i> <b>183</b>, 347–362 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2020.08.053" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2020.08.053" data-track-item_id="10.1016/j.cell.2020.08.053">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitF2jtLfJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33064988" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20Ib%20trial%20of%20personalized%20neoantigen%20therapy%20plus%20anti-PD-1%20in%20patients%20with%20advanced%20melanoma%2C%20non-small%20cell%20lung%20cancer%2C%20or%20bladder%20cancer&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2020.08.053&amp;volume=183&amp;pages=347-362&amp;publication_year=2020&amp;author=Ott%2CPA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> <b>547</b>, 217–221 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature22991" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature22991" data-track-item_id="10.1038/nature22991">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtFaqt7rO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28678778" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577644" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=An%20immunogenic%20personal%20neoantigen%20vaccine%20for%20patients%20with%20melanoma&amp;journal=Nature&amp;doi=10.1038%2Fnature22991&amp;volume=547&amp;pages=217-221&amp;publication_year=2017&amp;author=Ott%2CPA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Andersen, M. H. Anti-cancer immunotherapy: breakthroughs and future strategies. <i>Semin. Immunopathol.</i> <b>41</b>, 1–3 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00281-018-0711-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00281-018-0711-z" data-track-item_id="10.1007/s00281-018-0711-z">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30242450" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-cancer%20immunotherapy%3A%20breakthroughs%20and%20future%20strategies&amp;journal=Semin.%20Immunopathol.&amp;doi=10.1007%2Fs00281-018-0711-z&amp;volume=41&amp;pages=1-3&amp;publication_year=2019&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Munir, S., Andersen, G. H., Svane, I. M. &amp; Andersen, M. H. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4<sup>+</sup> T cells. <i>Oncoimmunology</i> <b>2</b>, e23991 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4161%2Fonci.23991" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4161/onci.23991" data-track-item_id="10.4161/onci.23991">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23734334" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654604" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20checkpoint%20regulator%20PD-L1%20is%20a%20specific%20target%20for%20naturally%20occurring%20CD4%2B%20T%20cells&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.23991&amp;volume=2&amp;publication_year=2013&amp;author=Munir%2CS&amp;author=Andersen%2CGH&amp;author=Svane%2CIM&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Ahmad, S. M., Borch, T. H., Hansen, M. &amp; Andersen, M. H. PD-L1-specific T cells. <i>Cancer Immunol. Immunother.</i> <b>65</b>, 797–804 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-015-1783-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-015-1783-4" data-track-item_id="10.1007/s00262-015-1783-4">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XksFGrtQ%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26724936" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1-specific%20T%20cells&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-015-1783-4&amp;volume=65&amp;pages=797-804&amp;publication_year=2016&amp;author=Ahmad%2CSM&amp;author=Borch%2CTH&amp;author=Hansen%2CM&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Andersen, M. H. The specific targeting of immune regulation: T-cell responses against indoleamine 2,3-dioxygenase. <i>Cancer Immunol. Immunother.</i> <b>61</b>, 1289–1297 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-012-1234-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-012-1234-4" data-track-item_id="10.1007/s00262-012-1234-4">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XhtVOhtL7L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22388712" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401509" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20specific%20targeting%20of%20immune%20regulation%3A%20T-cell%20responses%20against%20indoleamine%202%2C3-dioxygenase&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-012-1234-4&amp;volume=61&amp;pages=1289-1297&amp;publication_year=2012&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Sørensen, R. B. et al. Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2. <i>Cancer Res.</i> <b>71</b>, 2038–2044 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-10-3403" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-10-3403" data-track-item_id="10.1158/0008-5472.CAN-10-3403">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21406395" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Spontaneous%20cytotoxic%20T-cell%20reactivity%20against%20indoleamine%202%2C3-dioxygenase-2&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-10-3403&amp;volume=71&amp;pages=2038-2044&amp;publication_year=2011&amp;author=S%C3%B8rensen%2CRB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Ahmad, S. M., Larsen, S. K., Svane, I. M. &amp; Andersen, M. H. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. <i>Leukemia</i> <b>28</b>, 236–238 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fleu.2013.261" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/leu.2013.261" data-track-item_id="10.1038/leu.2013.261">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXhsF2ntrrN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24091833" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Harnessing%20PD-L1-specific%20cytotoxic%20T%20cells%20for%20anti-leukemia%20immunotherapy%20to%20defeat%20mechanisms%20of%20immune%20escape%20mediated%20by%20the%20PD-1%20pathway&amp;journal=Leukemia&amp;doi=10.1038%2Fleu.2013.261&amp;volume=28&amp;pages=236-238&amp;publication_year=2014&amp;author=Ahmad%2CSM&amp;author=Larsen%2CSK&amp;author=Svane%2CIM&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Andersen, M. H. CD4 responses against IDO. <i>Oncoimmunology</i> <b>1</b>, 1211–1212 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4161%2Fonci.20780" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4161/onci.20780" data-track-item_id="10.4161/onci.20780">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23170283" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494649" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD4%20responses%20against%20IDO&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.20780&amp;volume=1&amp;pages=1211-1212&amp;publication_year=2012&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Dey, S. et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8<sup>+</sup> and CD4<sup>+</sup> T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. <i>J. Immunother. Cancer</i> <b>8</b>, e000605 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1136%2Fjitc-2020-000605" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1136/jitc-2020-000605" data-track-item_id="10.1136/jitc-2020-000605">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32690770" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373332" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Peptide%20vaccination%20directed%20against%20IDO1-expressing%20immune%20cells%20elicits%20CD8%2B%20and%20CD4%2B%20T-cell-mediated%20antitumor%20immunity%20and%20enhanced%20anti-PD1%20responses&amp;journal=J.%20Immunother.%20Cancer&amp;doi=10.1136%2Fjitc-2020-000605&amp;volume=8&amp;publication_year=2020&amp;author=Dey%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Ellebaek, E. et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiol</i>. <b>73</b>, 101943 (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. <i>N. Engl. J. Med.</i> <b>373</b>, 23–34 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1504030" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1504030" data-track-item_id="10.1056/NEJMoa1504030">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26027431" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20nivolumab%20and%20ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1504030&amp;volume=373&amp;pages=23-34&amp;publication_year=2015&amp;author=Larkin%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Godard, B. et al. Optimization of an Elispot assay to detect cytomegalovirus-specific CD8<sup>+</sup> T lymphocytes. <i>Hum. Immunol.</i> <b>65</b>, 1307–1318 (2004).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.humimm.2004.06.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.humimm.2004.06.006" data-track-item_id="10.1016/j.humimm.2004.06.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2cXhtVSksb%2FE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15556681" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Optimization%20of%20an%20Elispot%20assay%20to%20detect%20cytomegalovirus-specific%20CD8%2B%20T%20lymphocytes&amp;journal=Hum.%20Immunol.&amp;doi=10.1016%2Fj.humimm.2004.06.006&amp;volume=65&amp;pages=1307-1318&amp;publication_year=2004&amp;author=Godard%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Meier, A. et al. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. <i>Cancer Immunol. Immunother.</i> <b>54</b>, 219–228 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-004-0578-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-004-0578-9" data-track-item_id="10.1007/s00262-004-0578-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXjs1agtw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15580499" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Spontaneous%20T-cell%20responses%20against%20peptides%20derived%20from%20the%20Taxol%20resistance-associated%20gene-3%20%28TRAG-3%29%20protein%20in%20cancer%20patients&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-004-0578-9&amp;volume=54&amp;pages=219-228&amp;publication_year=2005&amp;author=Meier%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Calarota, S. A. et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. <i>J. Immunol.</i> <b>180</b>, 5907–5915 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4049%2Fjimmunol.180.9.5907" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4049/jimmunol.180.9.5907" data-track-item_id="10.4049/jimmunol.180.9.5907">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXkvVCjs78%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18424710" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=HIV-1-specific%20T%20cell%20precursors%20with%20high%20proliferative%20capacity%20correlate%20with%20low%20viremia%20and%20high%20CD4%20counts%20in%20untreated%20individuals&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.180.9.5907&amp;volume=180&amp;pages=5907-5915&amp;publication_year=2008&amp;author=Calarota%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N. Engl. J. Med.</i> <b>377</b>, 1345–1356 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1709684" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1709684" data-track-item_id="10.1056/NEJMoa1709684">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1Git73I" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28889792" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709684&amp;volume=377&amp;pages=1345-1356&amp;publication_year=2017&amp;author=Wolchok%2CJD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Robert, C. et al. Nivolumab in previously untreated melanoma without <i>BRAF</i> mutation. <i>N. Engl. J. Med.</i> <b>372</b>, 320–330 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1412082" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1412082" data-track-item_id="10.1056/NEJMoa1412082">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXisFGqsLg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25399552" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20in%20previously%20untreated%20melanoma%20without%20BRAF%20mutation&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1412082&amp;volume=372&amp;pages=320-330&amp;publication_year=2015&amp;author=Robert%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Iii, C. H. K. et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. <i>Clin. Cancer Res.</i> <b>24</b>, 5347–5356 (2019).</p><p class="c-reading-companion__reference-links"><a href="http://scholar.google.com/scholar_lookup?&amp;title=Age%20correlates%20with%20response%20to%20anti-PD1%2C%20reflecting%20age-related%20differences%20in%20intratumoral%20effector%20and%20regulatory%20T-cell%20populations&amp;journal=Clin.%20Cancer%20Res.&amp;volume=24&amp;pages=5347-5356&amp;publication_year=2019&amp;author=Iii%2CCHK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Bastholt, L. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>Eur. J. Cancer</i> <b>119</b>, 122–131 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2019.06.022" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2019.06.022" data-track-item_id="10.1016/j.ejca.2019.06.022">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFertrnI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31442816" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Age%20favoured%20overall%20survival%20in%20a%20large%20population-based%20Danish%20patient%20cohort%20treated%20with%20anti-PD1%20immune%20checkpoint%20inhibitor%20for%20metastatic%20melanoma&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2019.06.022&amp;volume=119&amp;pages=122-131&amp;publication_year=2019&amp;author=Bastholt%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Yan, X., Tian, X., Wu, Z. &amp; Han, W. Impact of age on the efficacy of immune checkpoint inhibitor-based combination therapy for non-small-cell lung cancer: a systematic review and meta-analysis. <i>Front. Oncol</i>. <b>10</b>, 1671 (2020).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Huang, X. Z. et al. Efficacy of immune checkpoint inhibitors and age in cancer patients. <i>Immunotherapy</i> <b>12</b>, 587–603 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.2217%2Fimt-2019-0124" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.2217/imt-2019-0124" data-track-item_id="10.2217/imt-2019-0124">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32378444" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20immune%20checkpoint%20inhibitors%20and%20age%20in%20cancer%20patients&amp;journal=Immunotherapy&amp;doi=10.2217%2Fimt-2019-0124&amp;volume=12&amp;pages=587-603&amp;publication_year=2020&amp;author=Huang%2CXZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Khozin, S., Blumenthal, G. M. &amp; Pazdur, R. Real-world data for clinical evidence generation in oncology. <i>J. Natl Cancer Inst.</i> <b>109</b>, 1359–1360 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fjnci%2Fdjx187" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/jnci/djx187" data-track-item_id="10.1093/jnci/djx187">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Real-world%20data%20for%20clinical%20evidence%20generation%20in%20oncology&amp;journal=J.%20Natl%20Cancer%20Inst.&amp;doi=10.1093%2Fjnci%2Fdjx187&amp;volume=109&amp;pages=1359-1360&amp;publication_year=2017&amp;author=Khozin%2CS&amp;author=Blumenthal%2CGM&amp;author=Pazdur%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. <i>Cell</i> <b>170</b>, 1109–1119 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.cell.2017.08.027" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.cell.2017.08.027" data-track-item_id="10.1016/j.cell.2017.08.027">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVOhu7rJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28886381" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034392" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Oncolytic%20virotherapy%20promotes%20intratumoral%20T%20cell%20infiltration%20and%20improves%20anti-PD-1%20immunotherapy&amp;journal=Cell&amp;doi=10.1016%2Fj.cell.2017.08.027&amp;volume=170&amp;pages=1109-1119&amp;publication_year=2017&amp;author=Ribas%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Long, G. et al. 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB–IVM1c melanoma. <i>J. Immunother. Cancer</i> <b>8</b>, A261 (2020).</p><p class="c-reading-companion__reference-links"><a href="http://scholar.google.com/scholar_lookup?&amp;title=429%20Long-term%20analysis%20of%20MASTERKEY-265%20phase%201b%20trial%20of%20talimogene%20laherparepvec%20%28T-VEC%29%20plus%20pembrolizumab%20in%20patients%20with%20unresectable%20stage%20IIIB%E2%80%93IVM1c%20melanoma&amp;journal=J.%20Immunother.%20Cancer&amp;volume=8&amp;publication_year=2020&amp;author=Long%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncol.</i> <b>20</b>, 1083–1097 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2819%2930274-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(19)30274-8" data-track-item_id="10.1016/S1470-2045(19)30274-8">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtF2kurbM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31221619" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Epacadostat%20plus%20pembrolizumab%20versus%20placebo%20plus%20pembrolizumab%20in%20patients%20with%20unresectable%20or%20metastatic%20melanoma%20%28ECHO-301%2FKEYNOTE-252%29%3A%20a%20phase%203%2C%20randomised%2C%20double-blind%20study&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2819%2930274-8&amp;volume=20&amp;pages=1083-1097&amp;publication_year=2019&amp;author=Long%2CGV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Iversen, T. Z. et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. <i>Clin. Cancer Res.</i> <b>20</b>, 221–232 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-13-1560" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-13-1560" data-track-item_id="10.1158/1078-0432.CCR-13-1560">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXislKksA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24218513" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Long-lasting%20disease%20stabilization%20in%20the%20absence%20of%20toxicity%20in%20metastatic%20lung%20cancer%20patients%20vaccinated%20with%20an%20epitope%20derived%20from%20indoleamine%202%2C3%20dioxygenase&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-13-1560&amp;volume=20&amp;pages=221-232&amp;publication_year=2014&amp;author=Iversen%2CTZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Kjeldsen, J. W. et al. Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study—a brief research report. <i>Front. Immunol.</i> <b>9</b>, 2145 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffimmu.2018.02145" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fimmu.2018.02145" data-track-item_id="10.3389/fimmu.2018.02145">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30283461" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157336" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Durable%20clinical%20responses%20and%20long-term%20follow-up%20of%20stage%20III%E2%80%93IV%20non-small-cell%20lung%20cancer%20%28NSCLC%29%20patients%20treated%20with%20IDO%20peptide%20vaccine%20in%20a%20phase%20I%20study%E2%80%94a%20brief%20research%20report&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2018.02145&amp;volume=9&amp;publication_year=2018&amp;author=Kjeldsen%2CJW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. <i>Nature</i> <b>585</b>, 107–112 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41586-020-2537-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41586-020-2537-9" data-track-item_id="10.1038/s41586-020-2537-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVygtLvK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32728218" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=An%20RNA%20vaccine%20drives%20immunity%20in%20checkpoint-inhibitor-treated%20melanoma&amp;journal=Nature&amp;doi=10.1038%2Fs41586-020-2537-9&amp;volume=585&amp;pages=107-112&amp;publication_year=2020&amp;author=Sahin%2CU" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Sørensen, R. B. et al. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. <i>Blood</i> <b>117</b>, 2200–2210 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2010-06-288498" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2010-06-288498" data-track-item_id="10.1182/blood-2010-06-288498">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21079151" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062329" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Indoleamine%202%2C3-dioxygenase%20specific%2C%20cytotoxic%20T%20cells%20as%20immune%20regulators&amp;journal=Blood&amp;doi=10.1182%2Fblood-2010-06-288498&amp;volume=117&amp;pages=2200-2210&amp;publication_year=2011&amp;author=S%C3%B8rensen%2CRB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Søorensen, R. B. et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> <b>4</b>, e6910 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0006910" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0006910" data-track-item_id="10.1371/journal.pone.0006910">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20immune%20system%20strikes%20back%3A%20cellular%20immune%20responses%20against%20indoleamine%202%2C3-dioxygenase&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0006910&amp;volume=4&amp;publication_year=2009&amp;author=S%C3%B8orensen%2CRB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Munir, S. et al. Natural CD4<sup>+</sup> T-cell responses against indoleamine 2,3-dioxygenase. <i>PLoS ONE</i> <b>7</b>, e34568 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0034568" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0034568" data-track-item_id="10.1371/journal.pone.0034568">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38Xmslaiurc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22539948" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335144" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Natural%20CD4%2B%20T-cell%20responses%20against%20indoleamine%202%2C3-dioxygenase&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0034568&amp;volume=7&amp;publication_year=2012&amp;author=Munir%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Munir, S. et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. <i>Cancer Res.</i> <b>73</b>, 1764–1776 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-12-3507" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-12-3507" data-track-item_id="10.1158/0008-5472.CAN-12-3507">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXktVGisrs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23328583" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=HLA-restricted%20CTL%20that%20are%20specific%20for%20the%20immune%20checkpoint%20ligand%20PD-L1%20occur%20with%20high%20frequency%20in%20cancer%20patients&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-12-3507&amp;volume=73&amp;pages=1764-1776&amp;publication_year=2013&amp;author=Munir%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Andersen, M. H. The targeting of tumor-associated macrophages by vaccination. <i>Cell Stress</i> <b>3</b>, 139–140 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.15698%2Fcst2019.05.185" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.15698/cst2019.05.185" data-track-item_id="10.15698/cst2019.05.185">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVCjsrfE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31225509" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551857" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20targeting%20of%20tumor-associated%20macrophages%20by%20vaccination&amp;journal=Cell%20Stress&amp;doi=10.15698%2Fcst2019.05.185&amp;volume=3&amp;pages=139-140&amp;publication_year=2019&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Andersen, R. et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. <i>Clin. Cancer Res.</i> <b>22</b>, 3734–3745 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-15-1879" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-15-1879" data-track-item_id="10.1158/1078-0432.CCR-15-1879">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xht1yhtb3L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27006492" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Long-lasting%20complete%20responses%20in%20patients%20with%20metastatic%20melanoma%20after%20adoptive%20cell%20therapy%20with%20tumor-infiltrating%20lymphocytes%20and%20an%20attenuated%20IL2%20regimen&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-15-1879&amp;volume=22&amp;pages=3734-3745&amp;publication_year=2016&amp;author=Andersen%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Jørgensen, N. G. et al. Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: a phase I first-in-human trial. <i>Front. Immunol.</i> <b>11</b>, 595035 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3389%2Ffimmu.2020.595035" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3389/fimmu.2020.595035" data-track-item_id="10.3389/fimmu.2020.595035">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33240282" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680803" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Peptide%20vaccination%20against%20PD-L1%20with%20IO103%20a%20novel%20immune%20modulatory%20vaccine%20in%20multiple%20myeloma%3A%20a%20phase%20I%20first-in-human%20trial&amp;journal=Front.%20Immunol.&amp;doi=10.3389%2Ffimmu.2020.595035&amp;volume=11&amp;publication_year=2020&amp;author=J%C3%B8rgensen%2CNG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> <b>515</b>, 568–571 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnature13954" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nature13954" data-track-item_id="10.1038/nature13954">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXitFanu7jL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25428505" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PD-1%20blockade%20induces%20responses%20by%20inhibiting%20adaptive%20immune%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fnature13954&amp;volume=515&amp;pages=568-571&amp;publication_year=2014&amp;author=Tumeh%2CPC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Wang, T. et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. <i>Nat. Commun.</i> <b>9</b>, 1532 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-018-03915-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-018-03915-4" data-track-item_id="10.1038/s41467-018-03915-4">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29670088" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906566" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20cancer%20vaccine-mediated%20postoperative%20immunotherapy%20for%20recurrent%20and%20metastatic%20tumors&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-018-03915-4&amp;volume=9&amp;publication_year=2018&amp;author=Wang%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Vilain, R. E. et al. Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma. <i>Clin. Cancer Res.</i> <b>23</b>, 5024–5033 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-16-0698" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-16-0698" data-track-item_id="10.1158/1078-0432.CCR-16-0698">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVCit7nN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28512174" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Dynamic%20changes%20in%20PD-L1%20expression%20and%20immune%20infiltrates%20early%20during%20treatment%20predict%20response%20to%20PD-1%20blockade%20in%20melanoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-16-0698&amp;volume=23&amp;pages=5024-5033&amp;publication_year=2017&amp;author=Vilain%2CRE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Andersen, M. H. The balance players of the adaptive immune system. <i>Cancer Res.</i> <b>78</b>, 1379–1382 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F0008-5472.CAN-17-3607" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/0008-5472.CAN-17-3607" data-track-item_id="10.1158/0008-5472.CAN-17-3607">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXks1yls7s%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29440147" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20balance%20players%20of%20the%20adaptive%20immune%20system&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F0008-5472.CAN-17-3607&amp;volume=78&amp;pages=1379-1382&amp;publication_year=2018&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. <i>Nat. Immunol.</i> <b>21</b>, 442–454 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41590-020-0620-x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41590-020-0620-x" data-track-item_id="10.1038/s41590-020-0620-x">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXksFeqtr8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32152508" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1%20engagement%20on%20T%20cells%20promotes%20self-tolerance%20and%20suppression%20of%20neighboring%20macrophages%20and%20effector%20T%20cells%20in%20cancer&amp;journal=Nat.%20Immunol.&amp;doi=10.1038%2Fs41590-020-0620-x&amp;volume=21&amp;pages=442-454&amp;publication_year=2020&amp;author=Diskin%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Ahmad, S. M., Svane, I. M. &amp; Andersen, M. H. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. <i>Blood Cancer J.</i> <b>4</b>, e230 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fbcj.2014.50" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/bcj.2014.50" data-track-item_id="10.1038/bcj.2014.50">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC2cbktlGnsQ%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25036801" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219446" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20stimulation%20of%20PD-L1-specific%20cytotoxic%20T%20lymphocytes%20can%20both%20directly%20and%20indirectly%20enhance%20antileukemic%20immunity&amp;journal=Blood%20Cancer%20J.&amp;doi=10.1038%2Fbcj.2014.50&amp;volume=4&amp;publication_year=2014&amp;author=Ahmad%2CSM&amp;author=Svane%2CIM&amp;author=Andersen%2CMH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Munir Ahmad, S. et al. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. <i>Oncoimmunology</i> <b>5</b>, e1202391 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1080%2F2162402X.2016.1202391" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1080/2162402X.2016.1202391" data-track-item_id="10.1080/2162402X.2016.1202391">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27622072" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007957" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1%20peptide%20co-stimulation%20increases%20immunogenicity%20of%20a%20dendritic%20cell-based%20cancer%20vaccine&amp;journal=Oncoimmunology&amp;doi=10.1080%2F2162402X.2016.1202391&amp;volume=5&amp;publication_year=2016&amp;author=Munir%20Ahmad%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. <i>Nat. Rev. Cancer</i> <b>12</b>, 252–264 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnrc3239" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nrc3239" data-track-item_id="10.1038/nrc3239">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XksVegtrw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22437870" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20blockade%20of%20immune%20checkpoints%20in%20cancer%20immunotherapy&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc3239&amp;volume=12&amp;pages=252-264&amp;publication_year=2012&amp;author=Pardoll%2CDM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. <i>Cancer Immunol. Immunother.</i> <b>59</b>, 1489–1501 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-010-0875-4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-010-0875-4" data-track-item_id="10.1007/s00262-010-0875-4">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BC3cnps1Gmtw%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20549207" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909425" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Response%20definition%20criteria%20for%20ELISPOT%20assays%20revisited&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-010-0875-4&amp;volume=59&amp;pages=1489-1501&amp;publication_year=2010&amp;author=Moodie%2CZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR51">Donia, M. et al. Characterization and comparison of ‘standard’ and ‘young’ tumor infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. <i>Scand. J. Immunol.</i> <b>75</b>, 157–167 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fj.1365-3083.2011.02640.x" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/j.1365-3083.2011.02640.x" data-track-item_id="10.1111/j.1365-3083.2011.02640.x">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20and%20comparison%20of%20%E2%80%98standard%E2%80%99%20and%20%E2%80%98young%E2%80%99%20tumor%20infiltrating%20lymphocytes%20for%20adoptive%20cell%20therapy%20at%20a%20Danish%20translational%20research%20institution&amp;journal=Scand.%20J.%20Immunol.&amp;doi=10.1111%2Fj.1365-3083.2011.02640.x&amp;volume=75&amp;pages=157-167&amp;publication_year=2011&amp;author=Donia%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR52">Hobo, W. et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8<sup>+</sup> T cells. <i>Blood</i> <b>116</b>, 4501–4511 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2010-04-278739" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2010-04-278739" data-track-item_id="10.1182/blood-2010-04-278739">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFGgtbvM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20682852" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=siRNA%20silencing%20of%20PD-L1%20and%20PD-L2%20on%20dendritic%20cells%20augments%20expansion%20and%20function%20of%20minor%20histocompatibility%20antigen-specific%20CD8%2B%20T%20cells&amp;journal=Blood&amp;doi=10.1182%2Fblood-2010-04-278739&amp;volume=116&amp;pages=4501-4511&amp;publication_year=2010&amp;author=Hobo%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR53">Met, Ö., Balslev, E., Flyger, H. &amp; Svane, I. M. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. <i>Breast Cancer Res. Treat.</i> <b>125</b>, 395–406 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s10549-010-0844-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s10549-010-0844-9" data-track-item_id="10.1007/s10549-010-0844-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsFCqt73J" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20336365" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High%20immunogenic%20potential%20of%20p53%20mRNA-transfected%20dendritic%20cells%20in%20patients%20with%20primary%20breast%20cancer&amp;journal=Breast%20Cancer%20Res.%20Treat.&amp;doi=10.1007%2Fs10549-010-0844-9&amp;volume=125&amp;pages=395-406&amp;publication_year=2011&amp;author=Met%2C%C3%96&amp;author=Balslev%2CE&amp;author=Flyger%2CH&amp;author=Svane%2CIM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR54">Bookout, A. L., Cummins, C. L., Mangelsdorf, D. J., Pesola, J. M. &amp; Kramer, M. F. High‐throughput real‐time quantitative reverse transcription PCR. <i>Curr. Protoc. Mol. Biol.</i> <b>73</b>, 15.8.1–15.8.28 (2006).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2F0471142727.mb1508s73" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/0471142727.mb1508s73" data-track-item_id="10.1002/0471142727.mb1508s73">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=High%E2%80%90throughput%20real%E2%80%90time%20quantitative%20reverse%20transcription%20PCR&amp;journal=Curr.%20Protoc.%20Mol.%20Biol.&amp;doi=10.1002%2F0471142727.mb1508s73&amp;volume=73&amp;pages=15.8.1-15.8.28&amp;publication_year=2006&amp;author=Bookout%2CAL&amp;author=Cummins%2CCL&amp;author=Mangelsdorf%2CDJ&amp;author=Pesola%2CJM&amp;author=Kramer%2CMF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR55">Robins, H. S. et al. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells. <i>Blood</i> <b>114</b>, 4099–4107 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2009-04-217604" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2009-04-217604" data-track-item_id="10.1182/blood-2009-04-217604">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsVGku7vN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19706884" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774550" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Comprehensive%20assessment%20of%20T-cell%20receptor%20%CE%B2-chain%20diversity%20in%20%CE%B1%CE%B2%20T%20cells&amp;journal=Blood&amp;doi=10.1182%2Fblood-2009-04-217604&amp;volume=114&amp;pages=4099-4107&amp;publication_year=2009&amp;author=Robins%2CHS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR56">Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. <i>Nat. Commun.</i> <b>4</b>, 2680 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms3680" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms3680" data-track-item_id="10.1038/ncomms3680">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24157944" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Using%20synthetic%20templates%20to%20design%20an%20unbiased%20multiplex%20PCR%20assay&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms3680&amp;volume=4&amp;publication_year=2013&amp;author=Carlson%2CCS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR57">Robins, H. et al. Ultra-sensitive detection of rare T cell clones. <i>J. Immunol. Methods</i> <b>375</b>, 14–19 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.jim.2011.09.001" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.jim.2011.09.001" data-track-item_id="10.1016/j.jim.2011.09.001">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XlsV2hsA%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21945395" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Ultra-sensitive%20detection%20of%20rare%20T%20cell%20clones&amp;journal=J.%20Immunol.%20Methods&amp;doi=10.1016%2Fj.jim.2011.09.001&amp;volume=375&amp;pages=14-19&amp;publication_year=2012&amp;author=Robins%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR58">DeWitt, W. S. et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. <i>J. Virol.</i> <b>89</b>, 4517–4526 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1128%2FJVI.03474-14" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1128/JVI.03474-14" data-track-item_id="10.1128/JVI.03474-14">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXlvVWlsb4%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25653453" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442358" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Dynamics%20of%20the%20cytotoxic%20T%20cell%20response%20to%20a%20model%20of%20acute%20viral%20infection&amp;journal=J.%20Virol.&amp;doi=10.1128%2FJVI.03474-14&amp;volume=89&amp;pages=4517-4526&amp;publication_year=2015&amp;author=DeWitt%2CWS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR59">Benjamini, Y. &amp; Gavrilov, Y. A simple forward selection procedure based on false discovery rate control. <i>Ann. Appl. Stat.</i> <b>3</b>, 179–198 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1214%2F08-AOAS194" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1214/08-AOAS194" data-track-item_id="10.1214/08-AOAS194">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20simple%20forward%20selection%20procedure%20based%20on%20false%20discovery%20rate%20control&amp;journal=Ann.%20Appl.%20Stat.&amp;doi=10.1214%2F08-AOAS194&amp;volume=3&amp;pages=179-198&amp;publication_year=2009&amp;author=Benjamini%2CY&amp;author=Gavrilov%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    


    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-transres" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: TranslationalResearch">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: TranslationalResearch">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Translational Research" src="/static/images/logos/nature-briefing-logo-transres-white-1245a3c374.svg" width="213" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Translational Research</em> newsletter — top stories in biotechnology, drug discovery and pharma.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/translational_research" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: TranslationalResearch">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="TransResBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="TransResBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:translational_research" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: TranslationalResearch">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in translational research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/translational-research/?brieferEntryPoint=TransResBriefingBanner">Sign up for Nature Briefing: Translational Research
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-021-01544-x&amp;format=js&amp;last_modified=2022-03-08" async=""></script>

<oon-dcxzmiwssrxq></oon-dcxzmiwssrxq><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>